UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
x QUARTERLY
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2015 |
or
¨ TRANSITION
REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to |
Commission file number
001-08696
CALMARE THERAPEUTICS INCORPORATED |
(Exact name of registrant as specified in
its charter)
www.calmaretherapeutics.com |
Delaware |
36-2664428 |
(State or other jurisdiction of incorporation or
organization) |
(I. R. S. Employer Identification No.) |
|
|
1375 Kings Highway East, Suite 400 Fairfield,
Connecticut |
06824 |
(Address of principal executive offices) |
(Zip Code) |
(203) 368-6044 |
(Registrant’s telephone number, including area code) |
|
|
(Former name, former address and former fiscal year, if changed since last report) |
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements
for the past 90 days.
Yes ¨
No x
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant
to Rule 405 of Regulation S-T during the preceding 12 months.
Yes x No
¨
Indicate by check mark whether the registrant is a large accelerated
filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of "accelerated filer,
large accelerated filer and smaller reporting company" as defined in Rule 12b-2 of the Exchange Act.
Large accelerated filer ¨ |
Accelerated filer ¨ |
Non-accelerated filer ¨ (Do not check if a smaller reporting company) |
Smaller reporting company x |
Indicate by check mark whether the registrant is a shell company
(as defined in rule 12b-2 of the Exchange Act).
Yes ¨ No
x
The number of shares of the registrant’s
common stock outstanding as of February 24, 2016 was 28,395,888 shares.
CALMARE THERAPEUTICS INCORPORATED
INDEX TO QUARTERLY REPORT ON FORM 10-Q
PART I. FINANCIAL INFORMATION
Item 1. Condensed Consolidated Interim Financial
Statements
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
Condensed Consolidated Balance Sheets
| |
September 30, 2015 | | |
December 31, 2014 | |
| |
(Unaudited) | | |
| |
Assets | |
| | | |
| | |
Current Assets: | |
| | | |
| | |
Cash | |
$ | 44,819 | | |
$ | 5,745 | |
Receivables, net of allowance of $317,659 at September 30, 2015 and December 31, 2014 | |
| 2,502 | | |
| 2,319 | |
Inventory | |
| 4,078,220 | | |
| 4,118,220 | |
Prepaid expenses and other current assets | |
| 61,853 | | |
| 253,102 | |
Total current assets | |
| 4,187,394 | | |
| 4,379,386 | |
| |
| | | |
| | |
Property and equipment, net | |
| 28,073 | | |
| 35,640 | |
Security deposits | |
| 15,000 | | |
| 15,000 | |
TOTAL ASSETS | |
$ | 4,230,467 | | |
$ | 4,430,026 | |
| |
| | | |
| | |
Liabilities and Shareholders' Deficit | |
| | | |
| | |
Current Liabilities: | |
| | | |
| | |
Accounts payable | |
$ | 1,545,804 | | |
$ | 1,346,138 | |
Liabilities under claims purchase agreement | |
| 1,995,320 | | |
| 1,995,320 | |
Accounts payable, GEOMC | |
| 4,182,380 | | |
| 4,182,380 | |
Accrued expenses and other liabilities | |
| 2,327,010 | | |
| 1,590,182 | |
Notes payable | |
| 3,288,326 | | |
| 2,536,830 | |
Deferred revenue | |
| 6,400 | | |
| 19,686 | |
Series C convertible preferred stock derivative liability | |
| 107,871 | | |
| 66,177 | |
Series C convertible preferred stock liability | |
| 375,000 | | |
| 375,000 | |
Total current liabilities | |
| 13,828,111 | | |
| 12,111,713 | |
| |
| | | |
| | |
Note payable – long-term | |
| 65,104 | | |
| 56,659 | |
| |
| | | |
| | |
Commitments and Contingencies | |
| | | |
| | |
Shareholders’ deficit: | |
| | | |
| | |
5% preferred stock, $25 par value, 35,920 shares authorized, 2,427 shares issued and outstanding | |
| 60,675 | | |
| 60,675 | |
Series B preferred stock, $0.001 par value, 20,000 shares authorized, no shares issued and outstanding | |
| - | | |
| - | |
Series C convertible preferred stock, $1,000 par value, 750 shares authorized, 375 shares issued and outstanding | |
| - | | |
| - | |
Common stock, $.01 par value, 40,000,000 shares authorized, 28,395,888 shares issued and outstanding at September 30, 2015 and 25,908,978 shares issued and outstanding at December 31, 2014 | |
| 283,958 | | |
| 259,089 | |
Capital in excess of par value | |
| 48,531,399 | | |
| 47,634,857 | |
Accumulated deficit | |
| (58,538,780 | ) | |
| (55,692,967 | ) |
Total shareholders’ deficit | |
| (9,662,748 | ) | |
| (7,738,346 | ) |
| |
| | | |
| | |
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT | |
$ | 4,230,467 | | |
$ | 4,430,026 | |
See accompanying notes
PART I. FINANCIAL INFORMATION
(Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
Condensed Consolidated Statements of Operations
(Unaudited)
| |
Three months | | |
Three months | |
| |
ended
September
30, 2015 | | |
ended
September 30, 2014 | |
Revenue | |
| | | |
| | |
Product sales | |
$ | 197,204 | | |
$ | 400,000 | |
Cost of product sales | |
| 59,830 | | |
| 247,184 | |
Gross profit from product sales | |
| 137,374 | | |
| 152,816 | |
| |
| | | |
| | |
Other Revenue | |
| | | |
| | |
Retained royalties | |
| 2,389 | | |
| 19,781 | |
Other income | |
| 13,673 | | |
| 14,204 | |
Total other revenue | |
| 16,062 | | |
| 33,985 | |
| |
| | | |
| | |
Operating expenses | |
| | | |
| | |
Selling expenses | |
| 67,791 | | |
| 38,470 | |
Personnel and consulting expenses | |
| 455,087 | | |
| 296,944 | |
General and administrative expenses | |
| 362,208 | | |
| 432,528 | |
Total operating expenses | |
| 885,086 | | |
| 767,942 | |
| |
| | | |
| | |
Operating loss | |
| (731,650 | ) | |
| (581,141 | ) |
| |
| | | |
| | |
Other expense | |
| | | |
| | |
Interest expense | |
| 300,361 | | |
| 574,840 | |
Loss on conversion of notes | |
| - | | |
| 5,500 | |
Unrealized loss on derivative instruments | |
| 30,791 | | |
| 67,631 | |
Total other expense | |
| 331,152 | | |
| 647,971 | |
| |
| | | |
| | |
Loss before income taxes | |
| (1,062,802 | ) | |
| (1,229,112 | ) |
Provision (benefit) for income taxes | |
| - | | |
| - | |
| |
| | | |
| | |
Net loss | |
$ | (1,062,802 | ) | |
$ | (1,229,112 | ) |
| |
| | | |
| | |
Basic and diluted loss per share | |
$ | (0.04 | ) | |
$ | (0.05 | ) |
| |
| | | |
| | |
Basic and diluted weighted average number of common shares outstanding: | |
| 28,370,953 | | |
| 24,974,613 | |
See accompanying notes
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
Condensed Consolidated Statements of Operations
(Unaudited)
| |
Nine months ended | | |
Nine months ended | |
| |
September
30, 2015 | | |
September 30, 2014 | |
Revenue | |
| | | |
| | |
Product sales | |
$ | 405,154 | | |
$ | 937,080 | |
Cost of product sales | |
| 108,070 | | |
| 415,550 | |
Gross profit from product sales | |
| 297,084 | | |
| 521,530 | |
| |
| | | |
| | |
Other Revenue | |
| | | |
| | |
Retained royalties | |
| 7,037 | | |
| 24,733 | |
Other income | |
| 39,206 | | |
| 31,677 | |
Total other revenue | |
| 46,243 | | |
| 56,410 | |
| |
| | | |
| | |
Operating expenses | |
| | | |
| | |
Selling expenses | |
| 112,131 | | |
| 176,496 | |
Personnel and consulting expenses | |
| 1,329,466 | | |
| 1,116,088 | |
General and administrative expenses | |
| 1,012,369 | | |
| 943,554 | |
Total operating expenses | |
| 2,453,966 | | |
| 2,236,138 | |
| |
| | | |
| | |
Operating loss | |
| (2,110,639 | ) | |
| (1,658,198 | ) |
| |
| | | |
| | |
Other expense | |
| | | |
| | |
Interest expense | |
| 690,892 | | |
| 792,520 | |
Interest expense – accelerated upon conversion of OID notes | |
| - | | |
| 35,109 | |
Loss on settlement of note and warrant | |
| - | | |
| 132,301 | |
Loss on conversion of notes | |
| 2,588 | | |
| 48,788 | |
Unrealized loss on derivative instruments | |
| 41,694 | | |
| 79,351 | |
Total other expense | |
| 735,174 | | |
| 1,088,069 | |
| |
| | | |
| | |
Loss before income taxes | |
| (2,845,813 | ) | |
| (2,746,267 | ) |
Provision (benefit) for income taxes | |
| - | | |
| - | |
| |
| | | |
| | |
Net loss | |
$ | (2,845,813 | ) | |
$ | (2,746,267 | ) |
| |
| | | |
| | |
Basic and diluted loss per share | |
$ | (0.10 | ) | |
$ | (0.12 | ) |
| |
| | | |
| | |
Basic and diluted weighted average number of common shares outstanding: | |
| 27,673,151 | | |
| 22,715,940 | |
See accompanying notes
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
Condensed Consolidated Statement of Changes
in Shareholders' Deficit
For the Nine Months Ended September 30,
2015
(Unaudited)
| |
Preferred Stock | | |
Common Stock | | |
Capital | | |
| | |
Total | |
| |
Shares
outstanding | | |
Amount | | |
Shares
outstanding | | |
Amount | | |
in excess
of par value | | |
Accumulated
deficit | | |
shareholders’
deficit | |
| |
| | |
| | |
| | |
| | |
| | |
| | |
| |
Balance January 1, 2015 | |
| 2,427 | | |
$ | 60,675 | | |
| 25,908,978 | | |
$ | 259,089 | | |
$ | 47,634,857 | | |
$ | (55,692,967 | ) | |
$ | (7,738,346 | ) |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Net loss | |
| - | | |
| - | | |
| - | | |
| - | | |
| - | | |
| (2,845,813 | ) | |
| (2,845,813 | ) |
Common stock issued to directors | |
| - | | |
| - | | |
| 12,500 | | |
| 125 | | |
| 2,000 | | |
| - | | |
| 2,125 | |
Stock option compensation expense | |
| - | | |
| - | | |
| - | | |
| - | | |
| 49,181 | | |
| - | | |
| 49,181 | |
Common stock issued for consulting services | |
| - | | |
| - | | |
| 620,000 | | |
| 6,200 | | |
| 101,400 | | |
| - | | |
| 107,600 | |
Common stock issued to convert OID note | |
| | | |
| | | |
| 29,410 | | |
| 294 | | |
| 5,588 | | |
| | | |
| 5,882 | |
Warrants issued for consulting services | |
| - | | |
| - | | |
| - | | |
| - | | |
| 75,000 | | |
| - | | |
| 75,000 | |
Private offering of common stock and warrants | |
| - | | |
| - | | |
| 1,825,000 | | |
| 18,250 | | |
| 346,750 | | |
| - | | |
| 365,000 | |
Warrant and beneficial conversion
feature on notes payable | |
| - | | |
| - | | |
| - | | |
| - | | |
| 316,623 | | |
| - | | |
| 316,623 | |
| |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | |
Balance September 30, 2015 | |
| 2,427 | | |
$ | 60,675 | | |
| 28,395,888 | | |
$ | 283,958 | | |
$ | 48,531,399 | | |
$ | (58,538,780 | ) | |
$ | (9,662,748 | ) |
See accompanying notes
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
Condensed Consolidated Statements of Cash
Flows
(Unaudited)
| |
Nine months ended | | |
Nine months ended | |
| |
September 30, 2015 | | |
September 30, 2014 | |
Cash flows from operating activities: | |
| | | |
| | |
| |
| | | |
| | |
Net loss | |
$ | (2,845,813 | ) | |
$ | (2,746,267 | ) |
Adjustments to reconcile net loss to net cash used in operating activities: | |
| | | |
| | |
Depreciation and amortization | |
| 12,267 | | |
| 11,976 | |
Stock option compensation expense | |
| 49,181 | | |
| 49,185 | |
Share-based compensation – common stock | |
| 2,125 | | |
| 4,038 | |
Common stock and warrants issued to consultants | |
| 182,600 | | |
| - | |
Bad debt expense | |
| - | | |
| 79,500 | |
Debt discount amortization | |
| 265,358 | | |
| 185,525 | |
Noncash finance charges | |
| - | | |
| 18,434 | |
Unrealized loss on derivative instruments | |
| 41,694 | | |
| 79,351 | |
Loss on conversion of notes | |
| 2,588 | | |
| 48,788 | |
Loss on settlement of note and warrant | |
| - | | |
| 132,301 | |
Changes in assets and liabilities: | |
| | | |
| | |
Receivables | |
| (183 | ) | |
| (171,883 | ) |
Prepaid expenses and other current assets | |
| 191,249 | | |
| (50,888 | ) |
Inventory | |
| 40,000 | | |
| 150,000 | |
Accounts payable, accrued expenses and other liabilities | |
| 936,494 | | |
| 1,417,832 | |
Deferred revenue | |
| (13,286 | ) | |
| 13,287 | |
Net cash used in operating activities | |
| (1,135,726 | ) | |
| (778,821 | ) |
| |
| | | |
| | |
Cash flows from investing activities: | |
| | | |
| | |
Purchase of property and equipment | |
| (4,700 | ) | |
| (47,688 | ) |
Cash used in investing activities | |
| (4,700 | ) | |
| (47,688 | ) |
| |
| | | |
| | |
Cash flows from financing activities: | |
| | | |
| | |
Proceeds from note payable | |
| 857,000 | | |
| 120,000 | |
Repayment of note and warrant settlement | |
| (42,500 | ) | |
| (242,000 | ) |
Proceeds from common stock and warrants | |
| 365,000 | | |
| 892,000 | |
Net cash provided by financing activities | |
| 1,179,500 | | |
| 770,000 | |
| |
| | | |
| | |
Net increase (decrease) in cash | |
| 39,074 | | |
| (56,509 | ) |
| |
| | | |
| | |
Cash at beginning of period | |
| 5,745 | | |
| 57,009 | |
| |
| | | |
| | |
Cash at end of period | |
$ | 44,819 | | |
$ | 500 | |
Supplemental disclosure of non-cash transactions:
During the quarter
ended March 31, 2015, the Company issued 500,000 shares with a fair value of $80,000 to an advisory firm for consulting services.
The Company is amortizing the $80,000 over the service period and recorded $20,000 and $60,000 of expense in the quarter and nine
months ended September 30, 2015, respectively.
During the quarter
ended March 31, 2015, the Company issued 120,000 shares to an advisory firm for consulting services. The shares vested in two tranches,
with 60,000 shares vesting in the quarter ended December 31, 2014 and remaining 60,000 shares vesting in the quarter ended March
31, 2015. The Company recorded consulting expenses of $10,800 in the quarter ended December 31, 2014 and $27,600 of consulting
expenses in the quarter ended March 31, 2015. In each instance, the expense was based on the fair value on the vesting date.
During the quarter
ended March 31, 2015, the Company issued 333,333 stock warrants for consulting services performed and recorded consulting expense
of $75,000 for the fair value of the warrants.
During the nine months
ended September 30, 2015, the Company allocated $316,623 of convertible note proceeds for the fair value of warrants and beneficial
conversion feature to additional paid-in capital.
During the nine months
ended September 2014, the Company issued 1,378,240 shares of common stock upon conversion of notes (see Note 11).
During the quarter
ended September 30, 2015, the Company issued 29,410 shares of common stock upon conversion of notes (see Note 11).
In September 2013 the Company issued 1,618,235 shares of the
Company’s common stock to ASC Recap. During September and October 2013, ASC Recap sold the Company’s common stock
and during the three months ended March 31, 2014 paid creditors approximately $80,000 from the proceeds and retained a service
fee of approximately $27,000 (see Note 10).
See accompanying notes
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
Notes to Condensed Consolidated Interim
Financial Statements
(Unaudited)
The interim condensed
consolidated financial information presented in the accompanying condensed consolidated financial statements and notes hereto is
unaudited.
Effective August 20,
2014, Competitive Technologies, Inc. changed its name to Calmare Therapeutics Incorporated.
Calmare Therapeutics
Incorporated (“CTI”) and its majority-owned (56.1%) subsidiary, Vector Vision, Inc. (“VVI”), (collectively,
the “Company”, “we” or “us”) is a medical device company developing and commercializing innovative
products and technologies. CTI is the licensed distributor of the non-invasive Calmare® Pain Therapy Device (the
“Calmare Device”), which was developed to treat neuropathic and cancer-derived pain.
These consolidated
financial statements include the accounts of CTI and VVI. Inter-company accounts and transactions have been eliminated
in consolidation.
We believe we have
made all adjustments necessary, consisting only of normal recurring adjustments, to present the unaudited condensed consolidated
financial statements in conformity with accounting principles generally accepted in the U.S. The results for the three
and nine months ended September 30, 2015 are not necessarily indicative of the results that can be expected for the full year ending
December 31, 2015.
The interim unaudited
condensed consolidated financial statements and notes thereto, should be read in conjunction with our Annual Report on Form 10-K
for the year ended December 31, 2014 filed with the Securities and Exchange Commission (“SEC”) on June 24, 2015.
During the three and
nine months ended September 30, 2015, we had a significant concentration of revenues from the Calmare® Device. The
percentages of gross revenue attributed to sales and rentals of Calmare Devices, in the three and nine months ended September
30, 2015, were 95% and 94%, respectively; and 94% and 96%, respectively, in the three and nine months ended September 30,
2014. Additionally, the percentage of gross revenue attributed to other Calmare Device related sales of equipment and
training, in the three and nine months ended September 30, 2015, was 4% in both periods; and 2% and 1%, respectively, in the three
and nine months ended September 30, 2014. We continue to attempt to expand our sales activities for the Calmare Device
and expect the majority of our revenues to come from this technology.
The Company has incurred
operating losses since fiscal 2006 and has a working capital deficiency and shareholders’ deficiency at September 30, 2015. The
Company has taken steps to reduce its operating expenses as well as increase revenue from sales of Calmare Devices and related
sales. However, even at the reduced spending levels, should the anticipated increase in revenue from sales of Calmare Devices
and related sales not occur the Company may not have sufficient cash flow to fund operations through 2015 and into 2016. These
conditions raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements
do not include adjustments to reflect the possible future effect of the recoverability and classification of assets or amounts
and classifications of liabilities that may result from the outcome of this uncertainty.
The Company's continuation
as a going concern is dependent upon its developing recurring revenue streams sufficient to cover operating costs. The
Company does not have any significant individual cash or capital requirements in the budget going forward. If necessary,
the Company will attempt to meet anticipated operating cash requirements by further reducing costs, issuing debt and/or equity,
and/or pursuing sales of certain assets and technologies while we pursue licensing and distribution opportunities for our remaining
legacy portfolio of technologies. There can be no assurance that the Company will be successful in such efforts. Failure
to develop a recurring revenue stream sufficient to cover operating expenses could negatively affect the Company’s financial
position.
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
Our liquidity requirements
arise principally from our working capital needs, including funds needed to sell our current technologies and obtain new technologies
or products, and protect and enforce our intellectual property rights, if necessary. We fund our liquidity requirements with a
combination of cash on hand, debt and equity financing, sales of common stock and cash flows from operations, if any, including
royalty legal awards. At September 30, 2015, the Company had outstanding debt in the form of promissory notes with a total principal
amount of $4,177,000 and a carrying value of $3,839,000.
In 2007, the Company
secured the exclusive, worldwide rights to the patented, chronic pain reduction technology (the “Technology”) behind
the Company’s flagship medical device – the Calmare Device. The Company’s 2007 agreement (the “2007 Agreement”)
with Giuseppe Marineo, an inventor of the Technology, and Delta Research and Development (“Delta”), authorized the
Company to manufacture and sell worldwide the Calmare Device developed from the patented Technology. The 2007 Agreement was amended
in 2011 (the “2011 Amendment”) to provide the Company with exclusive rights to the Technology through March 31, 2016.
In July 2012, the Company attempted to negotiate a five-year extension to the agreement with Marineo and Delta (the “2012
Amendment”). However, the Company believes that the 2012 Amendment is neither valid nor enforceable as it was never duly
signed or authorized and subsequently deemed null and void. Therefore, the Company’s rights are determined by the 2011 Amendment
which provides the Company with the exclusive rights to manufacture and sell the Calmare Device worldwide using the Technology.
(see Footnote 13. CONTRACTUAL OBLIGATIONS AND CONTINGENCIES, the Company’s Distribution Rights, Marineo and Delta)
The Technology is patented
in Italy and in the United States. Applications for patents have been filed internationally as well and are pending approval. The
Calmare Device has CE Marking certification under the expressed jurisdiction from the European Commission’s Competitiveness
and Innovation Program (“CIP”). The Calmare Device also has a 510(k) clearance from the U.S. Food and
Drug Administration (#K081255) for sales in the United States and reciprocity countries. The Company partners with GEOMC Co., Ltd.
(“GEOMC”) of Korea to manufacture the Calmare Device commercially.
| 2. | NET LOSS PER COMMON SHARE |
The following sets
forth the denominator used in the calculations of basic net loss per share and net loss per share assuming dilution:
| |
Three
months
ended | | |
Three months
ended | | |
Nine
months
ended | | |
Nine
months
ended | |
| |
September 30, 2015 | | |
September
30, 2014 | | |
September
30, 2015 | | |
September
30, 2014 | |
Denominator for basic net loss per share, weighted average shares outstanding | |
| 28,370,953 | | |
| 24,974,613 | | |
| 27,673,151 | | |
| 22,715,940 | |
| |
| | | |
| | | |
| | | |
| | |
Dilutive effect of common stock options | |
| N/A | | |
| N/A | | |
| N/A | | |
| N/A | |
| |
| | | |
| | | |
| | | |
| | |
Dilutive effect of Series C convertible preferred stock, convertible debt and warrants | |
| N/A | | |
| N/A | | |
| N/A | | |
| N/A | |
| |
| | | |
| | | |
| | | |
| | |
Denominator for diluted net loss per share, weighted average shares outstanding | |
| 28,370,953 | | |
| 24,974,613 | | |
| 27,673,151 | | |
| 22,715,940 | |
Due to the net loss
incurred for the three and nine months ended September 30, 2015, and 2014, the denominator used in the calculation of basic net
loss per share was the same as that used for net loss per share, assuming dilution, since the effect of any options, convertible
preferred shares, convertible debt or warrants would have been anti-dilutive.
Potentially dilutive securities outstanding are summarized as
follows:
| |
September 30, 2015 | | |
September 30, 2014 | |
Exercise of common stock options | |
| 2,042,500 | | |
| 1,692,500 | |
Exercise of common stock warrants | |
| 7,864,013 | | |
| 3,398,890 | |
Conversion of Series C convertible preferred stock | |
| 1,857,194 | | |
| 2,673,797 | |
Conversion of convertible debt | |
| 9,089,153 | | |
| 3,171,776 | |
Total | |
| 20,852,860 | | |
| 10,936,963 | |
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
| 3. | RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS |
In May 2014, the Financial Accounting Standards
Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with
Customers, as amended by ASU 2015-14, that outlines a single comprehensive model for entities to use in accounting for revenue
recognition and supersedes most current revenue recognition guidance, including industry-specific guidance. The amendments in this
accounting standard update are intended to provide a more robust framework for addressing revenue issues, improve comparability
of revenue recognition practices, and improve disclosure requirements. The amendments in this accounting standard update are effective
for interim and annual reporting periods beginning after December 15, 2017; with early adoption permitted after December 15, 2016.
The Company is currently assessing the impact that this standard will have on its consolidated financial statements.
In August 2014, the FASB issued ASU No.
2014-15, Presentation of Financial Statements – Going Concern, which provides guidance on management’s responsibility
in evaluating whether there is substantial doubt about a company’s ability to continue as a going concern and the related
footnote disclosure. For each reporting period, management will be required to evaluate whether there are conditions or events
that raise substantial doubt about a company’s ability to continue as a going concern within one year from the date the financials
are issued. When management identifies conditions or events that raise substantial doubt about the entity’s ability
to continue as a going concern, the ASU also outlines disclosures that are required in the company’s footnotes based on whether
or not there are any plans intended to mitigate the relevant conditions or events to alleviate the substantial doubt. The
ASU becomes effective for annual periods ending after December 15, 2016, and for any annual and interim periods thereafter.
Early application is permitted. The Company is currently assessing the impact that this standard will have on its consolidated
financial statements.
In July 2015, the FASB issued ASU No. 2015-11,
Inventory – Simplifying the Measurement of Inventory, which requires that inventory be measured at the lower of cost
and net realizable value. Prior to the issuance of the new guidance, inventory was measured at the lower of cost or market. Replacing
the concept of market with the single measurement of net realizable value is intended to create efficiencies for preparers. Inventory
measured using the last-in, first-out (LIFO) method and the retail inventory method are not impacted by the new guidance. The ASU
becomes effective for fiscal years beginning after December 15, 2016, including interim periods with those fiscal years. Early
application is permitted. We do not expect the adoption to have a material impact on our consolidated financial statements.
Receivables consist
of the following:
| |
September 30, 2015 | | |
December 31, 2014 | |
Calmare device sales receivable, net of allowance of $209,533 at September 30, 2015 and
December 31, 2014 | |
$ | - | | |
$ | - | |
Royalties, net of allowance of $101,154 at September 30, 2015 and December 31, 2014 | |
| - | | |
| - | |
Other, net of allowance of $6,972 at September 30, 2015 and December 31, 2014 | |
| 2,502 | | |
| 2,319 | |
Total | |
$ | 2,502 | | |
$ | 2,319 | |
| 5. | AVAILABLE-FOR-SALE AND EQUITY SECURITIES |
The fair value of the
equity securities we held were categorized as available-for-sale securities, which were carried at a fair value of zero, consisted
of shares in Security Innovation and Xion Pharmaceutical Corporation (“Xion”). We own 223,317 shares of
stock in the privately held Security Innovation, an independent provider of secure software located in Wilmington, MA.
In September 2009 we
announced the formation of a joint venture with Xion for the commercialization of our patented melanocortin analogues for treating
sexual dysfunction and obesity. CTI currently owns 60 shares of common stock or 30% of the outstanding stock of privately
held Xion.
| 6. | FAIR VALUE MEASUREMEMENTS |
The Company measures
fair value in accordance with Topic 820 of the FASB Accounting Standards Codification (“ASC”), Fair Value Measurement
(“ASC 820”), which provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure
fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities
(Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value
hierarchy under ASC 820 are described as follows:
|
Level 1 - |
Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. |
|
|
|
|
|
Level 2 - |
Inputs to the valuation methodology include: |
|
|
● |
Quoted prices for similar assets or liabilities in active markets; |
|
|
● |
Quoted prices for identical or similar assets or liabilities in inactive markets; |
|
|
● |
Inputs other than quoted prices that are observable for the asset or liability; |
|
|
● |
Inputs that are derived principally from or corroborated by
observable market data by correlation or other means.
|
|
|
If the asset or liability has a specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. |
|
|
|
|
|
Level 3 - |
Inputs to the valuation methodology are unobservable and significant to the fair value measurement |
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
The asset's or liability's
fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the
fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable
inputs.
The Company values
its derivative liability associated with the variable conversion feature on its Series C Convertible Preferred Stock (Note 12)
based on the market price of its common stock. For each reporting period the Company calculates the amount of potential
common stock that the Series C Preferred Stock could convert into based on the conversion formula (incorporating market value of
our common stock) and multiplies those converted shares by the market price of its common stock on that reporting date. The
total converted value is subtracted by the consideration paid to determine the fair value of the derivative liability. The Company
classified the derivative liability of approximately $108,000 at September 30, 2015 and $66,000 at December 31, 2014, in Level
2 of the fair value hierarchy.
The methods described
above may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values.
Furthermore, while the Company believes its valuation method is appropriate and consistent with other market participants, the
use of different methodologies or assumptions to determine the fair value could result in a different fair value measurement at
the reporting date.
The carrying amounts
reported in our Condensed Consolidated Balance Sheet for cash, accounts receivable, notes payable, deferred revenue, and preferred
stock liability approximate fair value due to the short-term maturity of those financial instruments.
| 7. | PREPAID EXPENSES AND OTHER CURRENT ASSETS |
Prepaid expenses and
other current assets consist of the following:
| |
September 30, 2015 | | |
December 31, 2014 | |
Prepaid insurance | |
$ | 30,987 | | |
$ | 71,651 | |
Prepaid consulting services | |
| 20,000 | | |
| 37,500 | |
Clinical trial | |
| - | | |
| 109,119 | |
Other | |
| 10,866 | | |
| 34,832 | |
Prepaid expenses and other current assets | |
$ | 61,853 | | |
$ | 253,102 | |
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
Property and equipment,
net, consist of the following:
| |
September 30, 2015 | | |
December 31, 2014 | |
Property and equipment, gross | |
$ | 220,191 | | |
$ | 215,491 | |
Accumulated depreciation and amortization | |
| (192,118 | ) | |
| (179,851 | ) |
Property and equipment, net | |
$ | 28,073 | | |
$ | 35,640 | |
Depreciation and amortization expense was
$3,904 and $12,267, respectively, during the three and nine months ended September 30, 2015, and $5,630 and $11,976, respectively,
for the three and nine months ended September 30, 2014.
| 9. | ACCRUED EXPENSES AND OTHER LIABILITIES |
Accrued expenses and
other liabilities consist of the following:
| |
September 30, 2015 | | |
December 31, 2014 | |
Royalties payable | |
$ | 375,067 | | |
$ | 314,787 | |
Accrued compensation | |
| 196,723 | | |
| 23,573 | |
Accrued interest payable | |
| 1,409,150 | | |
| 987,659 | |
Other | |
| 346,070 | | |
| 264,163 | |
Accrued expenses and other liabilities, net | |
$ | 2,327,010 | | |
$ | 1,590,182 | |
Excluded above is approximately
$217,000 of accrued expenses and other liabilities at September 30, 2015 and December 31, 2014, that fall under the Liability Purchase
Agreement (“LPA”) with ASC Recap, LLC (“ASC Recap”), and are expected to be repaid using the process as
described in Note 10. Because there can be no assurance that the Company will be successful in completing this process,
the Company retains ultimate responsibility for these liabilities, until fully paid down.
| 10. | LIABILITIES ASSIGNED TO LIABILITY PURCHASE AGREEMENT |
During the third quarter
of 2013, the Company negotiated a LPA with Southridge, Partners II, L.P. (“Southridge”). The LPA takes advantage of
a provision in the Securities Act of 1933, Section 3(a)(10), that allows the exchange of claims, securities, or property for stock
when the arrangement is approved for fairness by a court proceeding. The process, approved by the court in August 2013, has the
potential to eliminate nearly $2.1 million of our financial obligations to existing creditors who agreed to participate and executed
claims purchase agreements with Southridge’s affiliate ASC Recap accounting for $2,093,303 of existing payables, accrued
expenses and other current liabilities, and notes payable. The process began with the issuance in September 2013 of 1,618,235 shares
of the Company’s common stock to ASC Recap. During September and October 2013, ASC Recap sold the Company’s common
stock and during the three months ended March 31, 2014 paid creditors approximately $80,000 from the proceeds and retained a service
fee of approximately $27,000. During 2014, the Company also made cash payments of $18,000 for accrued expenses previously included
in the LPA amount. As of February 24, 2016, no further shares of the Company’s common stock had been issued to ASC Recap
to settle creditors’ balances.
There can be no assurance
that the Company will be successful in completing this process with Southridge, and the Company retains ultimate responsibility
for this debt, until fully paid.
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
Notes payable consist of the following:
| |
September 30, 2015 | | |
December 31, 2014 | |
90 day Convertible Notes (Chairman of the Board) | |
$ | 2,498,980 | | |
$ | 2,498,980 | |
24 month Convertible Notes ($100,000 to Board member) | |
| 225,000 | | |
| 225,000 | |
10 day Note (Board member) | |
| - | | |
| 42,500 | |
Series A-3 15% OID Convertible Notes and Warrants | |
| 14,353 | | |
| 11,765 | |
Series B-1 OID Convertible Notes and Warrants | |
| 65,104 | | |
| 56,659 | |
Series B-2 OID Convertible Notes and Warrants | |
| 1,035,973 | | |
| 244,565 | |
Notes Payable, gross | |
| 3,839,410 | | |
| 3,079,469 | |
Less LPA amount | |
| (485,980 | ) | |
| (485,980 | ) |
Notes Payable, net | |
$ | 3,353,430 | | |
$ | 2,593,489 | |
Details of notes payable as of September
30, 2015 are as follows:
| |
Principal
Amount | | |
Carrying
Value | | |
Cash Interest
Rate | | |
Common
Stock Conversion Price | | |
Maturity Date |
90 day
Convertible Notes (Chairman of the Board) | |
$ | 2,498,980 | | |
$ | 2,498,980 | | |
| 6 | % | |
$ | 1.05 | | |
Various 2014 |
24 month Convertible
Notes ($100,000 to Board member) | |
| 225,000 | | |
| 225,000 | | |
| 6 | % | |
| 1.05 | | |
March 2014 – June 2014 |
Series A-3 15% OID
Convertible Notes and Warrants | |
| 11,765 | (1) | |
| 14,353 | (1) | |
| None | | |
| 0.25 | | |
January 2015 |
Series B-1 OID Convertible
Notes and Warrants | |
| 80,000 | | |
| 65,104 | | |
| None | | |
| 0.23 | | |
March 2017 |
Series
B-2 OID Convertible Notes and Warrants | |
| 1,361,177 | | |
| 1,035,973 | | |
| None | | |
| 0.20-0.25 | | |
Aug. 2015 – July 2016 |
Notes
Payable, gross | |
$ | 4,176,922 | | |
| 3,839,410 | | |
| | | |
| | | |
|
Less
LPA amount | |
| | | |
| (485,980 | ) | |
| | | |
| | | |
|
Notes
Payable, net | |
| | | |
$ | 3,353,430 | | |
| | | |
| | | |
|
| (1) | Includes $2,588 of accrued loss on conversion of OID
note. |
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
90 day Convertible Notes
The Company has issued
90-day notes payable to borrow funds from a director, now the chairman of our Board, as follows:
2013 | |
$ | 1,188,980 | |
2012 | |
| 1,210,000 | |
2011 | |
| 100,000 | |
Total | |
$ | 2,498,980 | |
These notes have been
extended several times and all bear 6.00% simple interest. A conversion feature was added to the Notes when they were
extended, which allows for conversion of the eligible principal amounts to common stock at any time after the six month anniversary
of the effective date – the date the funds are received – at a rate of $1.05 per share. Additional
terms have been added to all Notes to include additional interest of 1% simple interest per month on all amounts outstanding for
all Notes if extended beyond their original maturity dates and to provide the lender with a security interest in unencumbered inventory
and intangible assets of the Company other than proceeds relating to the Calmare Device and accounts receivable.
Due to the Board’s
February 10, 2014 decision authorizing management to nullify certain actions taken by prior management, the additional terms noted
above were not approved and therefore, the additional interest for the extension of the Notes was not recorded. During 2014,
management has been in negotiations to modify the terms of the Notes. However, until those negotiations are resolved, the Company
has agreed to honor the additional terms and as such, the Company recorded additional interest of approximately $287,000 during
the nine months ended September 30, 2015, and has recorded additional interest in total of $906,000.
A total of $485,980
of the aforementioned notes issued between December 1, 2012 and March 31, 2013 fall under the LPA with ASC Recap, and are expected
to be repaid using the process as described in Note 10. Because there can be no assurance that the Company will be successful
in completing this process, the Company retains ultimate responsibility for this debt, until fully paid down. As a result,
the Company continues to accrue interest on these notes and they remain convertible as described above.
24 month Convertible Notes
In March 2012, the
Company issued a 24-month convertible promissory note to borrow $100,000. Additional 24-month convertible promissory notes were
issued in April 2012 ($25,000) and in June 2012 ($100,000). All of the notes bear 6.00% simple interest. Conversion of the eligible
principal amounts to common stock is allowed at any time at a rate of $1.05 per share.
As of February 24,
2016 the Company has not repaid the principal due on the March 2012 $100,000 note, the April 2012 $25,000 note or the June 2012
$100,000 note and is in default under the terms of the notes. As of September 30, 2015, there is also unpaid interest of $28,000
related to these notes.
10 day Note
In late December 2014,
the Company issued a 10 day non-interest bearing note to a Board member in the amount of $42,500. This note was repaid in early
January 2015.
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
Series A-3 15% Original Issue Discount
(“OID”) Convertible Notes and Warrants
During the quarter
ended March 31, 2014, the Company did a private offering of a third tranche of convertible notes and warrants, under which it issued
$64,706 of convertible promissory notes for consideration of $55,000, the difference between the proceeds from the notes and principal
amount consists of $9,706 of original issue discount. The notes are convertible at an initial conversion price of $0.25 per share
any time after issuance thereby having an embedded beneficial conversion feature.
The note holders were
also issued market-related warrants for 129,412 in shares of common stock. The warrants have an exercise price of $0.60 and a term
of 2 years. The beneficial conversion feature, if any, and the warrants were recorded to additional paid-in-capital. The Company
allocated the proceeds received to the notes, the beneficial conversion feature and the warrants on a relative fair value basis
at the time of issuance. The total debt discount is amortized over the life of the notes to interest expense.
The beneficial conversion
feature was valued at the intrinsic value on the issuance date. The intrinsic value represents the difference between the conversion
price and the fair value of the common stock multiplied by the number of share into which the note is convertible. We estimated
the fair value of the warrants on the issue date using a Black-Scholes pricing model with the following assumptions:
| |
Warrants | |
Expected term | |
| 2 years | |
Volatility | |
| 184.88 | % |
Risk Free Rate | |
| 0.32 | % |
The proceeds of the
Notes issued during the three months ended March 31, 2014 were allocated to the components as follows:
| |
Proceeds
allocated at issue date | |
Private Offering Notes | |
$ | 32,390 | |
Private Offering Warrants | |
| 14,845 | |
Beneficial Conversion feature | |
| 7,765 | |
Total | |
$ | 55,000 | |
During the quarter
ended June 30, 2014, certain holders of Series A-3 OID convertible notes and warrants delivered to the Company a notice of conversion
related to the Series A-3 OID convertible notes. Due to the timing of receipt of the notices by the Company, certain Note holders
(“Noteholders”) received their shares during the quarter ended June 30, 2014, while other Noteholders received or are
due to receive their shares after June 30, 2014. Additionally, the Company offered certain Noteholders an inducement to convert
their notes to shares. The inducement, when offered, provided Noteholders a conversion price of $0.20. All other original terms,
including the warrant terms, remained the same. Upon notice of conversion and irrespective of whether the shares were delivered
in the quarter ended June 30, 2014 or subsequent to June 30, 2014 to the Company: (i) accelerated and recognized as interest expense
in the current period any remaining discount, and (ii) recognized a loss for the fair value of the additional shares offered as
the conversion inducement.
Presented below is
summary information related to the conversion:
Statement of Operations | |
| | |
Loss on conversion of notes | |
$ | 43,288 | |
Accelerated interest expense | |
$ | 35,109 | |
| |
| | |
Balance Sheet | |
| | |
Shares issued as of June 30, 2014 | |
| 798,825 | |
Shares to be issued subsequent to June 30, 2014 | |
| 529,415 | |
Principal amount of notes converted | |
$ | 265,648 | |
During the quarter
ended March 31, 2015, a holder of Series A-3 OID convertible notes and warrants delivered to the Company a notice of conversion
related to the Series A-3 OID convertible notes. Additionally, the Company offered the Noteholder an inducement to convert his/her
notes to shares. The inducement provided the Noteholder a conversion price of $0.20. All other original terms, including the warrant
terms, remained the same. Upon notice of conversion, the Company: (i) accelerated and recognized as interest expense in the current
period any remaining discount, and (ii) recognized a loss for the fair value of the additional shares offered as the conversion
inducement. As of February 24, 2016, the Company had not issued the shares due related to the conversion notice.
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
Presented below is
summary information related to the conversion:
Statement of Operations | |
| | |
Loss on conversion of notes | |
$ | 2,588 | |
Accelerated interest expense | |
$ | - | |
| |
| | |
Balance Sheet | |
| | |
Shares issued | |
| - | |
| |
| | |
Principal amount of notes converted | |
$ | 11,765 | |
Series B-1 Original Issue Discount
Convertible Notes and Warrants
During the quarter
ended March 31, 2014, the Company did a private offering of convertible notes and warrants, under which it issued $80,000 of convertible
promissory notes for consideration of $65,000, the difference between the proceeds from the notes and principal amount consists
of $15,000 of original issue discount. The notes are convertible at an initial conversion price of $0.35 per share any time after
issuance thereby having an embedded beneficial conversion feature. The note holders were also issued market-related warrants for
185,714 in shares of common stock. The warrants have an exercise price of $0.45 and a 4-year term. The beneficial conversion feature
and the warrants were recorded to additional paid-in-capital. The Company allocated the proceeds received to the notes, the beneficial
conversion feature and the warrants on a relative fair value basis at the time of issuance. The total debt discount is amortized
over the life of the notes to interest expense.
The beneficial conversion
feature was valued at the intrinsic value on the issuance date. The intrinsic value represents the difference between the conversion
price and the fair value of the common stock multiplied by the number of share into which the note is convertible. We estimated
the fair value of the warrants on the issue date using a Black-Scholes pricing model with the following assumptions:
| |
Warrants March 20,
2014 | |
Expected term | |
| 4 years | |
Volatility | |
| 151.52 | % |
Risk Free Rate | |
| 1.32 | % |
The proceeds of the
Notes were allocated to the components as follows:
| |
Proceeds
allocated at issue date | |
Private Offering Notes | |
$ | 34,272 | |
Private Offering Warrants | |
| 26,811 | |
Beneficial Conversion feature | |
| 3,917 | |
Total | |
$ | 65,000 | |
The Series B-1 OID
notes include an anti-dilution provision that if the Company issues more than 20 million shares of its common stock, subject to
certain exceptions, the conversion price of the notes and the conversion price of the warrants would be subject to an automatic
pre-determined price adjustment. During the quarter ended December 31, 2014 the Series B-1 OID noteholder and the Company agreed
that this anti-dilution provision had been triggered and the Series B-1 OID note share conversion price was adjusted down to $0.23
per share, which increased the number of shares available upon conversion to 347,826. The anti-dilution provision in the Warrant
changed the share purchase price downward to $0.33 per share but did not change the number of shares available under the Warrant.
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
As a result of the triggering of the above
noted one time anti-dilution provision, the Company reallocated the proceeds of the Notes during the quarter ended December 31,
2014 as follows:
| |
Proceeds allocated at issue date | |
Private Offering Notes | |
$ | 46,222 | |
Private Offering Warrants | |
| 18,778 | |
Beneficial Conversion feature | |
| - | |
Total | |
$ | 65,000 | |
Series B-2 OID Convertible Notes and Warrants
During the quarter
ended March 31, 2015, the Company did an additional private offering of convertible notes and warrants, under which it issued $302,353
of convertible promissory notes for consideration of $257,000, the difference between the proceeds from the notes and principal
amount consists of $45,353 of original issue discount. The notes are convertible at an initial conversion price of $0.20 per share
any time after issuance thereby having an embedded beneficial conversion feature. The note holders were also issued market-related
warrants for 755,882 in shares of common stock. The warrants have an exercise price of $0.60 and a 1-year term. The beneficial
conversion feature and the warrants were recorded to additional paid-in-capital. The Company allocated the proceeds received to
the notes, the beneficial conversion feature and the warrants on a relative fair value basis at the time of issuance. The total
debt discount is amortized over the life of the notes to interest expense.
The beneficial conversion
feature was valued at the intrinsic value on the issuance date. The intrinsic value represents the difference between the conversion
price and the fair value of the common stock multiplied by the number of shares into which the note is convertible. We estimated
the fair value of the warrants on the issue date using a Black-Scholes pricing model with the following assumptions:
|
|
Warrants
three months
ended March 31, 2015 |
|
Expected term |
|
|
1 year |
|
Volatility |
|
|
180.15-185.71 |
% |
Risk Free Rate |
|
|
0.18-0.22 |
% |
The proceeds of the
Notes were allocated to the components as follows:
| |
Proceeds allocated at issue date | |
Private Offering Notes | |
$ | 197,521 | |
Private Offering Warrants | |
| 46,097 | |
Beneficial Conversion feature | |
| 13,382 | |
Total | |
$ | 257,000 | |
During the quarter
ended June 30, 2015, a holder of Series B-2 OID convertible notes and warrants delivered to the Company a notice of conversion
related to the Series B-2 OID convertible notes, with a principal amount of $5,882. In the quarter ended September 30, 2015, the
Company issued 29,410 shares due related to the conversion notice.
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
During the quarter
ended September 30, 2015, the Company did an additional private offering of convertible notes and warrants, under which it issued
$705,882 of convertible promissory notes for consideration of $600,000, the difference between the proceeds from the notes and
principal amount consists of $105,882 of original issue discount. The notes are convertible at an initial conversion price of $0.25
per share any time after issuance thereby having an embedded beneficial conversion feature. The note holders were also issued market-related
warrants for 1,411,764 in shares of common stock. The warrants have an exercise price of $0.60 and a 1-year term. The beneficial
conversion feature and the warrants were recorded to additional paid-in-capital. The Company allocated the proceeds received to
the notes, the beneficial conversion feature and the warrants on a relative fair value basis at the time of issuance. The total
debt discount is amortized over the life of the notes to interest expense.
The beneficial conversion
feature was valued at the intrinsic value on the issuance date. The intrinsic value represents the difference between the conversion
price and the fair value of the common stock multiplied by the number of shares into which the note is convertible. We estimated
the fair value of the warrants on the issue date using a Black-Scholes pricing model with the following assumptions:
| |
Warrants three months ended September 30, 2015 | |
Expected term | |
| 1 year | |
Volatility | |
| 171.36 | % |
Risk Free Rate | |
| 0.28 | % |
The proceeds of the
Notes were allocated to the components as follows:
| |
Proceeds allocated at issue date | |
Private Offering Notes | |
$ | 342,857 | |
Private Offering Warrants | |
| 120,000 | |
Beneficial Conversion feature | |
| 137,143 | |
Total | |
$ | 600,000 | |
Tonaquint 9% Original Issue Discount Convertible Notes
and Warrants
During the quarter
ended September 30, 2013, the Company entered into a securities purchase agreement with Tonaquint, Inc., under which it was issued
a $112,500 convertible promissory note in consideration for $100,000, the difference between the proceeds from the Note and the
principal amount consisted of a $10,000 original issue discount and a carried transaction expense of $2,500. The original issue
discount was being amortized over the life of the note. The note was convertible at an initial conversion price of $0.30 per share
at any time, and contained a “down-round protection” feature that requires the valuation of a derivative liability
associated with the note. The note bore interest at 7% and was due in May 2014. Tonaquint was also issued a market-related warrant
for $112,500 in shares of common stock with a “cashless” exercise feature. The warrant had a $0.35 exercise price,
a 5-year term and included a “down-round protection” feature that required it to be classified as a liability rather
than as equity.
During the first quarter
of 2014 the Company executed a debt settlement agreement with Tonaquint related to the note and warrant. The warrant was settled
during the first quarter of 2014 for a cash payment of $98,000, resulting in a loss of $98,000. The note was settled during the
second quarter of 2014 for cash payments totaling $144,000 ($20,000 paid in the first quarter of 2014 and $124,000 paid in the
second quarter of 2014). Because the execution of the debt settlement agreement in the first quarter of 2014 resulted in a significant
modification of the original terms of the note agreement, the Company adjusted the carrying value of the note in the first quarter
of 2014 and recorded a related loss of approximately $34,000.
Southridge
During 2013, the Company
issued a six-month $12,000 convertible note payable to Southridge to cover legal expenses as part of the LPA. The convertible note
was convertible into the Company’s common stock at the greater of $0.25 or 85% of the average closing bid price during the
five (5) trading days prior to conversion and was due in June 2014.
During the third quarter
of 2014, the Company issued to Southridge 50,000 shares in exchange for and in full satisfaction for the note and recorded a $5,500
loss upon conversion of the note.
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
12. SHAREHOLDERS’ DEFICIENCY
Stock Option Plan
On May 2, 2011 the
Company adopted and executed the Employees’ Directors’ and Consultants Stock Option Plan (the “Plan”).
During the three months ended March 31, 2015, the Company granted 50,000 options to non-employee directors which were fully vested
upon issuance. During the three months ended March 31, 2014, the Company granted 42,500 options to non-employee directors which
were fully vested upon issuance. During the three months ended June 30, 2014, the Company granted 320,000 options to employees.
20% of the options vested upon issuance and the remaining options vest ratable over a four (4) year period. No options were granted
during the three months ended September 30, 2014. During the three months ended September 30, 2015, the Company granted 300,000
options to employees. 20% of the options vested upon issuance and the remaining options vest ratable over a four (4) year period.
We estimated the fair
value of each option on the grant date using a Black-Scholes option-pricing model with the following weighted average assumptions:
|
|
Nine -
months ended |
|
|
Nine -
months ended |
|
|
|
September 30, 2015 |
|
|
September 30, 2014 |
|
Dividend yield (1) |
|
|
0.00 |
% |
|
|
0.00 |
% |
Expected volatility (2) |
|
|
159.8-164.5 |
% |
|
|
118.5-122.4 |
% |
Risk-free interest rates (3) |
|
|
1.61 |
% |
|
|
1.19-1.72 |
% |
Expected lives (2) |
|
|
5.0 YEARS |
|
|
|
4.0-5.0YEARS |
|
| (1) | We
have not paid cash dividends on our common stock since 1981, and currently do not have plans to pay or declare cash dividends.
Consequently, we used an expected dividend rate of zero for the valuations. |
| (2) | Estimated
based on our historical experience. Volatility was based on historical experience over a period equivalent to the expected life
in years. |
| (3) | Based
on the U.S. Treasury constant maturity interest rate with a term consistent with the expected life of the options granted. |
During the nine months
ended September 30, 2015, the Company recognized expense of $7,963 for stock options issued to directors and recognized expense
of $25,006 and $41,218, respectively, for the three and nine months ended September 30, 2015, for stock options issued to employees.
During the nine months
ended September 30, 2014, the Company recognized expense of $11,178 for stock options issued to directors and recognized expense
of $8,062 and $38,007, respectively, for the three and nine months ended September 30, 2014, for stock options issued to employees.
Preferred Stock
Holders of 5% preferred
stock are entitled to receive, if, as, and when declared by the Board of Directors, out of funds legally available therefore, preferential
non-cumulative dividends at the rate of $1.25 per share per annum, payable quarterly, before any dividends may be declared or paid
upon or other distribution made in respect of any share of common stock. The 5% preferred stock is redeemable, in whole at any
time or in part from time to time, on 30 days' notice, at the option of the Company, at a redemption price of $25. In the event
of voluntary or involuntary liquidation, the holders of preferred stock are entitled to $25 per share in cash before any distribution
of assets can be made to holders of common stock.
Each share of 5% preferred
stock is entitled to one vote. Holders of 5% preferred stock have no preemptive or conversion rights. The preferred stock is not
registered to be publicly traded.
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
The rights of the Series
C Convertible Preferred Stock are as follows:
|
a) |
Dividend rights – The shares of Series C Convertible Preferred Stock accrue a 5% cumulative dividend on a quarterly basis and is payable on the last day of each fiscal quarter when declared by the Company’s Board. As of September 30, 2015, dividends declared were $98,473, of which $4,726 and $14,024, respectively, were declared during the three and nine months ended September 30, 2015 and $79,726 have not been paid and are shown in accrued and other liabilities at September 30, 2015. |
|
b) |
Voting rights – Holders of these shares of Series C Convertible Preferred Stock shall have voting rights equivalent to 1,000 votes per $1,000 par value Series C Convertible Preferred share voted together with the shares of Common Stock |
|
c) |
Liquidation rights – Upon any liquidation these Series C Convertible Preferred Stock shares shall be treated as equivalent to shares of Common stock to which they are convertible. |
|
d) |
Conversion rights – Holder has right to convert each share of Series C Convertible Preferred Stock at any time into shares of the Company's common stock at a conversion price for each share of common stock equal to 85% of the lower of (a) the closing market price at the date of notice of conversion or (b) the mid-point of the last bid price and the last ask price on the date of the notice of conversion. The variable conversion feature creates an embedded derivative that was bifurcated from the Series C Convertible Preferred Stock on the date of issuance and was recorded at fair value. The derivative liability will be recorded at fair value on each reporting date with any change recorded in the Statement of Operations as an unrealized (gain) loss on derivative instrument. |
The Company recorded
a convertible preferred stock derivative liability of $107,871 and $66,177, respectively, associated with the 375 shares of Series
C Convertible Preferred Stock outstanding at September 30, 2015 and December 31, 2014.
The Company has classified
the Series C Convertible Preferred Stock as a liability at September 30, 2015 and December 31, 2014 because the variable conversion
feature may require the Company to settle the conversion in a variable number of its common shares.
Common Stock
During the quarter
ended March 31, 2014, the Company did a private offering of its common stock and warrants, for consideration of $500,000. 2,500,000
shares of common stock were issued at a per share price of $0.20. The common stock holders were also issued warrants to purchase
1,250,000 shares of common stock. The warrants have an exercise price of $0.60 and a 3-year term. The warrants were recorded to
additional paid-in-capital.
During the quarter
ended June 30, 2014, the Company did an additional private offering of its common stock and warrants, for consideration of $170,000.
850,000 shares of common stock were issued at a per share price of $0.20. The common stock holders were also issued warrants to
purchase 425,000 shares of common stock. The warrants have an exercise price of $0.60 and a 3-year term. The warrants were recorded
to additional paid-in-capital.
On August 14, 2014
the shareholders approved an amendment to the Company’s certification of incorporation to effect up to a one-for-ten reverse
stock split (the “reverse Stock Split” of the Company’s issued and authorized outstanding common stock. The Board
of Directors, in its sole discretion, has discretion to implement the Reverse Stock Split. As of February 24, 2016, the Board of
Directors has not implemented the Reverse Stock Split.
During the quarter
ended September 30, 2014, the Company did an additional private offering of its common stock and warrants, for consideration of
$232,000. 1,160,000 shares of common stock were issued at a per share price of $0.20. The common stock holders were also issued
warrants to purchase 580,000 shares of common stock. The warrants have an exercise price of $0.60 and a 3-year term. The warrants
were recorded to additional paid-in-capital.
During the quarter
ended March 31, 2015, the Company issued 500,000 shares with a fair value of $80,000 to an advisory firm for consulting services.
The Company is amortizing the $80,000 over the service period and recorded $20,000 of expense in the quarter ended September 30,
2015 and $60,000 of expense in the nine months ended September 30, 2015.
During the quarter
ended March 31, 2015, the Company issued 120,000 shares to an advisory firm for consulting services. The shares vested in two tranches,
with 60,000 shares vesting in the quarter ended December 31, 2014 and remaining 60,000 shares vesting in the quarter ended March
31, 2015. The Company recorded consulting expenses of $10,800 in the quarter ended December 31, 2014 and $27,600 of consulting
expenses in the quarter ended March 31, 2015. In each instance, the expense was based on the fair value on the vesting date.
During the quarter
ended March 31, 2015, the Company issued 333,333 stock warrants for consulting services performed and recorded consulting expense
of $75,000 for the fair value of the warrants.
During the quarter
ended March 31, 2015, the Company did a private offering of its common stock and warrants, for consideration of $75,000. 375,000
shares of common stock were issued at a per share price of $0.20. The common stock holders were also issued warrants to purchase
187,500 shares of common stock. The warrants have an exercise price of $0.60 and a 3-year term. The warrants were recorded to additional
paid-in-capital.
During the quarter
ended June 30, 2015, the Company did an additional private offering of its common stock and warrants, for consideration of $290,000.
1,450,000 shares of common stock were issued at a per share price of $0.20. The common stock holders were also issued warrants
to purchase 725,000 shares of common stock. The warrants have an exercise price of $0.60 and a 3-year term. The warrants were recorded
to additional paid-in-capital.
On October 15, 2015
the shareholders approved an increase in the number of authorized shares of common stock from 40 million to 100 million.
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
During the three months
ended March 31, 2015 and 2014, the Company issued 12,500 and 10,625 shares of its common stock to non-employee directors under
its Director Compensation Plan. The Company recorded expense of $2,125 and $4,038 for director stock compensation expense in the
three months ended March 31, 2015 and 2014. No shares were issued during the three months ended September 30, 2015 and 2014. Additionally,
no expense was recorded in the three months ended September 30, 2015 and 2014.
| 13. | CONTRACTUAL OBLIGATIONS AND CONTINGENCIES |
As of September 30,
2015, the Company and its majority owned subsidiary, VVI, have remaining obligations, contingent upon receipt of certain revenues,
to repay up to $165,788 and $198,334, respectively, in consideration of grant funding received in 1994 and 1995. The
Company also is obligated to pay at the rate of 7.5% of its revenues, if any, from transferring rights to certain inventions supported
by the grant funds. VVI is obligated to pay at rates of 1.5% of its net sales of supported products or 15% of its revenues
from licensing supported products, if any.
Contingencies –
Litigation
Tim Conley (case
pending) - On August 18, 2014, notice was issued to the Company that on June 23, 2014, Timothy Conley (the “Plaintiff”)
filed a complaint against the Company, in the United States District Court for the District of Rhode Island. The complaint alleges
that the Company’s former acting interim CEO, Johnnie Johnson, and Plaintiff entered into an agreement whereby the Company
agreed to make payments to Plaintiff. Among other allegations, Plaintiff claims that the Company’s nonpayment to Plaintiff
constitutes a breach of contract. The Company believes it has meritorious defenses to the allegations and the Company intends to
vigorously defend against the litigation.
GEOMC (case
pending) - On August 22, 2014, GEOMC filed a complaint against the Company in the United States District Court for the
District of Connecticut. The complaint alleges that the Company and GEOMC entered into a security agreement whereby in exchange
for GEOMC’s sale and delivery of the Scrambler Therapy devices (the “Devices”), the Company would grant GEOMC
a security interest in the Devices. Among other allegations, GEOMC claims that the Company has failed to comply with the terms
of the security agreement and seeks an order to the Court to replevy the Devices or collect damages. The Company believes it has
meritorious defenses to the allegations and the Company intends to vigorously defend against the litigation. On February 4, 2016,
the Company announced that it is discussing a settlement with GEOMC, however, to date, no settlement has been reached.
Summary –
We may be a party to other legal actions and proceedings from time to time. We are unable to estimate legal expenses or losses
we may incur, if any, or possible damages we may recover, and we have not recorded any potential judgment losses or proceeds in
our financial statements to date. We record expenses in connection with these suits as incurred.
An unfavorable resolution
of any or all matters, and/or our incurrence of significant legal fees and other costs to defend or prosecute any of these actions
and proceedings may, depending on the amount and timing, have a material adverse effect on our consolidated financial position,
results of operations or cash flows in a particular period.
PART I. FINANCIAL INFORMATION (Continued)
CALMARE THERAPEUTICS INCORPORATED AND
SUBSIDIARY
The Company’s
Distribution Rights, Marineo and Delta
On April 8, 2014, Mr.
Giuseppe Marineo, Delta Research and Development (“Delta”), Mr. Marineo’s research company, and Delta International
Services and Logistics (“DIS&L”), Delta’s commercial arm in which Mr. Marineo is the sole beneficiary of
all proceeds as its founder and sole owner (collectively the “Group”), issued a press release (the “Group’s
Press Release”) regarding the Company stating that the Company did not have authority to sell, distribute and manufacture
the Calmare Device as an exclusive agent of the Group. The Company issued a corporate response in a press release dated April 11,
2014 stating that the Group’s Press Release was inaccurate and, as assured by the wire service, had the Group’s Press
Release purged from the wire services’ foreign desk.
This issue between
the Company and the Group is over the validity of the 2012 Amendment to a Sales and Representation Agreement which, if valid and
enforceable, may have compromised the Company’s rights to sell, distribute and manufacture the Calmare Device as an exclusive
agent of the Group in the global marketplace, especially in the European, Middle Eastern and North African (“EMENA”)
territory which was responsible for approximately 70% of gross Calmare Device sales in 2011. However, the Company believes that
the 2012 Amendment is neither valid nor enforceable as it was never duly signed or authorized and subsequently deemed null and
void as so disclosed on April 16, 2014 in the Form 10-K filing. Therefore, the Company’s rights are determined by the 2011
Amendment which provides the Company with the exclusive rights to manufacture and sell the Calmare Device worldwide using the Technology.
On April 16, 2014,
counsel for the Group (“Group Counsel”) sent a cease and desist letter (“Cease and Desist Letter”) to the
Company, requesting a confirmation that the Company would no longer hold itself out as an agent of the Group permitted to sell,
distribute and manufacture the Calmare Device world-wide including the EMENA territory.
The Company responded
on April 25, 2014 to the Cease and Desist Letter, disputing Group Counsel’s interpretation of the events surrounding the
execution of the 2012 Amendment. At this time, the Company continues to work to find a reasonable and amicable resolution to the
situation.
Unsigned Agreements
The Company uses two
unrelated firms to provide marketing and investor relations services, CME Acuity (“CMEA”) and Legend Capital Management
(“LCM”), respectively. The LCM and CMEA agreements were not signed due to an inability to come to final terms due to
certain nuances in either agreement that included but were not limited to assignment of human capital and allowable performance
based bonus(es). However, from the start date until September 30, 2015, the respective firms were being compensated for services
rendered on a “pay-as-we go” basis (the “Arrangement”). The aforementioned Arrangement is expected to continue
for the next few consecutive quarters until such time as their agreements can be consummated.
| 14. | RELATED PARTY TRANSACTIONS |
Our Board of Directors
determined that when a director's services are outside the normal duties of a director, we compensate the director at the rate
of $1,000 per day, plus expenses, which is the same amount we pay a director for attending a one-day Board meeting. We
classify these amounts as consulting expenses, included in personnel and consulting expenses.
At September 30, 2015,
$2,598,980 of the outstanding Notes payable were Notes payable to related parties; $2,498,980 to the Chairman of the Board and
$100,000 to another director.
On September 15, 2015,
the Company announced the appointment of Stephen J. D’Amato, M.D. as chief medical officer of the Company. During 2010, Calmar
Pain Relief, LLC, purchased 10 Calmare devices from the Company for an aggregate purchase price of $550,000. Additionally, during
2015 and 2014, Calmar Pain Relief purchased certain supplies from the Company. Dr. D’Amato is one of the managing members
of Calmar Pain Relief, LLC.
On October 15, 2015,
the Company entered into a consulting agreement with VADM Robert T. Conway, Jr., U.S. Navy, (Ret) (the “Admiral”),
a member of the Company’s Board of Directors. The agreement is for one year and includes compensation of a monthly retainer
fee of $7,500 and a five year warrant to purchase 167,000 shares of common stock of the Company, fully vested on the date of issuance,
at a strike price of $.60 per share with an aggregate estimate fair value of $33,734. As a result of this agreement, the Board
of Directors has determined that the Admiral is no longer an independent director of the Company.
From October 1, 2015
to December 18, 2015, the Company obtained additional funding, including $400,000 of hybrid debt funding. From October 1, 2015
to December 18, 2015, the Company did a private offering of convertible notes and warrants, under which it issued $470,588 of convertible
promissory notes for consideration of $400,000, the difference between the proceeds from the notes and principal amount consists
of $70,588 of original issue discount. The notes are convertible at a conversion price of $0.20 per share. The note holder was
also issued market-related warrants for 470,588 in shares of common stock. The warrants have an exercise price of $0.60 and a 1-year
term.
On January 8, 2016,
the Board of Directors of the Company determined that it would not be continuing to employ Ian Rhodes as the Company’s Executive
Vice President and Chief Financial Officer. Mr. Rhodes’ termination from employment was effective on January 8, 2016. Mr.
Rhodes termination did not result from disagreement with the Company on any matter relating to the Company’s operations,
policies or practices. On January 11, 2016, the Company appointed Thomas P. Richtarich as Chief Financial Officer of the Company.
Mr. Richtarich served as a consultant to the Company prior to being hired as the Company’s Chief Financial Officer. The Company
does not currently have an employment agreement in place with Mr. Richtarich. However, the Company will continue to provide Mr.
Richtarich with the compensation he received as a consultant equal to $9,500 per month plus expenses.
On January 15,
2016, the Company appointed Dr. Christine Chansky, M.D., J.D., F.C.L.M. as its chief regulatory officer (CRO). As part of her
duties, she will spearhead all of the Clinical studies sponsored by the Company and oversee all global regulatory issues
related to the Company’s medical device practice.
On February 18, 2016,
the Company announced it has been issued a general supply order contract from the U.S. Government (GSA contract number #V797P-4300B).
The Company estimates this contract will total $15 million over the next 60 months.
Item 2. Management's Discussion and Analysis of
Financial Condition and Results of Operations
Forward-Looking Statements
Statements about our
future expectations are “forward-looking statements” within the meaning of applicable Federal Securities Laws, and
are not guarantees of future performance. When used in herein, the words “may,” “will,” “should,”
“anticipate,” “believe,” “intend,” “plan,” “expect,” “estimate,”
“approximate,” and similar expressions are intended to identify such forward-looking statements. These statements involve
risks and uncertainties inherent in our business, including those set forth in Item 1A under the caption "Risk Factors,"
in our most recent Annual Report on Form 10-K for the year ended December 31, 2014, filed with the Securities and Exchange Commission
(“SEC”) on June 24, 2015, and other filings with the SEC, and are subject to change at any time. Our actual results
could differ materially from these forward-looking statements. We undertake no obligation to update publicly any forward-looking
statement.
Overview
Calmare Therapeutics
Incorporated (the “Company”) was incorporated in Delaware in 1971 as Competitive Technologies, Inc., succeeding an
Illinois corporation incorporated in 1968. The Company and its majority-owned subsidiary (collectively, "we,” “our,”
or “us”), is a medical device company developing and commercializing innovative products and technologies for chronic
neuropathic pain and wound care affliction patients. The Company’s flagship medical device, the Calmare® Pain
Therapy Device (the “Calmare Device”), is the world’s only non-invasive and non-addictive modality that can successfully
treat chronic, neuropathic pain.
In 2007, the Company
secured the exclusive, worldwide rights to the patented, chronic pain reduction technology (the “Technology”) behind
the Company’s flagship medical device – the Calmare Device. The Company’s 2007 agreement (the “2007 Agreement”)
with Giuseppe Marineo, an inventor of the Technology, and Delta Research and Development (“Delta”), authorized the
Company to manufacture and sell worldwide the Calmare Device developed from the patented Technology. The 2007 Agreement was amended
in 2011 (the “2011 Amendment”) to provide the Company with exclusive rights to the Technology through March 31, 2016.
In July 2012, the Company attempted to negotiate a five-year extension to the agreement with Marineo and Delta (the “2012
Amendment”). However, the Company believes that the 2012 Amendment is neither valid nor enforceable as it was never duly
signed or authorized and subsequently deemed null and void. Therefore, the Company’s rights are determined by the 2011 Amendment
which provides the Company with the exclusive rights to manufacture and sell the Calmare Device worldwide using the Technology.
(see the Company’s Distribution Rights, Marineo and Delta in Footnote 13. CONTRACTUAL OBLIGATIONS AND CONTINGENCIES
and below)
Since 2011, the Company
has controlled the sales process for the Calmare Device. We are the primary obligor, responsible for delivering devices as well
as training our customers in the proper use of the Calmare Device. We deal directly with customers, setting pricing and providing
training, contribute to the development, new specifications and changes thereto, select and contract with manufacturing partners,
and retain significant credit risk for amounts billed to customers. Therefore, all product sales are recorded following a gross
revenue methodology. We record in product sales the total funds earned from customers and record the costs of the Calmare Device
as cost of product sales, with gross profit from product sales being the result.
The Technology supporting the Calmare Device has patent protection in Italy and the United States. Additional applications for
patents have been filed internationally and are pending approval. The Calmare Device has CE Mark certification from the European
Union as well as U.S. FDA 510(k) clearance.
In June 15, 2010, the
Company became a government contractor and was granted its first General Services Administration (“GSA”) contract (V797P-4300B)
from the U.S. Veterans Administration (the “VA”) for Calmare Devices.
Effective August 20,
2014, the Company changed its name from Competitive Technologies, Inc. to Calmare Therapeutics Incorporated.
The Company’s
Distribution Rights, Marineo and Delta
On April 8, 2014, Mr.
Giuseppe Marineo, an inventor of the Technology, and Delta Research and Development (“Delta”), Mr. Marineo’s
research company, and Delta International Services and Logistics (“DIS&L”), Delta’s commercial arm in which
Mr. Marineo is the sole beneficiary of all proceeds as its founder and sole owner (collectively the “Group”), issued
a press release (the “Group’s Press Release”) regarding CTI, stating that the Company did not have authority
to sell, distribute and manufacture the Calmare Device as an exclusive agent of the Group. CTI issued a corporate response in a
press release dated April 11, 2014 stating that the Group’s Press Release was inaccurate and has since been purged by the
overseeing body of wire services.
This issue between
the Company and the Group is over the validity of a 2012 Amendment to a Sales and Representation Agreement (the “Amendment”)
which, if valid and enforceable, may have compromised its rights to sell, distribute and manufacture the Calmare Device as an exclusive
agent of the Group in the global marketplace, especially in the European, Middle Eastern and North African (“EMENA”)
territory which was responsible for approximately 70% of gross Calmare Device sales in 2011. However, the Company believes that
the Amendment is neither valid nor enforceable as it was never duly signed or authorized and subsequently deemed null and void.
Therefore, the parties’ rights are determined by an earlier agreement whereby the Company still possesses the authority to
sell, distribute and manufacture Calmare Devices as a world-wide exclusive agent of the Group.
On April 16, 2014,
counsel for the Group (“Group Counsel”) sent a cease and desist letter (“Cease and Desist Letter”) to the
Company, requesting a confirmation that the Company would no longer hold itself out as an agent of the Group permitted to sell,
distribute and manufacture Calmare Devices world-wide including the EMENA territory.
The Company responded
on April 25, 2014 to the Cease and Desist Letter, disputing Group Counsel’s interpretation of the events surrounding the
execution of the Amendment. At this time, the Company continues to work to find a reasonable and amicable resolution to the situation.
Presentation
All amounts in this
Item 2 are rounded to the nearest thousand dollars.
The following discussion
and analysis provides information that we believe is relevant to an assessment and understanding of our financial condition and
results of operations. This discussion and analysis should be read in conjunction with our Consolidated Financial Statements
and Notes thereto.
Results of Operations – Three months ended September
30, 2015 vs. three months ended September 30, 2014
Summary of Results
Our net loss, for the
quarter ended September 30, 2015, decreased to $1,063,000 or $0.04 per basic and diluted share as compared with a net loss of $1,229,000
or $0.05 per basic and diluted share for the comparable quarter of 2014. This net loss decrease is primarily attributable
to a $275,000 decrease in interest expense.
Revenue and Gross
Profit from Sales
Revenue from the
sale and shipment of Calmare Devices in the three months ended September 30, 2015, decreased $203,000 to $197,000 as compared
with $400,000 for the comparable quarter of 2014.
Cost of product
sales, in the three months ended September 30, 2015, decreased $187,000 to $60,000 as compared with $247,000 for the comparable
quarter of 2014. This decrease in cost of product sold is attributable to the decrease in sales as well as an increase in gross
margin.
Calmare Device sales,
in the three months ended September 30, 2015, decreased with the sale of two (2) Calmare Devices as compared with eight (8)
Device sales for the comparable quarter of 2014. Calmare Device sales for the three months ended September 30, 2015 were comprised
of two (2) U.S. private sector sales. Calmare Device sales for the three months ended September 30, 2014 were comprised of three
(3) U.S. private sector and five (5) international sales. International sales for the three months ended September 30, 2014 were
to distributors, and as such, had a lower sales price as compared to non-international sales.
Due to the relatively
long sales cycle for a Calmare Device, Calmare Device sales and related revenues and expenses can and will vary significantly from
quarter to quarter.
Other Revenue
Retained royalties,
in the three months ended September 30, 2015 of $2,000, decreased $18,000 compared to $20,000 in the three months ended September
30, 2014. The decrease is primarily the result of the timing of certain royalties that occurred in the three months ended December
31, 2015 as compared to the three months September 30, 2014.
Other income, for the
three months ended September 30, 2015, was $14,000, substantially unchanged as compared with $14,000 in the three months ended
September 30, 2014. Other income includes:
| |
Three Months Ended September 30, 2015 | | |
Three Months Ended September 30, 2014 | |
Training payments and the sale of supplies i.e., electrodes and cables for use with our Calmare Devices | |
$ | 8,000 | | |
$ | 8,000 | |
Rental income from customers who were renting Calmare Devices from us | |
$ | 6,000 | | |
$ | 6,000 | |
Expenses
Total expenses decreased
$200,000 or 14% to $1,216,000 in the three months ended September 30, 2015 as compared with $1,416,000 in the three months ended
September 30, 2014.
Total operating
expenses increased $117,000 or 15% to $885,000 in the three months ended September 30, 2015 as compared with $768,000 in the
three months ended September 30, 2014.
Selling expenses
increased 79% or $30,000 to $68,000 in the three months ended September 30, 2015 as compared with $38,000 in the three months
ended September 30, 2014 and reflects increased commissions as a result of the change in the mix of sales between periods as well
as an increase in the commission per sale as a result of the increase in the average sale price per device between periods.
Personnel and consulting
expenses, in the three months ended September 30, 2015, increased 53% or $158,000 to $455,000 as compared with $297,000 in
the three months ended September 30, 2014. This increase is attributable to an increase in personnel costs as a result of increased
headcount and performance bonuses as well as increased consulting costs, primarily in the form of share-based compensation, related
to sales and corporate activities.
General and administrative
expenses, in the three months ended September 30, 2015, decreased 16% or $71,000 to $362,000 as compared with $433,000 in the
three months ended September 30, 2014. The decrease primarily relates to a decrease in corporate, sales and marketing
travel costs, partially offset by an increase in litigation costs.
Interest expense, in the
three months ended September 30, 2015, decreased $275,000 or 48% to $300,000 as compared with $575,000 in the three months ended
September 30, 2014 primarily as a result of the 1% additional monthly interest for the 90 day Convertible Notes recorded in Q3
2014 (see Note 11 of the Notes to Condensed Consolidated Interim Financial Statements).
Unrealized loss
on derivative instruments, in the three months ended September 30, 2015, was $31,000, as compared with a $68,000 loss in the
three months ended September 30, 2014. This reflects the impact of the movement in CTI’s share price on the Class
C Preferred Stock at the end of each period.
Results of Operations – Nine months ended September
30, 2015 vs. nine months ended September 30, 2014
Summary of Results
Our net loss, for the
nine months ended September 30, 2015, increased to $2,846,000 or $0.10 per basic and diluted share as compared with a net loss
of $2,746,000 or $0.12 per basic and diluted share for the comparable nine months of 2014. This net loss increase is
primarily attributable to $225,000 decrease in gross profit from product sales related to a $532,000 decrease in products sales,
coupled with a $281,000 increase in personnel and consulting expenses and general and administrative expenses, partially offset
by a $353,000 decrease in other expenses which is principally the result of a $178,000 decrease in loss on settlement of note and
warrant and loss on conversion of notes coupled with a $137,000 decrease in interest expense.
Revenue and Gross
Profit from Sales
Revenue from the
sale and shipment of Calmare Devices in the nine months ended September 30, 2015, decreased $532,000 to $405,000 as compared
with $937,000 for the comparable nine months of 2014.
Cost of product
sales, in the nine months ended September 30, 2015, decreased $308,000 to $108,000 as compared with $416,000 for the comparable
nine months of 2014. This decrease in cost of product sold is attributable to the decrease in sales as well as an increase in gross
margin.
Calmare Device sales,
in the nine months ended September 30, 2015, decreased with the sale of four (4) Calmare Devices as compared with fifteen (15)
Calmare Device sales for the comparable nine months of 2014. Calmare Device sales for the nine months ended September 30, 2015
were comprised of four (4) U.S. private sector sales. Calmare Device sales for the nine months ended September 30, 2014 were comprised
of nine (9) U.S. private sector, five (5) international and one (1) U.S. military sale. International sales for the nine months
ended September 30, 2014 were to distributors, and as such, had a lower sales price as compared to non-international sales.
Due to the relatively
long sales cycle for a Calmare Device, Calmare Device sales and related revenues and expenses can and will vary significantly from
quarter to quarter.
Other Revenue
Retained royalties,
in the nine months ended September 30, 2015 of $7,000, decreased $18,000 compared to $25,000 in the nine months ended September
30, 2014. The decrease is primarily the result of the timing of certain royalties that occurred in the three months ended December
31, 2015 as compared to the three months September 30, 2014.
Other income, for the
nine months ended September 30, 2015, was $39,000 as compared with $32,000 in the nine months ended September 30, 2014. Other
income includes:
| |
Nine Months Ended September 30, 2015 | | |
Nine Months Ended September 30, 2014 | |
Training payments and the sale of supplies i.e., electrodes and cables for use with our Calmare Devices | |
$ | 19,000 | | |
$ | 13,000 | |
Rental income from customers who were renting Calmare Devices from us | |
$ | 20,000 | | |
$ | 19,000 | |
Expenses
Total expenses decreased
$135,000 or 4% to $3,189,000 in the nine months ended September 30, 2015 as compared with $3,324,000 in the nine months ended September
30, 2014.
Total operating
expenses increased $218,000 or 10% to $2,454,000 in the nine months ended September 30, 2015 as compared with $2,236,000 in
the nine months ended September 30, 2014.
Selling expenses
decreased 36% or $64,000 to $112,000 in the nine months ended September 30, 2015 as compared with $176,000 in the nine months
ended September 30, 2014 and reflects decreased commissions as a result of decreased Devices sales.
Personnel and consulting
expenses, in the nine months ended September 30, 2015, increased 19% or $213,000 to $1,329,000 as compared with $1,116,000
in the nine months ended September 30, 2014. This increase is primarily related to an increase in consulting costs, principally
in the form of equity compensation (stock and warrants) in the areas of sales and investor advisory services, partially offset
by a decrease in personnel costs, principally related to incentive compensation.
General and administrative
expenses, in the nine months ended September 30, 2015, increased 7% or $68,000 to $1,012,000 as compared with $944,000 in the
nine months ended September 30, 2014. The increase primarily relates an increase in litigation costs, partially offset
by a decrease in corporate, sales and marketing travel costs.
Interest expense, in the
nine months ended September 30, 2015, decreased $102,000 or 13% to $691,000 as compared with $793,000 in the nine months ended
September 30, 2014 primarily as a result of the 1% additional monthly interest for the 90 day Convertible Notes recorded in Q3
2014 (see Note 11 of the Notes to Condensed Consolidated Interim Financial Statements).
Unrealized loss
on derivative instruments, in the nine months ended September 30, 2015, was $42,000, as compared with a $79,000 loss in the
nine months ended September 30, 2014. This reflects the impact of the movement in the Company’s share price on
the Class C Preferred Stock at the end of each period.
Financial Condition
and Liquidity
Our liquidity requirements
arise principally from our working capital needs, including funds needed to sell our current technologies and obtain new technologies
or products, and protect and enforce our intellectual property rights, if necessary. We fund our liquidity requirements with a
combination of cash on hand, debt and equity financing, sales of common stock and cash flows from operations, if any. At September
30, 2015, the Company had outstanding debt in the form of promissory notes with a total principal amount of $4,177,000 and a carrying
value of $3,839,000.
Our future cash requirements
depend on many factors, including results of our operations and marketing efforts, results and costs of our legal proceedings,
and our equity financing. To achieve and sustain profitability, we are implementing a corporate reengineering effort,
which commenced on September 26, 2013 under the direction of the Company’s president & CEO, Mr. Conrad Mir. This plan
design will change the inherent design of the current distributor network and focus on opportunities within the US Departments
of Defense (the “DOD”) and Veterans Affairs (“VA”), and set out to upgrade the Company’s current
U.S. Food and Drug Administration (“FDA”) clearance designation for the Calmare Device to approval. Although we cannot
be certain that we will be successful in these efforts, we believe the combination of our cash on hand and revenue from executing
our strategic plan will be sufficient to meet our obligations of current and anticipated operating cash requirements.
In fiscal 2010, the
Company incorporated revenue from the sale of inventory into its revenue stream. That source of revenue is expected
to continue as sales of its Calmare Device continue to expand and other products are added to the Company's portfolio of technologies.
At September 30, 2015,
cash was $45,000, as compared with $6,000 at December 31, 2014. Net cash used in operating activities was $(1,136,000) for the
nine months ended September 30, 2015 as compared to $(779,000) for the nine months ended September 30, 2014, primarily reflecting
an increase in non-cash equity expenses and an increase in debt discount amortization. There was minimal investing activity year
to date in both 2015 and 2014. Net cash provided by financing activities was $1,180,000 for the nine months ended September 30,
2015 as compared to $770,000 for the nine months ended September 30, 2014, primarily as a result of the Company’s debt and
equity financing activities in both periods.
We currently have the
benefit of using a portion of our accumulated net operating losses (“NOLs”) to eliminate any future regular federal
and state income tax liabilities. We will continue to receive this benefit until we have utilized all of our NOLs, federal
and state. However, we cannot determine when and if we will be profitable enough to utilize the benefit of the remaining
NOLs before they expire.
Going Concern
The Company has incurred
operating losses since fiscal 2006 and has a working capital deficiency at September 30, 2015. During the three and
nine months ended September 30, 2015 and 2014, we had a significant concentration of revenues from sales of our Calmare Devices. We
continue to seek revenue from new and existing technologies or products to mitigate the concentration of revenues, and replace
revenues from expiring licenses on other technologies.
Although we have taken
steps to significantly reduce operating expenses going forward, even at these reduced spending levels, should the anticipated increase
in revenue from sales of Calmare Devices and other technologies not occur, the Company may not have sufficient cash flow to fund
operations through 2015 and into 2016. These conditions raise substantial doubt about the Company’s ability to continue as
a going concern.
The Company's continuation
as a going concern is dependent upon its developing recurring revenue streams sufficient to cover operating costs. The
Company does not have any significant individual cash or capital requirements in the budget going forward. If necessary,
the Company will meet anticipated operating cash requirements by further reducing costs, issuing debt and/or equity, and/or attempt
to pursuing sales of certain assets and technologies while we pursue licensing and distribution opportunities for our remaining
legacy portfolio of technologies. There can be no assurance that the Company will be successful in such efforts. Failure
to develop a recurring revenue stream sufficient to cover operating expenses could negatively affect the Company’s financial
position.
Notes Payable
Details of notes payable
as of September 30, 2015 are as follows:
|
|
Principal
Amount |
|
|
Carrying
Value |
|
|
Cash
Interest
Rate |
|
|
Common
Stock
Conversion
Price |
|
|
Maturity
Date |
90
day Convertible Notes (Chairman of the Board) |
|
$ |
2,498,980 |
|
|
$ |
2,498,980 |
|
|
|
6 |
% |
|
$ |
1.05 |
|
|
Various
2014 |
24
month Convertible Notes ($100,000 to Board member) |
|
|
225,000 |
|
|
|
225,000 |
|
|
|
6 |
% |
|
|
1.05 |
|
|
March 2014
– June 2014 |
Series
A-3 15% OID Convertible Notes and Warrants |
|
|
11,765 |
|
(1) |
|
14,353 |
|
(1) |
|
None |
|
|
|
0.25 |
|
|
January 2015 |
Series
B-1 OID Convertible Notes and Warrants |
|
|
80,000 |
|
|
|
65,104 |
|
|
|
None |
|
|
|
0.23 |
|
|
March 2017 |
Series
B-2 OID Convertible Notes and Warrants |
|
|
1,361,177 |
|
|
|
1,035,973 |
|
|
|
None |
|
|
|
0.20-0.25 |
|
|
Aug. 2015 –
July 2016 |
Notes
Payable, gross |
|
$ |
4,176,922 |
|
|
|
3,839,410 |
|
|
|
|
|
|
|
|
|
|
|
Less
LPA amount |
|
|
|
|
|
|
(485,980 |
) |
|
|
|
|
|
|
|
|
|
|
Notes
Payable, net |
|
|
|
|
|
$ |
3,353,430 |
|
|
|
|
|
|
|
|
|
|
|
| (1) | Includes $2,588 of accrued loss on conversion of OID note. |
90 day Convertible
Notes
The Company has issued
90-day notes payable to borrow funds from a director, now the chairman of our Board, as follows:
2013 | |
$ | 1,188,980 | |
2012 | |
| 1,210,000 | |
2011 | |
| 100,000 | |
Total | |
$ | 2,498,980 | |
These notes have been
extended several times and all bear 6.00% simple interest. A conversion feature was added to the Notes when they were
extended, which allows for conversion of the eligible principal amounts to common stock at any time after the six month anniversary
of the effective date – the date the funds are received – at a rate of $1.05 per share. Additional
terms have been added to all Notes to include additional interest 1% simple interest per month on all amounts outstanding for all
Notes if extended beyond their original maturity dates and to provide the lender with a security interest in unencumbered inventory
and intangible assets of the Company other than proceeds relating to the Calmare Device and accounts receivable.
Due to the Board’s
February 10, 2014 decision authorizing management to nullify certain actions taken by prior management, the additional terms noted
above were not approved and therefore, the additional interest for the extension of the Notes was not recorded. During 2014,
management has been in negotiations to modify the terms of the Notes. However, until those negotiations are resolved, the Company
has agreed to honor the additional terms and as such, the Company recorded additional interest of approximately $287,000 during
the nine months ended September 30, 2015, and has recorded additional interest in total of $906,000.
A total of $485,980
of the aforementioned notes issued between December 1, 2012 and March 31, 2013 fall under the liabilities purchase agreement with
ASC Recap, and are expected to be repaid using the process as described in Note 10. Because there can be no assurance
that the Company will be successful in completing this process, the Company retains ultimate responsibility for this debt, until
fully paid down. As a result, the Company continues to accrue interest on these notes and they remain convertible as
described above.
24 month Convertible
Notes
In March 2012, the
Company issued a 24-month convertible promissory note to borrow $100,000. Additional 24-month convertible promissory notes were
issued in April 2012 ($25,000) and in June 2012 ($100,000). All of the notes bear 6.00% simple interest. Conversion of the eligible
principal amounts to common stock is allowed at any time after at a rate of $1.05 per share.
As of February 24,
2016 the Company has not repaid the principal due on the March 2012 $100,000 note, the April 2012 $25,000 note or the June 2012
$100,000 note and is in default under the terms of the notes. As of September 30, 2015, there is also unpaid interest of $28,000
related to these notes.
Series A-3 15% Original
Issue Discount Convertible Notes and Warrants
During the quarter
ended March 31, 2014, the Company did a private offering of a third tranche of convertible notes and warrants, under which it issued
$64,706 of convertible promissory notes for consideration of $55,000, the difference between the proceeds from the notes and principal
amount consists of $9,706 of original issue discount. The notes are convertible at an initial conversion price of $0.25 per share
any time after issuance thereby having an embedded beneficial conversion feature.
The note holders were
also issued market-related warrants for 129,412 (third tranche) and 958,179 (all tranches) in shares of common stock. The warrants
have exercise prices that range from $0.40 to $0.60 and a term of 2 years. The beneficial conversion feature, if any, and the warrants
were recorded to additional paid-in-capital. The total debt discount is amortized over the life of the notes to interest expense.
During the quarter
ended June 30, 2014, certain holders of Series A-3 OID convertible notes and warrants delivered to the Company a notice of conversion
related to the Series A-3 OID convertible notes. Due to the timing of receipt of the notices by the Company, certain Note holders
(“Noteholders”) received their shares during the quarter ended June 30, 2014, while other Noteholders received or are
due to receive their shares after June 30, 2014. Additionally, the Company offered certain Noteholders an inducement to convert
their notes to shares. The inducement, when offered, provided Noteholders a conversion price of $0.20. All other original terms,
including the warrant terms, remained the same. Upon notice of conversion and irrespective of whether the shares were delivered
in the quarter ended June 30, 2014 or subsequent to June 30, 2014 to the Company: (i) accelerated and recognized as interest expense
in the current period any remaining discount, and (ii) recognized a loss for the fair value of the additional shares offered as
the conversion inducement.
During the quarter
ended March 31, 2015, certain holders of Series A-3 OID convertible notes and warrants delivered to the Company a notice of conversion
related to the Series A-3 OID convertible notes. Additionally, the Company offered certain Noteholders an inducement to convert
their notes to shares. The inducement, when offered, provided Noteholders a conversion price of $0.20. All other original terms,
including the warrant terms, remained the same. Upon notice of conversion Company: (i) accelerated and recognized as interest expense
in the current period any remaining discount and (ii) recognized a loss for the fair value of the additional shares offered as
the conversion inducement. As of February 24, 2016, the Company had not issued the shares due related to the conversion notice.
Series B-1 Original
Issue Discount Convertible Notes and Warrants
During the quarter
ended March 31, 2014, the Company did a private offering of convertible notes and warrants, under which it issued $80,000 of convertible
promissory notes for consideration of $65,000, the difference between the proceeds from the notes and principal amount consists
of $15,000 of original issue discount. The notes are convertible at an initial conversion price of $0.35 per share any time after
issuance thereby having an embedded beneficial conversion feature. The note holders were also issued market-related warrants for
185,714 in shares of common stock. The warrants have an exercise price of $0.45 and a 4-year term. The beneficial conversion feature
and the warrants were recorded to additional paid-in-capital. The Company allocated the proceeds received to the notes, the beneficial
conversion feature and the warrants on a relative fair value basis at the time of issuance. The total debt discount is amortized
over the life of the notes to interest expense.
The Series B-1 OID notes include an anti-dilution provision
that if the Company issues more than 20 million shares of its common stock, subject to certain exceptions, the conversion price
of the notes and the conversion price of the warrants would be subject to an automatic pre-determined price adjustment. During
the quarter ended December 31, 2014 the Series B-1 OID noteholder and the Company agreed that this anti-dilution provision had
been triggered and the Series B-1 OID note share conversion price was adjusted down to $0.23 per share, which increased the number
of shares available upon conversion to 347,826. The anti-dilution provision in the Warrant changed the share purchase price downward
to $0.33 per share but did not change the number of shares available under the Warrant.
Series B-2 OID Convertible Notes and
Warrants
During the quarter
ended March 31, 2015, the Company did an additional private offering of convertible notes and warrants, under which it issued $302,353
of convertible promissory notes for consideration of $257,000, the difference between the proceeds from the notes and principal
amount consists of $45,353 of original issue discount. The notes are convertible at an initial conversion price of $0.20 per share
any time after issuance thereby having an embedded beneficial conversion feature. The note holders were also issued market-related
warrants for 755,882 in shares of common stock. The warrants have an exercise price of $0.60 and a 1-year term. The beneficial
conversion feature and the warrants were recorded to additional paid-in-capital. The Company allocated the proceeds received to
the notes, the beneficial conversion feature and the warrants on a relative fair value basis at the time of issuance. The total
debt discount is amortized over the life of the notes to interest expense.
During the quarter
ended June 30, 2015, a holder of Series B-2 OID convertible notes and warrants delivered to the Company a notice of conversion
related to the Series B-2 OID convertible notes, with a principal amount of $5,882. In the quarter ended September 30, 2015, the
Company issued 29,410 shares due related to the conversion notice.
During the quarter
ended September 30, 2015, the Company did an additional private offering of convertible notes and warrants, under which it issued
$705,882 of convertible promissory notes for consideration of $600,000, the difference between the proceeds from the notes and
principal amount consists of $105,882 of original issue discount. The notes are convertible at an initial conversion price of $0.25
per share any time after issuance thereby having an embedded beneficial conversion feature. The note holders were also issued market-related
warrants for 1,411,764 in shares of common stock. The warrants have an exercise price of $0.60 and a 1-year term. The beneficial
conversion feature and the warrants were recorded to additional paid-in-capital. The Company allocated the proceeds received to
the notes, the beneficial conversion feature and the warrants on a relative fair value basis at the time of issuance. The total
debt discount is amortized over the life of the notes to interest expense.
Capital requirements
We continue to seek
revenue from new technology licenses to mitigate the concentration of revenue, and replace revenue from expiring licenses. We
have created a new business model for appropriate technologies that allows us to move beyond our usual royalty arrangement and
share in the profits of distribution.
For 2015, we expect
our capital expenditures to be less than $100,000.
Contractual Obligations and Contingencies
Contingencies
Our directors, officers,
employees and agents may claim indemnification in certain circumstances.
Many of our license
and service agreements provide that upfront license fees, license fees and/or royalties we receive are applied against amounts
that our clients or we have incurred for patent application, prosecution, issuance and maintenance costs. If we incur
such costs, we expense them as incurred, and reduce our expense if we are reimbursed from future fees and/or royalties we receive. If
the reimbursement belongs to our client, we record no revenue or expense.
As of September 30,
2015, the Company and its majority-owned subsidiary, VVI, have remaining obligations, contingent upon receipt of certain revenue,
to repay up to $165,788 and $198,334, respectively, in consideration of grant funding received in 1994 and 1995. The
Company also is obligated to pay at the rate of 7.5% of its revenues, if any, from transferring rights to certain inventions supported
by the grant funds. VVI is obligated to pay at rates of 1.5% of its net sales of supported products or 15% of its revenues
from licensing supported products, if any.
Critical Accounting Estimates
There have been no
significant changes in our accounting estimates described under the caption “Critical Accounting Estimates” included
in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,”
in our Annual report on Form 10-K for the year ended December 31, 2014.
Item 3. Quantitative and Qualitative Disclosures
About Market Risk
Not applicable.
Item 4. Controls and Procedures
| (a) | Evaluation of disclosure controls and procedures |
Management evaluated
the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Securities Exchange Act
Rules 13a-15(e) and 15d-15(e)) as of September 30, 2014. Our disclosure controls and procedures are designed to ensure
that information required to be disclosed by the issuer in the reports that it files or submits under the Act (15 U.S.C. 78a et
seq.) is recorded, processed, summarized, and reported, within the time periods specified in the Commission’s rules and forms. Disclosure
controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be
disclosed by an issuer in the reports that it files or submits under the Act is accumulated and communicated to the issuer's management,
including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to
allow timely decisions regarding required disclosure. Based on this evaluation, management concluded that our disclosure
controls and procedures were effective as of September 30, 2015.
| (b) | Change in Internal Controls |
During the period
ending September 30, 2015, there were no changes in our internal control over financial reporting during that period that have
materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II – OTHER INFORMATION
Item 1. Legal Proceedings
Tim Conley (case
pending) - On August 18, 2014, notice was issued to the Company that on June 23, 2014, Timothy Conley (the “Plaintiff”)
filed a complaint against the Company, in the United States District Court for the District of Rhode Island. The complaint alleges
that the Company’s former acting interim CEO, Johnnie Johnson, and Plaintiff entered into an agreement whereby the Company
agreed to make payments to Plaintiff. Among other allegations, Plaintiff claims that the Company’s nonpayment to Plaintiff
constitutes a breach of contract. The Company believes it has meritorious defenses to the allegations and the Company intends to
vigorously defend against the litigation.
GEOMC (case pending) - On
August 22, 2014, GEOMC filed a complaint against the Company in the United States District Court for the District of Connecticut.
The complaint alleges that the Company and GEOMC entered into a security agreement whereby in exchange for GEOMC’s sale and
delivery of the Scrambler Therapy devices (the “Devices”), the Company would grant GEOMC a security interest in the
Devices. Among other allegations, GEOMC claims that the Company has failed to comply with the terms of the security agreement and
seeks an order to the Court to replevy the Devices or collect damages. The Company believes it has meritorious defenses to the
allegations and the Company intends to vigorously defend against the litigation. On February 4, 2016, the Company announced that
it is discussing a settlement with GEOMC, however, to date, no settlement has been reached.
Item 1A. Risk Factors
We are a smaller reporting company and are not required to provide
the information under this item.
Item 2. Unregistered Sales of Equity Securities and Use of
Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
On October 15, 2015,
the Company entered into a consulting agreement with VADM Robert T. Conway, Jr., U.S. Navy, (Ret) (the “Admiral”),
a member of the Company’s Board of Directors. The agreement is for one year and includes compensation of a monthly retainer
fee of $7,500 and a five year warrant to purchase 167,000 shares of common stock of the Company, fully vested on the date of issuance,
at a strike price of $.60 per share with an aggregate estimate fair value of $33,734. As a result of this agreement, the Board
of Directors has determined that the Admiral is no longer an independent director of the Company.
From October 1, 2015
to December 18, 2015, the Company obtained additional funding, including $400,000 of hybrid debt funding. From October 1, 2015
to December 18, 2015, the Company did a private offering of convertible notes and warrants, under which it issued $470,588 of convertible
promissory notes for consideration of $400,000, the difference between the proceeds from the notes and principal amount consists
of $70,588 of original issue discount. The notes are convertible at a conversion price of $0.20 per share. The note holder was
also issued market-related warrants for 470,588 in shares of common stock. The warrants have an exercise price of $0.60 and a 1-year
term.
On January 8, 2016,
the Board of Directors of the Company determined that it would not be continuing to employ Ian Rhodes as the Company’s Executive
Vice President and Chief Financial Officer. Mr. Rhodes’ termination from employment was effective on January 8, 2016. Mr.
Rhodes termination did not result from disagreement with the Company on any matter relating to the Company’s operations,
policies or practices. On January 11, 2016, the Company appointed Thomas P. Richtarich as Chief Financial Officer of the Company.
Mr. Richtarich served as a consultant to the Company prior to being hired as the Company’s Chief Financial Officer. The Company
does not currently have an employment agreement in place with Mr. Richtarich. However, the Company will continue to provide Mr.
Richtarich with the compensation he received as a consultant equal to $9,500 per month plus expenses.
On January 15, 2016,
the Company appointed Dr. Christine Chansky, MD, JD, FCLM, Board Certified as Chief Regulatory Officer of the Company. Dr.
Chansky’s appointment is subject to a sixty (60)-day trial period. The Company does not currently have an employment agreement
in place with Dr. Chansky; however, Dr, Chansky was provided with an offer letter, which sets certain key terms of her compensation.
The Company intends to enter into a formal employment agreement further memorializing the terms and conditions of Dr. Chansky’s
employment once the sixty (60)-day trial period has expired.
Under the terms set
forth in the offer letter, Dr. Chansky will receive base salary of $185, 000 per year and will be eligible to receive an annual
bonus equal to 40% of Dr. Chansky’s base pay and payable in a combination of cash and equity. Such annual bonus shall be
based on the achievement of certain defined goals and objectives. Additionally, the Company agreed to grant Dr. Chansky 300,000
warrants that will be subject to an equity plan that the Company intends to establish in the near term.
Christine Chansky,
MD, JD, FCLM, Board Certified, age 47, has held roles in pharmaceuticals, academia regulatory affairs and corporate operations
for over twenty years. From 2011 through 2015, Dr. Chansky served as Chief Regulatory Counsel and Chief Clinical Officer for a
researcher and manufacturer of biotherapeutic products with operations in Florida, New York and New Jersey where she was responsible
for the development and review of all regulatory strategies, submissions and compliance and clinical development plans, trial design,
launch campaigns and educational materials. Prior to this role, Dr. Chansky was also in private practice from 2010-2015 with Emergency
Medical Care NY & STAT Medical Associates in New York City, New York and also served as the Executive Director of Product Development-
Oncology, Immunotherapy for Advaxis, Inc. in North Brunswick, New Jersey from 2008-2010.
Dr. Chansky began
her professional career in various corporate, laboratory and research positions in medical affairs, research and development, regulatory
affairs and product development. Dr. Chansky received her B.A. from Georgetown University in 1990, M.D. from Georgetown University
School of Medicine in 1994 and J.D. from Seton Hall University School of Law in 2003. Dr. Chansky is currently licensed to practice
medicine in New York. Dr. Chansky will spend 100% percent of her time serving as the Company’s Chief Regulatory Officer.
There are no family
relationships between Dr. Chansky and any previous officers or directors of the Company.
There are no related
party transactions involving Dr. Chansky.
The Company has provided
Dr. Chansky with an offer letter setting forth certain key terms of her compensation. The Company intends to enter into a formal
employment agreement with Dr. Chansky following the expiration of the sixty (60)-day trial period. The Company will disclose the
terms of such employment agreement in a Current Report on Form 8-K once it has been entered into.
The foregoing description of the offer
letter is qualified in its entirety by the full text of the offer letter filed herewith as Exhibit 10.3 and incorporated herein
by reference.
On February 18, 2016, the Company announced it has been issued a general supply order contract from the
U.S. Government (GSA contract number #V797P-4300B). The Company estimates this contract will total $15 million over the next 60
months
Item 6. Exhibits
Exhibit No |
|
Description |
|
Filing Method |
3.1 |
|
Unofficial restated certificate of incorporation of the registrant as amended to date filed.(1) |
|
Incorporated by reference |
|
|
|
|
|
3.2 |
|
Bylaws of the registrant as amended effective October 14, 2005.(2) |
|
Incorporated by reference |
|
|
|
|
|
10.1 |
|
Securities Purchase Agreement with Tonaquint, Inc. dated July 16, 2013.(3) |
|
Incorporated by reference |
|
|
|
|
|
10.2 |
|
Equity Purchase Agreement with Southridge Partners II, L.P. dated September 10, 2013.(4) |
|
Incorporated by reference |
|
|
|
|
|
10.3 |
|
Offer Letter to Dr. Chansky, dated January 15, 2016 |
|
Filed herewith |
|
|
|
|
|
31.1 |
|
Certification by the Chief Executive Officer of Calmare Therapeutics Incorporated pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)). |
|
Filed herewith |
|
|
|
|
|
31.2 |
|
Certification by the Chief Financial Officer of Calmare Therapeutics Incorporated pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (Rule 13a-14(a) or Rule 15d-14(a)). |
|
Filed herewith |
|
|
|
|
|
32.1 |
|
Certification by the Chief Executive Officer of Calmare Therapeutics Incorporated pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350). |
|
Filed
herewith |
|
|
|
|
|
32.2 |
|
Certification by the Chief Financial Officer of Calmare Therapeutics Incorporated pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. 1350). |
|
Filed
herewith |
|
|
|
|
|
99.1 |
|
Press Release- Appointment of Dr. Chansky |
|
Filed herewith |
|
|
|
|
|
101.INS |
|
XBRL Instance Document |
|
Filed herewith |
|
|
|
|
|
101.SCH |
|
XBRL Taxonomy Schema |
|
Filed herewith |
|
|
|
|
|
101.CAL |
|
XBRL Taxonomy Calculation Linkbase |
|
Filed herewith |
|
|
|
|
|
101.DEF |
|
XBRL Taxonomy Definition Linkbase |
|
Filed herewith |
|
|
|
|
|
101.LAB |
|
XBRL Taxonomy Label Linkbase |
|
Filed herewith |
|
|
|
|
|
101.PRE |
|
XBRL Taxonomy Presentation Linkbase |
|
Filed herewith |
|
(1) |
Filed as Exhibit 4.1 to the registrant’s registration statement on Form S-8 with the SEC on April 1, 1998. |
|
(2) |
Filed as Exhibit 3.2 to the registrant’s Quarterly Report on Form 10-Q filed with the SEC on December 12, 2005. |
|
(3) |
Filed as Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the SEC on September 5, 2013. |
|
(4) |
Filed as Exhibit 10.1 to the registrant’s Current Report on Form 8-K filed with the SEC on September 11, 2013. |
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
CALMARE THERAPEUTICS INCORPORATED |
|
(the registrant) |
|
|
|
|
By |
/s/ Conrad Mir |
|
|
Conrad Mir |
|
|
President and Chief Executive Officer |
February 29, 2016 |
|
Authorized Signer (Duly Authorized Officer and Principal Executive Officer) |
|
|
|
|
By |
/s/ Thomas P. Richtarich |
|
|
Thomas P. Richtarich |
|
|
Chief Financial Officer |
February 29, 2016 |
|
Authorized Signer (Duly Authorized Officer and Principal Financial Officer) |
Exhibit 10.3
Conrad Mir
President & CEO
cmir@calmaretherapeutics.com
January 15, 2016
Christine Chansky, MD, JD
Westfield, NJ
christinechansky@aol.com
Re: Employment Term Sheet
Dear Dr.
Chansky;
As per our conversations, I
am pleased to confirm Calmare Therapeutics Incorporated’s (CTI) offer of employment as follows. Upon your approval, we will
draft a formal employment agreement which will include milestones as well as the following:
| 1) | Position Title: Chief Regulatory Officer of Calmare Therapeutics Incorporated |
| 2) | Trial Period: 60 (sixty) days from start date. |
| 3) | Base salary: $185,000 per annum. |
| 4) | Bonus: 40% of base, payable annually, subject to clearly meeting goals and objectives. Payment of the bonus will
be comprised of a cash and equity component. Specific goals and objectives will be submitted in the formal Employment
Agreement. In the interim, several milestones, integral to the position of CRO, are set forth below (See Objectives). |
| 5) | Incentive: You will be granted Three Hundred Thousand (300,000) incentive warrants (Incentive) that will be subject
to a new employee equity plan (Equity Plan) soon to be in effect by the CTI. Strike price and vesting will be subject the aforementioned
Equity Plan. |
| 6) | Benefits: If so desired, you will be enrolled in CTI’s benefit program for medical, dental and vision. Details of the
program will be submitted under separate cover. |
| 7) | Start Date: January 15, 2016. |
My sincerest regards, |
|
|
|
/s/ Conrad Mir |
|
Conrad Mir |
|
President & CEO |
|
Calmare Therapeutics Incorporated |
|
|
|
ACCEPTED: |
|
|
|
/s/ Dr. Christine Chansky 1/26/16 |
|
Dr. Christine Chansky, M.D., J.D. |
|
1375
Kings Highway East, Suite 400, Fairfield, CT 06824 • 203.368.6044 • Fax: 203.368.5399
www.calmaretherapeutics.com • www.calmarett.com
Cti - Letter Employment Agreement
- Chansky Md Jd -
01.15.16
January 25, 2016
Page 2
“Top 5” Objectives
| a) | Provide senior executive leadership regarding CTI’s medical
program and any and all issues related to the treatment of patients with the Calmare® Pain Therapy device as CTI’s
chief regulatory authority. |
| b) | Regulatory oversight and involvement in all medical matters, which include: medical policy and legal documentation; clinical
trials, pivotal studies, abstracts and related matters; corporate litigation and intellectual property issues; CTI’s Centers of
Excellence and its respective launches, roll-outs, human resources matters, et al.; medical device approval(s) and technologies;
and the similar duties. |
| c) | Internal and external interfacing with medical staff, the medical community and similarly inclined professionals on behalf
of CTI in conjunction with CTI’s chief medical officer. |
| d) | Interact and interface with the associated medical organizations, entities, institutions, et al, on behalf of the Company
and at the direction of the CEO to assure effective and efficient delivery of quality medical treatment and/or diagnoses consistent
with the mission and vision of CTI. |
| e) | Identify objectives, strategies and action plans to improve all aspects of the medical division of CTI in conjunction
with CTI’s CMO. |
Exhibit 31.1
CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Conrad Mir, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q of Calmare Therapeutics Incorporated; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have: |
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; |
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals; |
| (c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and |
| (d) | Disclosed in this report any change in the registrant’s internal control over financing reporting
that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s
board of directors (or persons performing the equivalent functions): |
| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize
and report financial information; and |
| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant’s internal control over financial reporting. |
By: |
/s/ Conrad Mir |
|
|
Conrad Mir |
|
|
Principal Executive Officer |
|
Dated: February 29, 2016
Exhibit 31.2
CERTIFICATION OF PRINCIPAL EXECUTIVE
OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT of 2002
In connection with the Quarterly Report
of Calmare Therapeutics Incorporated (the “Company”) on Form 10-Q for the period ended September 30, 2015 as filed
with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), Conrad Mir, Chief Executive
Officer of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:
| 1. | The Quarterly Report, fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Quarterly Report fairly presents,
in all material respects, the financial condition and results of operations of the Company. |
By: |
/s/ Conrad Mir |
|
|
Conrad Mir |
|
|
Principal Executive Officer |
|
Dated: February 29, 2016
Exhibit 32.1
CERTIFICATION OF PRINCIPAL FINANCIAL
OFFICER
PURSUANT TO EXCHANGE ACT RULE 13a-14(a)/15d-14(a)
AS ADOPTED PURSUANT TO SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Thomas P. Richtarich, certify that:
| 1. | I have reviewed this Quarterly Report on Form 10-Q of Calmare Therapeutics Incorporated; |
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or
omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this
report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant
as of, and for, the periods presented in this report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining
disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
reporting (as defined in Exchange Act Rules 13-a-15(f) and 15d-15(f)) for the registrant and have: |
| (a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures
to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being
prepared; |
| (b) | Designed such internal control over financial reporting, or caused such internal control over financial
reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting
and the preparation of financial statements for external purposes in accordance with generally accepted accounting principals; |
| (c) | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented
in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and |
| (d) | Disclosed in this report any change in the registrant’s internal control over financing reporting
that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to
materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent
evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s
board of directors (or persons performing the equivalent functions): |
| (a) | All significant deficiencies and material weaknesses in the design or operation of internal control
over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize
and report financial information; and |
| (b) | Any fraud, whether or not material, that involves management or other employees who have a significant
role in the registrant’s internal control over financial reporting. |
By: |
/s/ Thomas P. Richtarich |
|
|
Thomas P. Richtarich |
|
|
Principal Financial Officer |
|
Dated: February 29, 2016
Exhibit 32.2
CERTIFICATION OF PRINCIPAL FINANCIAL
OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT of 2002
In connection with the Quarterly Report
of Calmare Therapeutics Incorporated (the “Company”) on Form 10-Q for the period ended September 30, 2015 as filed
with the Securities and Exchange Commission on the date hereof (the “Quarterly Report”), Thomas P. Richtarich, Chief
Financial Officer of the Company, certifies, pursuant to 18 U.S.C. section 1350 of the Sarbanes-Oxley Act of 2002, that:
| 1. | The Quarterly Report, fully complies with the requirements of Section
13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| 2. | The information contained in the Quarterly Report fairly presents,
in all material respects, the financial condition and results of operations of the Company. |
By: |
/s/ Thomas P. Richtarich |
|
|
Thomas P. Richtarich |
|
|
Principal Financial Officer |
|
Dated: February 29, 2016
Exhibit 99.1
Calmare
Therapeutics Incorporated Appoints Christine Chansky, M.D., J.D.,
F.C.L.M.,
Chief Regulatory Officer®
February 17, 2016 02:45
PM Eastern Standard Time
FAIRFIELD, Conn.—(BUSINESS
WIRE) — Calmare Therapeutics Incorporated, (OTCQB:CTTC) (CTI), the Calmare® chronic pain and
wound care company, has appointed Dr. Christine Chansky, M.D., J.D., F.C.L.M., chief regulatory officer (CRO) of Calmare Therapeutics.
As part of Dr. Chansky’s duties and responsibilities
as the Company’s chief regulatory officer and corporate
executive, she will spearhead all of CTI-sponsored
clinical studies, and oversee all global regulatory issues related to the Company’s medical device practice.
On being offered the opportunity to be CTI’s first
regulatory officer, Dr. Chansky said, “Working with the CTI team is
an exciting opportunity for
me to apply by regulatory and clinical knowledge to the continued development of CTl’s novel devices in order to improve patient
care. My clinical interests and expertise fit perfectly with the CTI portfolio.”
Dr. Chansky’s will discontinue her private medical
practice and devote all of her time to CTI.
“This
is a significant step forward for the Company,” said Calmare Therapeutics President & CEO Conrad Mir. “She will be
instrumental in establishing CTI as a medical device powehouse in the chronic neuropathic pain and wound ailment space.”
About Dr. Christine Chansky, M.D., F.C.L.M.
Dr. Chansky has been licensed, practicing physician
and attorney for over 20 years. She has a comprehensive background in global regulatory affairs and regulatory law with a proven
track of applying expertise in R&D, pharmacovigilance, regulatory, compliance, clinical development and global medical affairs.
Her multiple therapeutic expertise in immunotherapy, oncology, infectious disease and hematology, has allowed her to leverage her
extensive relationships with the U.S. Food and Drug Administration and resulted in the successful submissions of over fifteen (15)
investigational new drug applications (IND’s), new drug applications (NDA’s), and biologics license applications (BLA’s).
Prior to her new position with CTI, she served as
chief regulatory counsel and chief clinical officer for BioTest
Pharmaceuticals where she was
responsible for the development and review of all regulatory strategies, submissions and compliance, clinical development plans,
trial design, launch campaigns and educational materials. Contemporaneously, she was the medical director of her private medical
practice, Emergency Medical Care N.Y. & STAT Medical Associates in New York City. And before that, she had held senior executive
regulatory positions in such notable companies as Aventis (NYSE: SNY), Johnson & Johnson (NYSE: JNJ), Glaxo Wellcome (OTC:
GAXF) and Roche Holdings A.G. (OTC: RHHBY).
Dr. Chansky is a licensed Medical Doctor
in New York and a licensed attomey in New Jersey. She was an adjunct assistant professor of global regulatory affairs at Temple
University, and is Board Certified as a Fellow of the American College of Legal Medicine. She received her bachelor’s degree, magma
cum laude, from Georgetown University, and her medical degree from Georgetown University. Dr. Chansky received her law degree from Seton Hall University.
About the Company
Calmare Therapeutics Incorporated,
the Calmare Pain Mitigation Therapy™ company, researches, develops and commercializes chronic, neuropathic pain and wound
affliction devices. Our flagship medical device – the Calmare® Pain Therapy Device (the “Calmare Device”)
– is the world’s only non-invasive and non-addictive modality that can successfully treat chronic, neuropathic
pain. The Company holds a U.S. Food & Drug Administration 510k clearance designation on its flagship device, which grants
it the exclusive right to sell, market, research and develop the medical device in the United. Calmare Devices are commercially
sold to medical practices throughout the world. They are also found in U.S. military hospitals, clinics and on installations via
CTl’s General Services Administration (GSA) military contract (V797P-4300B).
Forward-Looking Statement
Certain statements contained
in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that
are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current
plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve
known and unknown risks and uncertainties that may cause the Company’s actual results in future periods to differ materially from
what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to
time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results,
levels of activity, performance or achievements.
www.calmaretherapeutics.com
Contacts
Calmare Therapeutics Incorporated
Conrad Mir, 203.368.6044
President and CEO
cmir@calmaretherapeutics.com
or
Catalyst Research Management
Marc Robins CFA, 503.445.2850
President
marc@catalystresearch.com
or
JV Public Relations
Janet Vasquez, 212.645.5498
Managing Director
jvasquez@jvprny.com
v3.3.1.900
X |
- DefinitionIf the value is true, then the document is an amendment to previously-filed/accepted document.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEnd date of current fiscal year in the format --MM-DD.
+ References
+ Details
Name: |
dei_CurrentFiscalYearEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gMonthDayItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.
+ References
+ Details
Name: |
dei_DocumentFiscalPeriodFocus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fiscalPeriodItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThis is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
+ Details
Name: |
dei_DocumentFiscalYearFocus |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:gYearItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
+ Details
Name: |
dei_EntityCommonStockSharesOutstanding |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionIndicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityCurrentReportingStatus |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
+ Details
Name: |
dei_EntityFilerCategory |
Namespace Prefix: |
dei_ |
Data Type: |
dei:filerCategoryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation 12B -Number 240 -Section 12b -Subsection 1
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
+ References
+ Details
Name: |
dei_EntityVoluntaryFilers |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.
+ References
+ Details
Name: |
dei_EntityWellKnownSeasonedIssuer |
Namespace Prefix: |
dei_ |
Data Type: |
dei:yesNoItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
|
Sep. 30, 2015 |
Dec. 31, 2014 |
Current Assets: |
|
|
Cash |
$ 44,819
|
$ 5,745
|
Receivables, net of allowance of $317,659 at September 30, 2015 and December 31, 2014 |
2,502
|
2,319
|
Inventory |
4,078,220
|
4,118,220
|
Prepaid expenses and other current assets |
61,853
|
253,102
|
Total current assets |
4,187,394
|
4,379,386
|
Property and equipment, net |
28,073
|
35,640
|
Security deposits |
15,000
|
15,000
|
TOTAL ASSETS |
4,230,467
|
4,430,026
|
Current Liabilities: |
|
|
Accounts payable |
1,545,804
|
1,346,138
|
Liabilities under claims purchase agreement |
1,995,320
|
1,995,320
|
Accounts payable, GEOMC |
4,182,380
|
4,182,380
|
Accrued expenses and other liabilities |
2,327,010
|
1,590,182
|
Notes payable |
3,288,326
|
2,536,830
|
Deferred revenue |
6,400
|
19,686
|
Series C convertible preferred stock derivative liability |
107,871
|
66,177
|
Series C convertible preferred stock liability |
375,000
|
375,000
|
Total current liabilities |
13,828,111
|
12,111,713
|
Note payable - long-term |
$ 65,104
|
$ 56,659
|
Commitments and Contingencies |
|
|
Shareholders' deficit: |
|
|
Common stock, $.01 par value, 40,000,000 shares authorized, 28,395,888 shares issued and outstanding at September 30, 2015 and 25,908,978 shares issued and outstanding at December 31, 2014 |
$ 283,958
|
$ 259,089
|
Capital in excess of par value |
48,531,399
|
47,634,857
|
Accumulated deficit |
(58,538,780)
|
(55,692,967)
|
Total shareholders' deficit |
(9,662,748)
|
(7,738,346)
|
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT |
4,230,467
|
4,430,026
|
5% Preferred Stock [Member] |
|
|
Shareholders' deficit: |
|
|
Preferred stock |
60,675
|
60,675
|
Total shareholders' deficit |
$ 60,675
|
$ 60,675
|
Series B Preferred Stock [Member] |
|
|
Shareholders' deficit: |
|
|
Preferred stock |
|
|
Series C Convertible Preferred Stock [Member] |
|
|
Shareholders' deficit: |
|
|
Preferred stock |
|
|
X |
- DefinitionThe amount of accounts payable GEOMC.
+ References
+ Details
Name: |
cttc_AccountsPayableGEOMCCurrent |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe amount of liabiliies under purchase agreement.
+ References
+ Details
Name: |
cttc_LiabilitiesUnderPurchaseAgreement |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionRefers to amount of convertible preferred stock liability in series A.
+ References
+ Details
Name: |
cttc_StockLiabilitiesCurrent |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, and other costs not separately disclosed in the balance sheet that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.
+ References
+ Details
Name: |
us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_AccountsPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionExcess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.30(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5
+ Details
Name: |
us-gaap_AdditionalPaidInCapital |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.18) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 12 -Article 7
+ Details
Name: |
us-gaap_Assets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.9) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6801-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details
Name: |
us-gaap_AssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_AssetsCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_Cash |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.(a),19) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14326-108349
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.17) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_CommitmentsAndContingencies |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A
+ Details
Name: |
us-gaap_DeferredRevenueCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611
+ Details
Name: |
us-gaap_DerivativeLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.6(a)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 35 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=51655945&loc=d3e3927-108312
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
+ Details
Name: |
us-gaap_InventoryNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.32) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 25 -Article 7
+ Details
Name: |
us-gaap_LiabilitiesAndStockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.21) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_LiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_LiabilitiesCurrentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_LongTermNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_NotesPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5
+ Details
Name: |
us-gaap_PreferredStockValue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 8 -Article 5
+ Details
Name: |
us-gaap_PrepaidExpenseAndOtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3,4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a -Article 5
+ Details
Name: |
us-gaap_ReceivablesNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe cumulative amount of the reporting entity's undistributed earnings or deficit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.31(a)(3)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Article 3
+ Details
Name: |
us-gaap_RetainedEarningsAccumulatedDeficit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8,17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_SecurityDeposit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_SeriesBPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_SeriesCPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
|
Sep. 30, 2015 |
Dec. 31, 2014 |
Allowance on receivables |
$ 317,659
|
$ 317,659
|
Common stock, authorized |
40,000,000
|
40,000,000
|
Common stock, par value (in dollars per share) |
$ 0.01
|
$ 0.01
|
Common stock, issued |
28,395,888
|
25,908,978
|
Common stock, outstanding |
28,395,888
|
25,908,978
|
Series B Preferred Stock [Member] |
|
|
Preferred stock, authorized |
20,000
|
20,000
|
Preferred stock, par value (in dollars per share) |
$ 0.001
|
$ 0.001
|
Series C Convertible Preferred Stock [Member] |
|
|
Preferred stock, authorized |
750
|
750
|
Preferred stock, par value (in dollars per share) |
$ 1,000
|
$ 1,000
|
Preferred stock, issued |
375
|
375
|
Preferred stock, outstanding |
375
|
375
|
5% Preferred Stock [Member] |
|
|
Preferred stock, authorized |
35,920
|
35,920
|
Preferred stock, par value (in dollars per share) |
$ 25
|
$ 25
|
Preferred stock, issued |
2,427
|
2,427
|
Preferred stock, outstanding |
2,427
|
2,427
|
X |
- DefinitionFace amount or stated value per share of common stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionA valuation allowance for financing receivables that are expected to be uncollectible.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 50 -Paragraph 11B -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=49124121&loc=SL6953423-111524
+ Details
Name: |
us-gaap_FinancingReceivableAllowanceForCreditLosses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5
+ Details
Name: |
us-gaap_PreferredStockParOrStatedValuePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5
+ Details
Name: |
us-gaap_PreferredStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionTotal number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5
+ Details
Name: |
us-gaap_PreferredStockSharesIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_SeriesBPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_SeriesCPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2015 |
Sep. 30, 2014 |
Sep. 30, 2015 |
Sep. 30, 2014 |
Revenue |
|
|
|
|
Product sales |
$ 197,204
|
$ 400,000
|
$ 405,154
|
$ 937,080
|
Cost of product sales |
59,830
|
247,184
|
108,070
|
415,550
|
Gross profit from product sales |
137,374
|
152,816
|
297,084
|
521,530
|
Other Revenue |
|
|
|
|
Retained royalties |
2,389
|
19,781
|
7,037
|
24,733
|
Other income |
13,673
|
14,204
|
39,206
|
31,677
|
Total other revenue |
16,062
|
33,985
|
46,243
|
56,410
|
Operating expenses |
|
|
|
|
Selling expenses |
67,791
|
38,470
|
112,131
|
176,496
|
Personnel and consulting expenses |
455,087
|
296,944
|
1,329,466
|
1,116,088
|
General and administrative expenses |
362,208
|
432,528
|
1,012,369
|
943,554
|
Total operating expenses |
885,086
|
767,942
|
2,453,966
|
2,236,138
|
Operating loss |
(731,650)
|
(581,141)
|
(2,110,639)
|
(1,658,198)
|
Other expense |
|
|
|
|
Interest expense |
$ 300,361
|
574,840
|
$ 690,892
|
792,520
|
Interest expense - accelerated upon conversion of OID notes |
|
|
|
35,109
|
Loss on settlement of note and warrant |
|
|
|
132,301
|
Loss on conversion of notes |
|
5,500
|
$ 2,588
|
48,788
|
Unrealized loss on derivative instruments |
$ 30,791
|
67,631
|
41,694
|
79,351
|
Total other expense |
331,152
|
647,971
|
735,174
|
1,088,069
|
Loss before income taxes |
$ (1,062,802)
|
$ (1,229,112)
|
$ (2,845,813)
|
$ (2,746,267)
|
Provision (benefit) for income taxes |
|
|
|
|
Net loss |
$ (1,062,802)
|
$ (1,229,112)
|
$ (2,845,813)
|
$ (2,746,267)
|
Basic and diluted loss per share (in dollars per share) |
$ (0.04)
|
$ (0.05)
|
$ (0.1)
|
$ (0.12)
|
Basic and diluted weighted average number of common shares outstanding: (in shares) |
28,370,953
|
24,974,613
|
27,673,151
|
22,715,940
|
X |
- References
+ Details
Name: |
cttc_OtherRevenueAbstract |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount, after sales adjustments, returns, allowances, and discounts, of revenue classified as other.
+ References
+ Details
Name: |
cttc_OtherRevenueNet |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionTotal costs related to goods produced and sold during the reporting period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2(a)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_CostOfGoodsSold |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
+ Details
Name: |
us-gaap_EarningsPerShareBasicAndDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959
+ Details
Name: |
us-gaap_GainLossOnDerivativeInstrumentsNetPretax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629
+ Details
Name: |
us-gaap_GainsLossesOnExtinguishmentOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_GeneralAndAdministrativeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1,2) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_GrossProfit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionConsideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=7656879&loc=d3e7290-112610
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 40 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=6928171&loc=d3e6835-112609
+ Details
Name: |
us-gaap_InducedConversionOfConvertibleDebtExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.9) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details
Name: |
us-gaap_InterestExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_InterestExpenseDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.7) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_NonoperatingIncomeExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NonoperatingIncomeExpenseAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionGenerally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
+ References
+ Details
Name: |
us-gaap_OperatingExpenses |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_OperatingExpensesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe net result for the period of deducting operating expenses from operating revenues.
+ References
+ Details
Name: |
us-gaap_OperatingIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionReflects the sum of all other revenue and income recognized by the entity in the period not otherwise specified in the income statement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.4) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
+ Details
Name: |
us-gaap_OtherIncome |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionA fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07.2(a),(b),(c),(d)) -URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 946 -SubTopic 225 -Section 45 -Paragraph 3 -Subparagraph (k) -URI http://asc.fasb.org/extlink&oid=6488370&loc=d3e13550-115849
+ Details
Name: |
us-gaap_ProfessionalFees |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionRevenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_RoyaltyRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_SalesRevenueGoodsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_SalesRevenueNetAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExpenses recognized in the period that are directly related to the selling and distribution of products or services.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_SellingExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAverage number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).
+ References
+ Details
Name: |
us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
Condensed Consolidated Statement of Changes in Shareholders' Deficit (Unaudited) - 9 months ended Sep. 30, 2015 - USD ($)
|
5% Preferred Stock [Member] |
Common Stock [Member] |
Capital in excess of par value [Member] |
Accumulated deficit [Member] |
Total |
Balance at beginning at Dec. 31, 2014 |
$ 60,675
|
$ 259,089
|
$ 47,634,857
|
$ (55,692,967)
|
$ (7,738,346)
|
Balance at beginning (in shares) at Dec. 31, 2014 |
2,427
|
25,908,978
|
|
|
|
Increase (Decrease) in Stockholders' Equity [Roll Forward] |
|
|
|
|
|
Net loss |
|
|
|
$ (2,845,813)
|
(2,845,813)
|
Common stock issued to directors |
|
$ 125
|
$ 2,000
|
|
2,125
|
Common stock issued to directors (in shares) |
|
12,500
|
|
|
|
Stock option compensation expense |
|
|
49,181
|
|
49,181
|
Common stock issued for consulting services |
|
$ 6,200
|
101,400
|
|
107,600
|
Common stock issued for consulting services (in shares) |
|
620,000
|
|
|
|
Common stock issued to convert OID note |
|
$ 294
|
5,588
|
|
5,882
|
Common stock issued to convert OID note (in shares) |
|
29,410
|
|
|
|
Warrants issued for consulting services |
|
|
75,000
|
|
75,000
|
Private offering of common stock and warrants |
|
$ 18,250
|
346,750
|
|
365,000
|
Private offering of common stock and warrants (in shares) |
|
1,825,000
|
|
|
|
Warrant and beneficial conversion feature on notes payable |
|
|
316,623
|
|
316,623
|
Balance at end at Sep. 30, 2015 |
$ 60,675
|
$ 283,958
|
$ 48,531,399
|
$ (58,538,780)
|
$ (9,662,748)
|
Balance at end (in shares) at Sep. 30, 2015 |
2,427
|
28,395,888
|
|
|
|
X |
- DefinitionThe number of stock and warrant issued during the period, which includes shares issued in private offering.
+ References
+ Details
Name: |
cttc_StockAndWarrantIssuedDuringPeriodSharesPrivateOffering |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe value of new stock and warrant issued during the period, which includes shares issued in private offering.
+ References
+ Details
Name: |
cttc_StockAndWarrantIssuedDuringPeriodValuePrivateOffering |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
cttc_StockIssuedDuringPeriodSharesIssuedForServices1 |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
cttc_StockIssuedDuringPeriodValueIssuedForServices1 |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase (decrease) in additional paid in capital (APIC) resulting from recognition of deferred taxes for convertible debt with a beneficial conversion feature.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 740 -SubTopic 10 -Section 55 -Paragraph 51 -URI http://asc.fasb.org/extlink&oid=51663037&loc=d3e34017-109320
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Beneficial Conversion Feature -URI http://asc.fasb.org/extlink&oid=6505963
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThis element represents the amount of recognized equity-based compensation related to stock options during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized).
+ References
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 25 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=28183637&loc=d3e4724-112606
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Warrant -URI http://asc.fasb.org/extlink&oid=6528364
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 31 -Article 5
+ Details
Name: |
us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.
+ References
+ Details
Name: |
us-gaap_IncreaseDecreaseInStockholdersEquityRollForward |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued which are neither cancelled nor held in the treasury.
+ References
+ Details
Name: |
us-gaap_SharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued during the period as a result of the conversion of convertible securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-30) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe gross value of stock issued during the period upon the conversion of convertible securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionTotal of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB TOPIC 4.E) -URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29-31) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section E
+ Details
Name: |
us-gaap_StockholdersEquity |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
|
9 Months Ended |
Sep. 30, 2015 |
Sep. 30, 2014 |
Cash flows from operating activities: |
|
|
Net loss |
$ (2,845,813)
|
$ (2,746,267)
|
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
Depreciation and amortization |
12,267
|
11,976
|
Stock option compensation expense |
49,181
|
49,185
|
Share-based compensation - common stock |
2,125
|
$ 4,038
|
Common stock and warrants issued to consultants |
$ 182,600
|
|
Bad debt expense |
|
$ 79,500
|
Debt discount amortization |
$ 265,358
|
185,525
|
Noncash finance charges |
|
18,434
|
Unrealized loss on derivative instruments |
$ 41,694
|
79,351
|
Loss on conversion of notes |
$ 2,588
|
48,788
|
Loss on settlement of note and warrant |
|
132,301
|
Changes in assets and liabilities: |
|
|
Receivables |
$ (183)
|
(171,883)
|
Prepaid expenses and other current assets |
191,249
|
(50,888)
|
Inventory |
40,000
|
150,000
|
Accounts payable, accrued expenses and other liabilities |
936,494
|
1,417,832
|
Deferred revenue |
(13,286)
|
13,287
|
Net cash used in operating activities |
(1,135,726)
|
(778,821)
|
Cash flows from investing activities: |
|
|
Purchase of property and equipment |
(4,700)
|
(47,688)
|
Cash used in investing activities |
(4,700)
|
(47,688)
|
Cash flows from financing activities: |
|
|
Proceeds from note payable |
857,000
|
120,000
|
Repayment of note and warrant settlement |
(42,500)
|
(242,000)
|
Proceeds from common stock and warrants |
365,000
|
892,000
|
Net cash provided by financing activities |
1,179,500
|
770,000
|
Net increase (decrease) in cash |
39,074
|
(56,509)
|
Cash at beginning of period |
5,745
|
57,009
|
Cash at end of period |
$ 44,819
|
$ 500
|
X |
- DefinitionThe cash inflow from the note and warrant settlement
+ References
+ Details
Name: |
cttc_ProceedsFromNoteAnWarrantSetlement |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from the note and warrant settlement.
+ References
+ Details
Name: |
cttc_RepaymentNoteAndWarrantSetlement |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_AmortizationOfDebtDiscountPremium |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Cash -URI http://asc.fasb.org/extlink&oid=6506951
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.1) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_Cash |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 830 -SubTopic 230 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=49171198&loc=d3e33268-110906
+ Details
Name: |
us-gaap_CashPeriodIncreaseDecrease |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_DepreciationDepletionAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 50 -Paragraph 4A -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56946850&loc=SL5618551-113959
+ Details
Name: |
us-gaap_GainLossOnDerivativeInstrumentsNetPretax |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629
+ Details
Name: |
us-gaap_GainsLossesOnExtinguishmentOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInDeferredRevenue |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInInventories |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncreaseDecreaseInOperatingCapitalAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInReceivables |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionConsideration given by issuer of convertible debt to provide an incentive for debt holders to convert the debt to equity securities. The expense is equal to the fair value of all securities and other consideration transferred in the transaction in excess of the fair value of securities issuable pursuant to the original conversion terms.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=7656879&loc=d3e7290-112610
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 40 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=6928171&loc=d3e6835-112609
+ Details
Name: |
us-gaap_InducedConversionOfConvertibleDebtExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionFair value of share-based compensation granted to nonemployees as payment for services rendered or acknowledged claims.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3574-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 24 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3521-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3536-108585
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Net Income -URI http://asc.fasb.org/extlink&oid=51831255
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.19) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.18) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04.22) -URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Other Comprehensive Income -URI http://asc.fasb.org/extlink&oid=51831270
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 19 -Article 5
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph 20 -Article 9
+ Details
Name: |
us-gaap_NetIncomeLoss |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionOther expenses or losses included in net income that result in no cash outflows or inflows in the period and are not separately disclosed.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_OtherNoncashExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3213-108585
+ Details
Name: |
us-gaap_PaymentsToAcquirePropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash inflow (outflow) from long-term debt supported by a written promise to pay an obligation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
+ Details
Name: |
us-gaap_ProceedsFromRepaymentsOfNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of expense related to write-down of receivables to the amount expected to be collected. Includes, but is not limited to, accounts receivable and notes receivable.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.5) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_ProvisionForDoubtfulAccounts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_StockOptionPlanExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
v3.3.1.900
BASIS OF PRESENTATION
|
9 Months Ended |
Sep. 30, 2015 |
Accounting Policies [Abstract] |
|
BASIS OF PRESENTATION |
The
interim condensed consolidated financial information presented in the accompanying condensed consolidated financial statements
and notes hereto is unaudited.
Effective
August 20, 2014, Competitive Technologies, Inc. changed its name to Calmare Therapeutics Incorporated.
Calmare
Therapeutics Incorporated (CTI) and its majority-owned (56.1%) subsidiary, Vector Vision, Inc. (VVI),
(collectively, the Company, we or us) is a medical device company developing and commercializing
innovative products and technologies. CTI is the licensed distributor of the non-invasive Calmare® Pain Therapy
Device (the Calmare Device), which was developed to treat neuropathic and cancer-derived pain.
These
consolidated financial statements include the accounts of CTI and VVI. Inter-company accounts and transactions have
been eliminated in consolidation.
We
believe we have made all adjustments necessary, consisting only of normal recurring adjustments, to present the unaudited condensed
consolidated financial statements in conformity with accounting principles generally accepted in the U.S. The results
for the three and nine months ended September 30, 2015 are not necessarily indicative of the results that can be expected for
the full year ending December 31, 2015.
The
interim unaudited condensed consolidated financial statements and notes thereto, should be read in conjunction with our Annual
Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission (SEC) on
June 24, 2015.
During
the three and nine months ended September 30, 2015, we had a significant concentration of revenues from the Calmare®
Device. The percentages of gross revenue attributed to sales and rentals of Calmare Devices, in the three
and nine months ended September 30, 2015, were 95% and 94%, respectively; and 94% and 96%, respectively, in the three and
nine months ended September 30, 2014. Additionally, the percentage of gross revenue attributed to other Calmare Device
related sales of equipment and training, in the three and nine months ended September 30, 2015, was 4% in both periods; and 2%
and 1%, respectively, in the three and nine months ended September 30, 2014. We continue to attempt to expand our sales
activities for the Calmare Device and expect the majority of our revenues to come from this technology.
The
Company has incurred operating losses since fiscal 2006 and has a working capital deficiency and shareholders deficiency
at September 30, 2015. The Company has taken steps to reduce its operating expenses as well as increase revenue from
sales of Calmare Devices and related sales. However, even at the reduced spending levels, should the anticipated increase
in revenue from sales of Calmare Devices and related sales not occur the Company may not have sufficient cash flow to fund
operations through 2015 and into 2016. These conditions raise substantial doubt about the Companys ability to
continue as a going concern. The financial statements do not include adjustments to reflect the possible future effect
of the recoverability and classification of assets or amounts and classifications of liabilities that may result from the outcome
of this uncertainty.
The
Company's continuation as a going concern is dependent upon its developing recurring revenue streams sufficient to cover operating
costs. The Company does not have any significant individual cash or capital requirements in the budget going forward. If
necessary, the Company will attempt to meet anticipated operating cash requirements by further reducing costs, issuing debt and/or
equity, and/or pursuing sales of certain assets and technologies while we pursue licensing and distribution opportunities for
our remaining legacy portfolio of technologies. There can be no assurance that the Company will be successful in such
efforts. Failure to develop a recurring revenue stream sufficient to cover operating expenses could negatively affect
the Companys financial position.
Our
liquidity requirements arise principally from our working capital needs, including funds needed to sell our current technologies
and obtain new technologies or products, and protect and enforce our intellectual property rights, if necessary. We fund our liquidity
requirements with a combination of cash on hand, debt and equity financing, sales of common stock and cash flows from operations,
if any, including royalty legal awards. At September 30, 2015, the Company had outstanding debt in the form of promissory notes
with a total principal amount of $4,177,000 and a carrying value of $3,839,000.
In
2007, the Company secured the exclusive, worldwide rights to the patented, chronic pain reduction technology (the Technology)
behind the Companys flagship medical device the Calmare Device. The Companys 2007 agreement (the 2007
Agreement) with Giuseppe Marineo, an inventor of the Technology, and Delta Research and Development (Delta),
authorized the Company to manufacture and sell worldwide the Calmare Device developed from the patented Technology. The 2007 Agreement
was amended in 2011 (the 2011 Amendment) to provide the Company with exclusive rights to the Technology through March
31, 2016. In July 2012, the Company attempted to negotiate a five-year extension to the agreement with Marineo and Delta (the
2012 Amendment). However, the Company believes that the 2012 Amendment is neither valid nor enforceable as it was
never duly signed or authorized and subsequently deemed null and void. Therefore, the Companys rights are determined by
the 2011 Amendment which provides the Company with the exclusive rights to manufacture and sell the Calmare Device worldwide using
the Technology. (see Footnote 13. CONTRACTUAL OBLIGATIONS AND CONTINGENCIES, the Companys Distribution Rights,
Marineo and Delta)
The
Technology is patented in Italy and in the United States. Applications for patents have been filed internationally as well and
are pending approval. The Calmare Device has CE Marking certification under the expressed jurisdiction from the European Commissions
Competitiveness and Innovation Program (CIP). The Calmare Device also has a 510(k) clearance from the
U.S. Food and Drug Administration (#K081255) for sales in the United States and reciprocity countries. The Company partners with
GEOMC Co., Ltd. (GEOMC) of Korea to manufacture the Calmare Device commercially.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingPoliciesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).
+ References
+ Details
Name: |
us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
NET LOSS PER COMMON SHARE
|
9 Months Ended |
Sep. 30, 2015 |
Earnings Per Share [Abstract] |
|
NET LOSS PER COMMON SHARE |
2. |
NET LOSS PER COMMON SHARE |
The
following sets forth the denominator used in the calculations of basic net loss per share and net loss per share assuming dilution:
|
|
Three months ended |
|
|
Three
months ended |
|
|
Nine months ended |
|
|
Nine months ended |
|
|
|
September
30, 2015 |
|
|
September 30, 2014 |
|
|
September 30, 2015 |
|
|
September 30, 2014 |
|
Denominator
for basic net loss per share, weighted average shares outstanding |
|
|
28,370,953 |
|
|
|
24,974,613 |
|
|
|
27,673,151 |
|
|
|
22,715,940 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dilutive
effect of common stock options |
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dilutive
effect of Series C convertible preferred stock, convertible debt and warrants |
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator
for diluted net loss per share, weighted average shares outstanding |
|
|
28,370,953 |
|
|
|
24,974,613 |
|
|
|
27,673,151 |
|
|
|
22,715,940 |
|
Due
to the net loss incurred for the three and nine months ended September 30, 2015, and 2014, the denominator used in the calculation
of basic net loss per share was the same as that used for net loss per share, assuming dilution, since the effect of any options,
convertible preferred shares, convertible debt or warrants would have been anti-dilutive.
Potentially
dilutive securities outstanding are summarized as follows:
|
|
September
30, 2015 |
|
|
September
30, 2014 |
|
Exercise of common stock
options |
|
|
2,042,500 |
|
|
|
1,692,500 |
|
Exercise of common stock warrants |
|
|
7,864,013 |
|
|
|
3,398,890 |
|
Conversion of Series
C convertible preferred stock |
|
|
1,857,194 |
|
|
|
2,673,797 |
|
Conversion
of convertible debt |
|
|
9,089,153 |
|
|
|
3,171,776 |
|
Total |
|
|
20,852,860 |
|
|
|
10,936,963 |
|
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for earnings per share.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1278-109256
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 55 -Paragraph 52 -URI http://asc.fasb.org/extlink&oid=32703322&loc=d3e4984-109258
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.21) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_EarningsPerShareTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
|
9 Months Ended |
Sep. 30, 2015 |
Accounting Changes and Error Corrections [Abstract] |
|
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS |
3. |
RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS |
In
May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2014-09,
Revenue from Contracts with Customers, as amended by ASU 2015-14, that outlines a single comprehensive model for entities
to use in accounting for revenue recognition and supersedes most current revenue recognition guidance, including industry-specific
guidance. The amendments in this accounting standard update are intended to provide a more robust framework for addressing revenue
issues, improve comparability of revenue recognition practices, and improve disclosure requirements. The amendments in this accounting
standard update are effective for interim and annual reporting periods beginning after December 15, 2017; with early adoption
permitted after December 15, 2016. The Company is currently assessing the impact that this standard will have on its consolidated
financial statements.
In
August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements Going Concern, which provides
guidance on managements responsibility in evaluating whether there is substantial doubt about a companys ability to
continue as a going concern and the related footnote disclosure. For each reporting period, management will be required
to evaluate whether there are conditions or events that raise substantial doubt about a companys ability to continue as
a going concern within one year from the date the financials are issued. When management identifies conditions or events
that raise substantial doubt about the entitys ability to continue as a going concern, the ASU also outlines disclosures
that are required in the companys footnotes based on whether or not there are any plans intended to mitigate the relevant
conditions or events to alleviate the substantial doubt. The ASU becomes effective for annual periods ending after December
15, 2016, and for any annual and interim periods thereafter. Early application is permitted. The Company is currently
assessing the impact that this standard will have on its consolidated financial statements.
In
July 2015, the FASB issued ASU No. 2015-11, Inventory Simplifying the Measurement of Inventory, which requires that
inventory be measured at the lower of cost and net realizable value. Prior to the issuance of the new guidance, inventory was
measured at the lower of cost or market. Replacing the concept of market with the single measurement of net realizable value is
intended to create efficiencies for preparers. Inventory measured using the last-in, first-out (LIFO) method and the retail inventory
method are not impacted by the new guidance. The ASU becomes effective for fiscal years beginning after December 15, 2016, including
interim periods with those fiscal years. Early application is permitted. We do not expect the adoption to have a material impact
on our consolidated financial statements.
|
X |
- References
+ Details
Name: |
us-gaap_AccountingChangesAndErrorCorrectionsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Change in Accounting Principle -URI http://asc.fasb.org/extlink&oid=6507316
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Direct Effects of a Change in Accounting Principle -URI http://asc.fasb.org/extlink&oid=6510796
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22583-107794
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Indirect Effects of a Change in Accounting Principle -URI http://asc.fasb.org/extlink&oid=6515603
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22580-107794
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.10-01.(b)(6)) -URI http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Accounting Change -URI http://asc.fasb.org/extlink&oid=6503790
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=56949863&loc=d3e22499-107794
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Retrospective Application -URI http://asc.fasb.org/extlink&oid=6523989
Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305
Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305
+ Details
Name: |
us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
RECEIVABLES
|
9 Months Ended |
Sep. 30, 2015 |
Receivables [Abstract] |
|
RECEIVABLES |
Receivables
consist of the following:
|
|
September 30, 2015 |
|
|
December 31, 2014 |
|
Calmare
device sales receivable, net of allowance of $209,533 at September 30, 2015 and December 31, 2014 |
|
$ |
- |
|
|
$ |
- |
|
Royalties,
net of allowance of $101,154 at September 30, 2015 and December 31, 2014 |
|
|
- |
|
|
|
- |
|
Other,
net of allowance of $6,972 at September 30, 2015 and December 31, 2014 |
|
|
2,502 |
|
|
|
2,319 |
|
Total |
|
$ |
2,502 |
|
|
$ |
2,319 |
|
|
X |
- DefinitionThe entire disclosure for financing receivables. Examples of financing receivables include, but are not limited to, loans, trade accounts receivables, notes receivable, credit cards, and receivables relating to a lessor's right(s) to payment(s) from a lease other than an operating lease that is recognized as assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 55 -Paragraph 14 -URI http://asc.fasb.org/extlink&oid=32702940&loc=SL6953791-111525
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e4975-111524
+ Details
Name: |
us-gaap_FinancingReceivablesTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_ReceivablesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
AVAILABLE-FOR-SALE AND EQUITY SECURITIES
|
9 Months Ended |
Sep. 30, 2015 |
Investments, Debt and Equity Securities [Abstract] |
|
AVAILABLE-FOR-SALE AND EQUITY SECURITIES |
|
5. |
AVAILABLE-FOR-SALE AND EQUITY SECURITIES |
The
fair value of the equity securities we held were categorized as available-for-sale securities, which were carried at a fair value
of zero, consisted of shares in Security Innovation and Xion Pharmaceutical Corporation (Xion). We own
223,317 shares of stock in the privately held Security Innovation, an independent provider of secure software located in Wilmington,
MA.
In
September 2009 we announced the formation of a joint venture with Xion for the commercialization of our patented melanocortin
analogues for treating sexual dysfunction and obesity. CTI currently owns 60 shares of common stock or 30% of the outstanding
stock of privately held Xion.
|
X |
- References
+ Details
Name: |
us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for investments in certain debt and equity securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -Glossary Debt Security -URI http://asc.fasb.org/extlink&oid=6509901
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27290-111563
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 30 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27232-111563
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -Glossary Equity Security -URI http://asc.fasb.org/extlink&oid=6511694
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27161-111563
Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27357-111563
Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=27724398&loc=d3e27405-111563
+ Details
Name: |
us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
FAIR VALUE MEASUREMEMENTS
|
9 Months Ended |
Sep. 30, 2015 |
Fair Value Disclosures [Abstract] |
|
FAIR VALUE MEASUREMEMENTS |
|
6. |
FAIR VALUE MEASUREMEMENTS |
The
Company measures fair value in accordance with Topic 820 of the FASB Accounting Standards Codification (ASC), Fair
Value Measurement (ASC 820), which provides a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical
assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three
levels of the fair value hierarchy under ASC 820 are described as follows:
|
Level 1 - |
Inputs to the valuation methodology
are unadjusted quoted prices for identical assets or liabilities in active markets that the Company has the ability to access. |
|
|
|
|
|
Level 2 - |
Inputs to the valuation methodology
include: |
|
|
● |
Quoted prices for similar assets or liabilities
in active markets; |
|
|
● |
Quoted prices for identical or similar assets
or liabilities in inactive markets; |
|
|
● |
Inputs other than quoted prices that are observable
for the asset or liability; |
|
|
● |
Inputs
that are derived principally from or corroborated by observable market data by correlation or other means. |
|
|
If the asset or liability has a
specified (contractual) term, the Level 2 input must be observable for substantially the full term of the asset or liability. |
|
|
|
|
|
Level 3 - |
Inputs to the valuation methodology
are unobservable and significant to the fair value measurement |
The
asset's or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input
that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and
minimize the use of unobservable inputs.
The
Company values its derivative liability associated with the variable conversion feature on its Series C Convertible Preferred
Stock (Note 12) based on the market price of its common stock. For each reporting period the Company calculates the
amount of potential common stock that the Series C Preferred Stock could convert into based on the conversion formula (incorporating
market value of our common stock) and multiplies those converted shares by the market price of its common stock on that reporting
date. The total converted value is subtracted by the consideration paid to determine the fair value of the derivative
liability. The Company classified the derivative liability of approximately $108,000 at September 30, 2015 and $66,000 at December
31, 2014, in Level 2 of the fair value hierarchy.
The
methods described above may produce a fair value calculation that may not be indicative of net realizable value or reflective
of future fair values. Furthermore, while the Company believes its valuation method is appropriate and consistent with other market
participants, the use of different methodologies or assumptions to determine the fair value could result in a different fair value
measurement at the reporting date.
The
carrying amounts reported in our Condensed Consolidated Balance Sheet for cash, accounts receivable, notes payable, deferred revenue,
and preferred stock liability approximate fair value due to the short-term maturity of those financial instruments.
|
X |
- References
+ Details
Name: |
us-gaap_FairValueDisclosuresAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13504-108611
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611
+ Details
Name: |
us-gaap_FairValueDisclosuresTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
PREPAID EXPENSES AND OTHER CURRENT ASSETS
|
9 Months Ended |
Sep. 30, 2015 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
PREPAID EXPENSES AND OTHER CURRENT ASSETS |
7. |
PREPAID EXPENSES AND OTHER CURRENT ASSETS |
Prepaid
expenses and other current assets consist of the following:
|
|
September
30, 2015 |
|
|
December
31, 2014 |
|
Prepaid
insurance |
|
$ |
30,987 |
|
|
$ |
71,651 |
|
Prepaid consulting
services |
|
|
20,000 |
|
|
|
37,500 |
|
Clinical trial |
|
|
- |
|
|
|
109,119 |
|
Other |
|
|
10,866 |
|
|
|
34,832 |
|
Prepaid
expenses and other current assets |
|
$ |
61,853 |
|
|
$ |
253,102 |
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for other current assets.
+ References
+ Details
Name: |
us-gaap_OtherCurrentAssetsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
PROPERTY AND EQUIPMENT
|
9 Months Ended |
Sep. 30, 2015 |
Property, Plant and Equipment [Abstract] |
|
PROPERTY AND EQUIPMENT |
|
8. |
PROPERTY AND EQUIPMENT |
Property
and equipment, net, consist of the following:
|
|
September
30, 2015 |
|
|
December
31, 2014 |
|
Property
and equipment, gross |
|
$ |
220,191 |
|
|
$ |
215,491 |
|
Accumulated
depreciation and amortization |
|
|
(192,118 |
) |
|
|
(179,851 |
) |
Property
and equipment, net |
|
$ |
28,073 |
|
|
$ |
35,640 |
|
Depreciation
and amortization expense was $3,904 and $12,267, respectively, during the three and nine months ended September 30, 2015, and
$5,630 and $11,976, respectively, for the three and nine months ended September 30, 2014.
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13-14) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2921-110230
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
ACCRUED EXPENSES AND OTHER LIABILITIES
|
9 Months Ended |
Sep. 30, 2015 |
Payables and Accruals [Abstract] |
|
ACCRUED EXPENSES AND OTHER LIABILITIES |
|
9. |
ACCRUED EXPENSES AND OTHER LIABILITIES |
Accrued
expenses and other liabilities consist of the following:
|
|
September
30, 2015 |
|
|
December
31, 2014 |
|
Royalties
payable |
|
$ |
375,067 |
|
|
$ |
314,787 |
|
Accrued compensation |
|
|
196,723 |
|
|
|
23,573 |
|
Accrued interest payable |
|
|
1,409,150 |
|
|
|
987,659 |
|
Other |
|
|
346,070 |
|
|
|
264,163 |
|
Accrued
expenses and other liabilities, net |
|
$ |
2,327,010 |
|
|
$ |
1,590,182 |
|
Excluded
above is approximately $217,000 of accrued expenses and other liabilities at September 30, 2015 and December 31, 2014, that fall
under the Liability Purchase Agreement (LPA) with ASC Recap, LLC (ASC Recap), and are expected to be repaid
using the process as described in Note 10. Because there can be no assurance that the Company will be successful in
completing this process, the Company retains ultimate responsibility for these liabilities, until fully paid down.
|
X |
- DefinitionThe entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.
+ References
+ Details
Name: |
us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_PayablesAndAccrualsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
LIABILITIES ASSIGNED TO LIABILITY PURCHASE AGREEMENT
|
9 Months Ended |
Sep. 30, 2015 |
Liabilities Assigned To Liability Purchase Agreement |
|
LIABILITIES ASSIGNED TO LIABILITY PURCHASE AGREEMENT |
|
10. |
LIABILITIES ASSIGNED TO LIABILITY PURCHASE
AGREEMENT |
During
the third quarter of 2013, the Company negotiated a LPA with Southridge, Partners II, L.P. (Southridge). The LPA takes
advantage of a provision in the Securities Act of 1933, Section 3(a)(10), that allows the exchange of claims, securities, or property
for stock when the arrangement is approved for fairness by a court proceeding. The process, approved by the court in August 2013,
has the potential to eliminate nearly $2.1 million of our financial obligations to existing creditors who agreed to participate
and executed claims purchase agreements with Southridges affiliate ASC Recap accounting for $2,093,303 of existing payables,
accrued expenses and other current liabilities, and notes payable. The process began with the issuance in September 2013 of 1,618,235
shares of the Companys common stock to ASC Recap. During September and October 2013, ASC Recap sold the Companys common
stock and during the three months ended March 31, 2014 paid creditors approximately $80,000 from the proceeds and retained a service
fee of approximately $27,000. During 2014, the Company also made cash payments of $18,000 for accrued expenses previously included
in the LPA amount. As of February 24, 2016, no further shares of the Companys common stock had been issued to ASC Recap
to settle creditors balances.
There
can be no assurance that the Company will be successful in completing this process with Southridge, and the Company retains ultimate
responsibility for this debt, until fully paid.
|
X |
- References
+ Details
Name: |
cttc_LiabilitiesAssignedToLiabilityPurchaseAgreementAbstract |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure of liabilities assigned to liability purchase agreement.
+ References
+ Details
Name: |
cttc_LiabilitiesAssignedToLiabilityPurchaseAgreementTextBlock |
Namespace Prefix: |
cttc_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
NOTES PAYABLE
|
9 Months Ended |
Sep. 30, 2015 |
Debt Disclosure [Abstract] |
|
NOTES PAYABLE |
Notes
payable consist of the following:
|
|
September 30, 2015 |
|
|
December 31, 2014 |
|
90 day
Convertible Notes (Chairman of the Board) |
|
$ |
2,498,980 |
|
|
$ |
2,498,980 |
|
24 month Convertible
Notes ($100,000 to Board member) |
|
|
225,000 |
|
|
|
225,000 |
|
10 day Note (Board
member) |
|
|
- |
|
|
|
42,500 |
|
Series A-3 15% OID
Convertible Notes and Warrants |
|
|
14,353 |
|
|
|
11,765 |
|
Series B-1 OID Convertible
Notes and Warrants |
|
|
65,104 |
|
|
|
56,659 |
|
Series
B-2 OID Convertible Notes and Warrants |
|
|
1,035,973 |
|
|
|
244,565 |
|
Notes Payable, gross |
|
|
3,839,410 |
|
|
|
3,079,469 |
|
Less
LPA amount |
|
|
(485,980 |
) |
|
|
(485,980 |
) |
Notes
Payable, net |
|
$ |
3,353,430 |
|
|
$ |
2,593,489 |
|
Details
of notes payable as of September 30, 2015 are as follows:
|
|
Principal
Amount |
|
|
Carrying
Value |
|
|
Cash
Interest Rate |
|
|
Common
Stock Conversion Price |
|
|
Maturity
Date |
90
day Convertible Notes (Chairman of the Board) |
|
$ |
2,498,980 |
|
|
$ |
2,498,980 |
|
|
|
6 |
% |
|
$ |
1.05 |
|
|
Various
2014 |
24
month Convertible Notes ($100,000 to Board member) |
|
|
225,000 |
|
|
|
225,000 |
|
|
|
6 |
% |
|
|
1.05 |
|
|
March
2014 June 2014 |
Series
A-3 15% OID Convertible Notes and Warrants |
|
|
11,765 |
(1) |
|
|
14,353 |
(1) |
|
|
None |
|
|
|
0.25 |
|
|
January
2015 |
Series
B-1 OID Convertible Notes and Warrants |
|
|
80,000 |
|
|
|
65,104 |
|
|
|
None |
|
|
|
0.23 |
|
|
March
2017 |
Series
B-2 OID Convertible Notes and Warrants |
|
|
1,361,177 |
|
|
|
1,035,973 |
|
|
|
None |
|
|
|
0.20-0.25 |
|
|
Aug.
2015 July 2016 |
Notes
Payable, gross |
|
$ |
4,176,922 |
|
|
|
3,839,410 |
|
|
|
|
|
|
|
|
|
|
|
Less
LPA amount |
|
|
|
|
|
|
(485,980 |
) |
|
|
|
|
|
|
|
|
|
|
Notes
Payable, net |
|
|
|
|
|
$ |
3,353,430 |
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Includes $2,588 of accrued loss on conversion
of OID note. |
90
day Convertible Notes
The
Company has issued 90-day notes payable to borrow funds from a director, now the chairman of our Board, as follows:
2013 |
|
$ |
1,188,980 |
|
2012 |
|
|
1,210,000 |
|
2011 |
|
|
100,000 |
|
Total |
|
$ |
2,498,980 |
|
These
notes have been extended several times and all bear 6.00% simple interest. A conversion feature was added to the Notes
when they were extended, which allows for conversion of the eligible principal amounts to common stock at any time after the six
month anniversary of the effective date the date the funds are received at a rate of $1.05 per share. Additional
terms have been added to all Notes to include additional interest of 1% simple interest per month on all amounts outstanding for
all Notes if extended beyond their original maturity dates and to provide the lender with a security interest in unencumbered
inventory and intangible assets of the Company other than proceeds relating to the Calmare Device and accounts receivable.
Due
to the Boards February 10, 2014 decision authorizing management to nullify certain actions taken by prior management, the
additional terms noted above were not approved and therefore, the additional interest for the extension of the Notes was not recorded.
During 2014, management has been in negotiations to modify the terms of the Notes. However, until those negotiations are resolved,
the Company has agreed to honor the additional terms and as such, the Company recorded additional interest of approximately $287,000
during the nine months ended September 30, 2015, and has recorded additional interest in total of $906,000.
A
total of $485,980 of the aforementioned notes issued between December 1, 2012 and March 31, 2013 fall under the LPA with ASC Recap,
and are expected to be repaid using the process as described in Note 10. Because there can be no assurance that the
Company will be successful in completing this process, the Company retains ultimate responsibility for this debt, until fully
paid down. As a result, the Company continues to accrue interest on these notes and they remain convertible as described
above.
24
month Convertible Notes
In
March 2012, the Company issued a 24-month convertible promissory note to borrow $100,000. Additional 24-month convertible promissory
notes were issued in April 2012 ($25,000) and in June 2012 ($100,000). All of the notes bear 6.00% simple interest. Conversion
of the eligible principal amounts to common stock is allowed at any time at a rate of $1.05 per share.
As
of February 24, 2016 the Company has not repaid the principal due on the March 2012 $100,000 note, the April 2012 $25,000 note
or the June 2012 $100,000 note and is in default under the terms of the notes. As of September 30, 2015, there is also unpaid
interest of $28,000 related to these notes.
10
day Note
In
late December 2014, the Company issued a 10 day non-interest bearing note to a Board member in the amount of $42,500. This note
was repaid in early January 2015.
Series
A-3 15% Original Issue Discount (OID) Convertible Notes and Warrants
During
the quarter ended March 31, 2014, the Company did a private offering of a third tranche of convertible notes and warrants, under
which it issued $64,706 of convertible promissory notes for consideration of $55,000, the difference between the proceeds from
the notes and principal amount consists of $9,706 of original issue discount. The notes are convertible at an initial conversion
price of $0.25 per share any time after issuance thereby having an embedded beneficial conversion feature.
The
note holders were also issued market-related warrants for 129,412 in shares of common stock. The warrants have an exercise price
of $0.60 and a term of 2 years. The beneficial conversion feature, if any, and the warrants were recorded to additional paid-in-capital.
The Company allocated the proceeds received to the notes, the beneficial conversion feature and the warrants on a relative fair
value basis at the time of issuance. The total debt discount is amortized over the life of the notes to interest expense.
The
beneficial conversion feature was valued at the intrinsic value on the issuance date. The intrinsic value represents the difference
between the conversion price and the fair value of the common stock multiplied by the number of share into which the note is convertible.
We estimated the fair value of the warrants on the issue date using a Black-Scholes pricing model with the following assumptions:
|
|
Warrants |
|
Expected term |
|
|
2 years |
|
Volatility |
|
|
184.88 |
% |
Risk Free Rate |
|
|
0.32 |
% |
The
proceeds of the Notes issued during the three months ended March 31, 2014 were allocated to the components as follows:
|
|
Proceeds allocated
at issue date |
|
Private
Offering Notes |
|
$ |
32,390 |
|
Private Offering Warrants |
|
|
14,845 |
|
Beneficial
Conversion feature |
|
|
7,765 |
|
Total |
|
$ |
55,000 |
|
During
the quarter ended June 30, 2014, certain holders of Series A-3 OID convertible notes and warrants delivered to the Company a notice
of conversion related to the Series A-3 OID convertible notes. Due to the timing of receipt of the notices by the Company, certain
Note holders (Noteholders) received their shares during the quarter ended June 30, 2014, while other Noteholders received
or are due to receive their shares after June 30, 2014. Additionally, the Company offered certain Noteholders an inducement to
convert their notes to shares. The inducement, when offered, provided Noteholders a conversion price of $0.20. All other original
terms, including the warrant terms, remained the same. Upon notice of conversion and irrespective of whether the shares were delivered
in the quarter ended June 30, 2014 or subsequent to June 30, 2014 to the Company: (i) accelerated and recognized as interest expense
in the current period any remaining discount, and (ii) recognized a loss for the fair value of the additional shares offered as
the conversion inducement.
Presented
below is summary information related to the conversion:
Statement
of Operations |
|
|
|
|
Loss on
conversion of notes |
|
$ |
43,288 |
|
Accelerated interest
expense |
|
$ |
35,109 |
|
|
|
|
|
|
Balance
Sheet |
|
|
|
|
Shares issued as of June 30, 2014 |
|
|
798,825 |
|
Shares to be issued
subsequent to June 30, 2014 |
|
|
529,415 |
|
Principal amount of
notes converted |
|
$ |
265,648 |
|
During
the quarter ended March 31, 2015, a holder of Series A-3 OID convertible notes and warrants delivered to the Company a notice
of conversion related to the Series A-3 OID convertible notes. Additionally, the Company offered the Noteholder an inducement
to convert his/her notes to shares. The inducement provided the Noteholder a conversion price of $0.20. All other original terms,
including the warrant terms, remained the same. Upon notice of conversion, the Company: (i) accelerated and recognized as interest
expense in the current period any remaining discount, and (ii) recognized a loss for the fair value of the additional shares offered
as the conversion inducement. As of February 24, 2016, the Company had not issued the shares due related to the conversion notice.
Presented
below is summary information related to the conversion:
Statement
of Operations |
|
|
|
|
Loss on
conversion of notes |
|
$ |
2,588 |
|
Accelerated interest
expense |
|
$ |
- |
|
|
|
|
|
|
Balance
Sheet |
|
|
|
|
Shares issued |
|
|
- |
|
|
|
|
|
|
Principal amount of
notes converted |
|
$ |
11,765 |
|
Series
B-1 Original Issue Discount Convertible Notes and Warrants
During
the quarter ended March 31, 2014, the Company did a private offering of convertible notes and warrants, under which it issued
$80,000 of convertible promissory notes for consideration of $65,000, the difference between the proceeds from the notes and principal
amount consists of $15,000 of original issue discount. The notes are convertible at an initial conversion price of $0.35 per share
any time after issuance thereby having an embedded beneficial conversion feature. The note holders were also issued market-related
warrants for 185,714 in shares of common stock. The warrants have an exercise price of $0.45 and a 4-year term. The beneficial
conversion feature and the warrants were recorded to additional paid-in-capital. The Company allocated the proceeds received to
the notes, the beneficial conversion feature and the warrants on a relative fair value basis at the time of issuance. The total
debt discount is amortized over the life of the notes to interest expense.
The
beneficial conversion feature was valued at the intrinsic value on the issuance date. The intrinsic value represents the difference
between the conversion price and the fair value of the common stock multiplied by the number of share into which the note is convertible.
We estimated the fair value of the warrants on the issue date using a Black-Scholes pricing model with the following assumptions:
|
|
Warrants
March 20, 2014 |
|
Expected term |
|
|
4 years |
|
Volatility |
|
|
151.52 |
% |
Risk Free Rate |
|
|
1.32 |
% |
The
proceeds of the Notes were allocated to the components as follows:
|
|
Proceeds allocated
at issue date |
|
Private
Offering Notes |
|
$ |
34,272 |
|
Private Offering Warrants |
|
|
26,811 |
|
Beneficial
Conversion feature |
|
|
3,917 |
|
Total |
|
$ |
65,000 |
|
The
Series B-1 OID notes include an anti-dilution provision that if the Company issues more than 20 million shares of its common stock,
subject to certain exceptions, the conversion price of the notes and the conversion price of the warrants would be subject to
an automatic pre-determined price adjustment. During the quarter ended December 31, 2014 the Series B-1 OID noteholder and the
Company agreed that this anti-dilution provision had been triggered and the Series B-1 OID note share conversion price was adjusted
down to $0.23 per share, which increased the number of shares available upon conversion to 347,826. The anti-dilution provision
in the Warrant changed the share purchase price downward to $0.33 per share but did not change the number of shares available
under the Warrant.
As
a result of the triggering of the above noted one time anti-dilution provision, the Company reallocated the proceeds of the Notes
during the quarter ended December 31, 2014 as follows:
|
|
Proceeds allocated
at issue date |
|
Private
Offering Notes |
|
$ |
46,222 |
|
Private Offering Warrants |
|
|
18,778 |
|
Beneficial
Conversion feature |
|
|
- |
|
Total |
|
$ |
65,000 |
|
Series
B-2 OID Convertible Notes and Warrants
During
the quarter ended March 31, 2015, the Company did an additional private offering of convertible notes and warrants, under which
it issued $302,353 of convertible promissory notes for consideration of $257,000, the difference between the proceeds from the
notes and principal amount consists of $45,353 of original issue discount. The notes are convertible at an initial conversion
price of $0.20 per share any time after issuance thereby having an embedded beneficial conversion feature. The note holders were
also issued market-related warrants for 755,882 in shares of common stock. The warrants have an exercise price of $0.60 and a
1-year term. The beneficial conversion feature and the warrants were recorded to additional paid-in-capital. The Company allocated
the proceeds received to the notes, the beneficial conversion feature and the warrants on a relative fair value basis at the time
of issuance. The total debt discount is amortized over the life of the notes to interest expense.
The
beneficial conversion feature was valued at the intrinsic value on the issuance date. The intrinsic value represents the difference
between the conversion price and the fair value of the common stock multiplied by the number of shares into which the note is
convertible. We estimated the fair value of the warrants on the issue date using a Black-Scholes pricing model with the following
assumptions:
|
|
Warrants
three months ended March 31, 2015 |
|
Expected term |
|
|
1
year |
|
Volatility |
|
|
180.15-185.71 |
% |
Risk Free Rate |
|
|
0.18-0.22 |
% |
The
proceeds of the Notes were allocated to the components as follows:
|
|
Proceeds allocated
at issue date |
|
Private
Offering Notes |
|
$ |
197,521 |
|
Private Offering Warrants |
|
|
46,097 |
|
Beneficial
Conversion feature |
|
|
13,382 |
|
Total |
|
$ |
257,000 |
|
During
the quarter ended June 30, 2015, a holder of Series B-2 OID convertible notes and warrants delivered to the Company a notice of
conversion related to the Series B-2 OID convertible notes, with a principal amount of $5,882. In the quarter ended September
30, 2015, the Company issued 29,410 shares due related to the conversion notice.
During
the quarter ended September 30, 2015, the Company did an additional private offering of convertible notes and warrants, under
which it issued $705,882 of convertible promissory notes for consideration of $600,000, the difference between the proceeds from
the notes and principal amount consists of $105,882 of original issue discount. The notes are convertible at an initial conversion
price of $0.25 per share any time after issuance thereby having an embedded beneficial conversion feature. The note holders were
also issued market-related warrants for 1,411,764 in shares of common stock. The warrants have an exercise price of $0.60 and
a 1-year term. The beneficial conversion feature and the warrants were recorded to additional paid-in-capital. The Company allocated
the proceeds received to the notes, the beneficial conversion feature and the warrants on a relative fair value basis at the time
of issuance. The total debt discount is amortized over the life of the notes to interest expense.
The
beneficial conversion feature was valued at the intrinsic value on the issuance date. The intrinsic value represents the difference
between the conversion price and the fair value of the common stock multiplied by the number of shares into which the note is
convertible. We estimated the fair value of the warrants on the issue date using a Black-Scholes pricing model with the following
assumptions:
|
|
Warrants
three months ended September 30, 2015 |
|
Expected term |
|
|
1
year |
|
Volatility |
|
|
171.36 |
% |
Risk Free Rate |
|
|
0.28 |
% |
The
proceeds of the Notes were allocated to the components as follows:
|
|
Proceeds allocated
at issue date |
|
Private
Offering Notes |
|
$ |
342,857 |
|
Private Offering Warrants |
|
|
120,000 |
|
Beneficial
Conversion feature |
|
|
137,143 |
|
Total |
|
$ |
600,000 |
|
Tonaquint
9% Original Issue Discount Convertible Notes and Warrants
During
the quarter ended September 30, 2013, the Company entered into a securities purchase agreement with Tonaquint, Inc., under which
it was issued a $112,500 convertible promissory note in consideration for $100,000, the difference between the proceeds from the
Note and the principal amount consisted of a $10,000 original issue discount and a carried transaction expense of $2,500. The
original issue discount was being amortized over the life of the note. The note was convertible at an initial conversion price
of $0.30 per share at any time, and contained a down-round protection feature that requires the valuation of a derivative
liability associated with the note. The note bore interest at 7% and was due in May 2014. Tonaquint was also issued a market-related
warrant for $112,500 in shares of common stock with a cashless exercise feature. The warrant had a $0.35 exercise
price, a 5-year term and included a down-round protection feature that required it to be classified as a liability
rather than as equity.
During
the first quarter of 2014 the Company executed a debt settlement agreement with Tonaquint related to the note and warrant. The
warrant was settled during the first quarter of 2014 for a cash payment of $98,000, resulting in a loss of $98,000. The note was
settled during the second quarter of 2014 for cash payments totaling $144,000 ($20,000 paid in the first quarter of 2014 and $124,000
paid in the second quarter of 2014). Because the execution of the debt settlement agreement in the first quarter of 2014 resulted
in a significant modification of the original terms of the note agreement, the Company adjusted the carrying value of the note
in the first quarter of 2014 and recorded a related loss of approximately $34,000.
Southridge
During
2013, the Company issued a six-month $12,000 convertible note payable to Southridge to cover legal expenses as part of the LPA.
The convertible note was convertible into the Companys common stock at the greater of $0.25 or 85% of the average closing
bid price during the five (5) trading days prior to conversion and was due in June 2014.
During
the third quarter of 2014, the Company issued to Southridge 50,000 shares in exchange for and in full satisfaction for the note
and recorded a $5,500 loss upon conversion of the note.
|
X |
- References
+ Details
Name: |
us-gaap_DebtDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20,22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_DebtDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
SHAREHOLDERS' DEFICIENCY
|
9 Months Ended |
Sep. 30, 2015 |
Stockholders' Equity Note [Abstract] |
|
SHAREHOLDERS' DEFICIENCY |
12.
SHAREHOLDERS DEFICIENCY
Stock
Option Plan
On
May 2, 2011 the Company adopted and executed the Employees Directors and Consultants Stock Option Plan (the Plan).
During the three months ended March 31, 2015, the Company granted 50,000 options to non-employee directors which were fully vested
upon issuance. During the three months ended March 31, 2014, the Company granted 42,500 options to non-employee directors which
were fully vested upon issuance. During the three months ended June 30, 2014, the Company granted 320,000 options to employees.
20% of the options vested upon issuance and the remaining options vest ratable over a four (4) year period. No options were granted
during the three months ended September 30, 2014. During the three months ended September 30, 2015, the Company granted 300,000
options to employees. 20% of the options vested upon issuance and the remaining options vest ratable over a four (4) year period.
We
estimated the fair value of each option on the grant date using a Black-Scholes option-pricing model with the following weighted
average assumptions:
|
|
Nine
- months ended |
|
|
Nine
- months ended |
|
|
|
September 30,
2015 |
|
|
September 30,
2014 |
|
Dividend
yield (1) |
|
|
0.00 |
% |
|
|
0.00 |
% |
Expected volatility (2) |
|
|
159.8-164.5
|
% |
|
|
118.5-122.4 |
% |
Risk-free interest rates (3) |
|
|
1.61 |
% |
|
|
1.19-1.72 |
% |
Expected lives (2) |
|
|
5.0
YEARS |
|
|
|
4.0-5.0YEARS |
|
|
(1) |
We have not paid cash dividends on our common
stock since 1981, and currently do not have plans to pay or declare cash dividends. Consequently, we used an expected dividend
rate of zero for the valuations. |
|
(2) |
Estimated based on our historical experience.
Volatility was based on historical experience over a period equivalent to the expected life in years. |
|
(3) |
Based on the U.S. Treasury constant maturity
interest rate with a term consistent with the expected life of the options granted. |
During
the nine months ended September 30, 2015, the Company recognized expense of $7,963 for stock options issued to directors and recognized
expense of $25,006 and $41,218, respectively, for the three and nine months ended September 30, 2015, for stock options issued
to employees.
During
the nine months ended September 30, 2014, the Company recognized expense of $11,178 for stock options issued to directors and
recognized expense of $8,062 and $38,007, respectively, for the three and nine months ended September 30, 2014, for stock options
issued to employees.
Preferred
Stock
Holders
of 5% preferred stock are entitled to receive, if, as, and when declared by the Board of Directors, out of funds legally available
therefore, preferential non-cumulative dividends at the rate of $1.25 per share per annum, payable quarterly, before any dividends
may be declared or paid upon or other distribution made in respect of any share of common stock. The 5% preferred stock is redeemable,
in whole at any time or in part from time to time, on 30 days' notice, at the option of the Company, at a redemption price of
$25. In the event of voluntary or involuntary liquidation, the holders of preferred stock are entitled to $25 per share in cash
before any distribution of assets can be made to holders of common stock.
Each
share of 5% preferred stock is entitled to one vote. Holders of 5% preferred stock have no preemptive or conversion rights. The
preferred stock is not registered to be publicly traded.
The
rights of the Series C Convertible Preferred Stock are as follows:
|
a) |
Dividend rights
The shares of Series C Convertible Preferred Stock accrue a 5% cumulative dividend on a quarterly basis and is payable on
the last day of each fiscal quarter when declared by the Companys Board. As of September 30, 2015, dividends declared
were $98,473, of which $4,726 and $14,024, respectively, were declared during the three and nine months ended September 30,
2015 and $79,726 have not been paid and are shown in accrued and other liabilities at September 30, 2015. |
|
b) |
Voting rights
Holders of these shares of Series C Convertible Preferred Stock shall have voting rights equivalent to 1,000 votes per $1,000
par value Series C Convertible Preferred share voted together with the shares of Common Stock |
|
c) |
Liquidation rights
Upon any liquidation these Series C Convertible Preferred Stock shares shall be treated as equivalent to shares of
Common stock to which they are convertible. |
|
d) |
Conversion rights
Holder has right to convert each share of Series C Convertible Preferred Stock at any time into shares of the Company's
common stock at a conversion price for each share of common stock equal to 85% of the lower of (a) the closing market price
at the date of notice of conversion or (b) the mid-point of the last bid price and the last ask price on the date of the notice
of conversion. The variable conversion feature creates an embedded derivative that was bifurcated from the Series C Convertible
Preferred Stock on the date of issuance and was recorded at fair value. The derivative liability will be recorded at fair
value on each reporting date with any change recorded in the Statement of Operations as an unrealized (gain) loss on derivative
instrument. |
The
Company recorded a convertible preferred stock derivative liability of $107,871 and $66,177, respectively, associated with the
375 shares of Series C Convertible Preferred Stock outstanding at September 30, 2015 and December 31, 2014.
The
Company has classified the Series C Convertible Preferred Stock as a liability at September 30, 2015 and December 31, 2014 because
the variable conversion feature may require the Company to settle the conversion in a variable number of its common shares.
Common
Stock
During
the quarter ended March 31, 2014, the Company did a private offering of its common stock and warrants, for consideration of $500,000.
2,500,000 shares of common stock were issued at a per share price of $0.20. The common stock holders were also issued warrants
to purchase 1,250,000 shares of common stock. The warrants have an exercise price of $0.60 and a 3-year term. The warrants were
recorded to additional paid-in-capital.
During
the quarter ended June 30, 2014, the Company did an additional private offering of its common stock and warrants, for consideration
of $170,000. 850,000 shares of common stock were issued at a per share price of $0.20. The common stock holders were also issued
warrants to purchase 425,000 shares of common stock. The warrants have an exercise price of $0.60 and a 3-year term. The warrants
were recorded to additional paid-in-capital.
On
August 14, 2014 the shareholders approved an amendment to the Companys certification of incorporation to effect up to a
one-for-ten reverse stock split (the reverse Stock Split of the Companys issued and authorized outstanding common
stock. The Board of Directors, in its sole discretion, has discretion to implement the Reverse Stock Split. As of February 24,
2016, the Board of Directors has not implemented the Reverse Stock Split.
During
the quarter ended September 30, 2014, the Company did an additional private offering of its common stock and warrants, for consideration
of $232,000. 1,160,000 shares of common stock were issued at a per share price of $0.20. The common stock holders were also issued
warrants to purchase 580,000 shares of common stock. The warrants have an exercise price of $0.60 and a 3-year term. The warrants
were recorded to additional paid-in-capital.
During
the quarter ended March 31, 2015, the Company issued 500,000 shares with a fair value of $80,000 to an advisory firm for consulting
services. The Company is amortizing the $80,000 over the service period and recorded $20,000 of expense in the quarter ended September
30, 2015 and $60,000 of expense in the nine months ended September 30, 2015.
During
the quarter ended March 31, 2015, the Company issued 120,000 shares to an advisory firm for consulting services. The shares vested
in two tranches, with 60,000 shares vesting in the quarter ended December 31, 2014 and remaining 60,000 shares vesting in the
quarter ended March 31, 2015. The Company recorded consulting expenses of $10,800 in the quarter ended December 31, 2014 and $27,600
of consulting expenses in the quarter ended March 31, 2015. In each instance, the expense was based on the fair value on the vesting
date.
During
the quarter ended March 31, 2015, the Company issued 333,333 stock warrants for consulting services performed and recorded consulting
expense of $75,000 for the fair value of the warrants.
During
the quarter ended March 31, 2015, the Company did a private offering of its common stock and warrants, for consideration of $75,000.
375,000 shares of common stock were issued at a per share price of $0.20. The common stock holders were also issued warrants to
purchase 187,500 shares of common stock. The warrants have an exercise price of $0.60 and a 3-year term. The warrants were recorded
to additional paid-in-capital.
During
the quarter ended June 30, 2015, the Company did an additional private offering of its common stock and warrants, for consideration
of $290,000. 1,450,000 shares of common stock were issued at a per share price of $0.20. The common stock holders were also issued
warrants to purchase 725,000 shares of common stock. The warrants have an exercise price of $0.60 and a 3-year term. The warrants
were recorded to additional paid-in-capital.
On
October 15, 2015 the shareholders approved an increase in the number of authorized shares of common stock from 40 million to 100
million.
During
the three months ended March 31, 2015 and 2014, the Company issued 12,500 and 10,625 shares of its common stock to non-employee
directors under its Director Compensation Plan. The Company recorded expense of $2,125 and $4,038 for director stock compensation
expense in the three months ended March 31, 2015 and 2014. No shares were issued during the three months ended September 30, 2015
and 2014. Additionally, no expense was recorded in the three months ended September 30, 2015 and 2014.
|
X |
- DefinitionThe entire disclosure for accounts comprising shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income, and compensation-related costs for equity-based compensation. Includes, but is not limited to, disclosure of policies, compensation plan details, equity-based arrangements to obtain goods and services, deferred compensation arrangements, and employee stock purchase plan details.
+ References
+ Details
Name: |
us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityNoteAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
CONTRACTUAL OBLIGATIONS AND CONTINGENCIES
|
9 Months Ended |
Sep. 30, 2015 |
Commitments and Contingencies Disclosure [Abstract] |
|
CONTRACTUAL OBLIGATIONS AND CONTINGENCIES |
13. |
CONTRACTUAL OBLIGATIONS AND CONTINGENCIES |
As
of September 30, 2015, the Company and its majority owned subsidiary, VVI, have remaining obligations, contingent upon receipt
of certain revenues, to repay up to $165,788 and $198,334, respectively, in consideration of grant funding received in 1994 and
1995. The Company also is obligated to pay at the rate of 7.5% of its revenues, if any, from transferring rights to
certain inventions supported by the grant funds. VVI is obligated to pay at rates of 1.5% of its net sales of supported
products or 15% of its revenues from licensing supported products, if any.
Contingencies
Litigation
Tim
Conley (case pending) - On August 18, 2014, notice was issued to the Company that on June 23, 2014, Timothy Conley (the
Plaintiff) filed a complaint against the Company, in the United States District Court for the District of Rhode Island.
The complaint alleges that the Companys former acting interim CEO, Johnnie Johnson, and Plaintiff entered into an agreement
whereby the Company agreed to make payments to Plaintiff. Among other allegations, Plaintiff claims that the Companys nonpayment
to Plaintiff constitutes a breach of contract. The Company believes it has meritorious defenses to the allegations and the Company
intends to vigorously defend against the litigation.
GEOMC
(case pending) - On August 22, 2014, GEOMC filed a complaint against the Company in the United States District
Court for the District of Connecticut. The complaint alleges that the Company and GEOMC entered into a security agreement whereby
in exchange for GEOMCs sale and delivery of the Scrambler Therapy devices (the Devices), the Company would grant
GEOMC a security interest in the Devices. Among other allegations, GEOMC claims that the Company has failed to comply with the
terms of the security agreement and seeks an order to the Court to replevy the Devices or collect damages. The Company believes
it has meritorious defenses to the allegations and the Company intends to vigorously defend against the litigation. On February
4, 2016, the Company announced that it is discussing a settlement with GEOMC, however, to date, no settlement has been reached.
Summary
We may be a party to other legal actions and proceedings from time to time. We are unable to estimate legal expenses
or losses we may incur, if any, or possible damages we may recover, and we have not recorded any potential judgment losses or
proceeds in our financial statements to date. We record expenses in connection with these suits as incurred.
An
unfavorable resolution of any or all matters, and/or our incurrence of significant legal fees and other costs to defend or prosecute
any of these actions and proceedings may, depending on the amount and timing, have a material adverse effect on our consolidated
financial position, results of operations or cash flows in a particular period.
The
Companys Distribution Rights, Marineo and Delta
On
April 8, 2014, Mr. Giuseppe Marineo, Delta Research and Development (Delta), Mr. Marineos research company,
and Delta International Services and Logistics (DIS&L), Deltas commercial arm in which Mr. Marineo is the
sole beneficiary of all proceeds as its founder and sole owner (collectively the Group), issued a press release (the
Groups Press Release) regarding the Company stating that the Company did not have authority to sell, distribute
and manufacture the Calmare Device as an exclusive agent of the Group. The Company issued a corporate response in a press release
dated April 11, 2014 stating that the Groups Press Release was inaccurate and, as assured by the wire service, had the Groups
Press Release purged from the wire services foreign desk.
This
issue between the Company and the Group is over the validity of the 2012 Amendment to a Sales and Representation Agreement which,
if valid and enforceable, may have compromised the Companys rights to sell, distribute and manufacture the Calmare Device
as an exclusive agent of the Group in the global marketplace, especially in the European, Middle Eastern and North African (EMENA)
territory which was responsible for approximately 70% of gross Calmare Device sales in 2011. However, the Company believes that
the 2012 Amendment is neither valid nor enforceable as it was never duly signed or authorized and subsequently deemed null and
void as so disclosed on April 16, 2014 in the Form 10-K filing. Therefore, the Companys rights are determined by the 2011
Amendment which provides the Company with the exclusive rights to manufacture and sell the Calmare Device worldwide using the
Technology.
On
April 16, 2014, counsel for the Group (Group Counsel) sent a cease and desist letter (Cease and Desist Letter)
to the Company, requesting a confirmation that the Company would no longer hold itself out as an agent of the Group permitted
to sell, distribute and manufacture the Calmare Device world-wide including the EMENA territory.
The
Company responded on April 25, 2014 to the Cease and Desist Letter, disputing Group Counsels interpretation of the events
surrounding the execution of the 2012 Amendment. At this time, the Company continues to work to find a reasonable and amicable
resolution to the situation.
Unsigned
Agreements
The
Company uses two unrelated firms to provide marketing and investor relations services, CME Acuity (CMEA) and Legend
Capital Management (LCM), respectively. The LCM and CMEA agreements were not signed due to an inability to come to
final terms due to certain nuances in either agreement that included but were not limited to assignment of human capital and allowable
performance based bonus(es). However, from the start date until September 30, 2015, the respective firms were being compensated
for services rendered on a pay-as-we go basis (the Arrangement). The aforementioned Arrangement is expected
to continue for the next few consecutive quarters until such time as their agreements can be consummated.
|
X |
- References
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for commitments and contingencies.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 460 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=51674963&loc=d3e12565-110249
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 450 -SubTopic 20 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=25496072&loc=d3e14435-108349
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.25) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 440 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308
+ Details
Name: |
us-gaap_CommitmentsAndContingenciesDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
RELATED PARTY TRANSACTIONS
|
9 Months Ended |
Sep. 30, 2015 |
Related Party Transactions [Abstract] |
|
RELATED PARTY TRANSACTIONS |
|
14. |
RELATED PARTY TRANSACTIONS |
Our
Board of Directors determined that when a director's services are outside the normal duties of a director, we compensate the director
at the rate of $1,000 per day, plus expenses, which is the same amount we pay a director for attending a one-day Board meeting. We
classify these amounts as consulting expenses, included in personnel and consulting expenses.
At
September 30, 2015, $2,598,980 of the outstanding Notes payable were Notes payable to related parties; $2,498,980 to the Chairman
of the Board and $100,000 to another director.
On
September 15, 2015, the Company announced the appointment of Stephen J. DAmato, M.D. as chief medical officer of the Company.
During 2010, Calmar Pain Relief, LLC, purchased 10 Calmare devices from the Company for an aggregate purchase price of $550,000.
Additionally, during 2015 and 2014, Calmar Pain Relief purchased certain supplies from the Company. Dr. DAmato is one of
the managing members of Calmar Pain Relief, LLC.
|
X |
- DefinitionThe entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 850 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(k)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 04 -Paragraph b -Article 3A
+ Details
Name: |
us-gaap_RelatedPartyTransactionsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
SUBSEQUENT EVENTS
|
9 Months Ended |
Sep. 30, 2015 |
Subsequent Events [Abstract] |
|
SUBSEQUENT EVENTS |
On
October 15, 2015, the Company entered into a consulting agreement with VADM Robert T. Conway, Jr., U.S. Navy, (Ret) (the Admiral),
a member of the Companys Board of Directors. The agreement is for one year and includes compensation of a monthly retainer
fee of $7,500 and a five year warrant to purchase 167,000 shares of common stock of the Company, fully vested on the date of issuance,
at a strike price of $.60 per share with an aggregate estimate fair value of $33,734. As a result of this agreement, the Board
of Directors has determined that the Admiral is no longer an independent director of the Company.
From
October 1, 2015 to December 18, 2015, the Company obtained additional funding, including $400,000 of hybrid debt funding. From
October 1, 2015 to December 18, 2015, the Company did a private offering of convertible notes and warrants, under which it issued
$470,588 of convertible promissory notes for consideration of $400,000, the difference between the proceeds from the notes and
principal amount consists of $70,588 of original issue discount. The notes are convertible at a conversion price of $0.20 per
share. The note holder was also issued market-related warrants for 470,588 in shares of common stock. The warrants have an exercise
price of $0.60 and a 1-year term.
On
January 8, 2016, the Board of Directors of the Company determined that it would not be continuing to employ Ian Rhodes as the
Companys Executive Vice President and Chief Financial Officer. Mr. Rhodes termination from employment was effective
on January 8, 2016. Mr. Rhodes termination did not result from disagreement with the Company on any matter relating to the Companys
operations, policies or practices. On January 11, 2016, the Company appointed Thomas P. Richtarich as Chief Financial Officer
of the Company. Mr. Richtarich served as a consultant to the Company prior to being hired as the Companys Chief Financial
Officer. The Company does not currently have an employment agreement in place with Mr. Richtarich. However, the Company will continue
to provide Mr. Richtarich with the compensation he received as a consultant equal to $9,500 per month plus expenses.
On
January 15, 2016, the Company appointed Dr. Christine Chansky, M.D., J.D., F.C.L.M. as its chief regulatory officer (CRO).
As part of her duties, she will spearhead all of the Clinical studies sponsored by the Company and oversee all global
regulatory issues related to the Companys medical device practice.
On
February 18, 2016, the Company announced it has been issued a general supply order contract from the U.S. Government (GSA contract
number #V797P-4300B). The Company estimates this contract will total $15 million over the next 60 months.
|
X |
- References
+ Details
Name: |
us-gaap_SubsequentEventsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.
+ References
+ Details
Name: |
us-gaap_SubsequentEventsTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
NET LOSS PER COMMON SHARE (Tables)
|
9 Months Ended |
Sep. 30, 2015 |
Earnings Per Share [Abstract] |
|
Schedule of basic net loss per share |
The
following sets forth the denominator used in the calculations of basic net loss per share and net loss per share assuming dilution:
|
|
Three months ended |
|
|
Three
months ended |
|
|
Nine months ended |
|
|
Nine months ended |
|
|
|
September
30, 2015 |
|
|
September 30, 2014 |
|
|
September 30, 2015 |
|
|
September 30, 2014 |
|
Denominator
for basic net loss per share, weighted average shares outstanding |
|
|
28,370,953 |
|
|
|
24,974,613 |
|
|
|
27,673,151 |
|
|
|
22,715,940 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dilutive
effect of common stock options |
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dilutive
effect of Series C convertible preferred stock, convertible debt and warrants |
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
N/A |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Denominator
for diluted net loss per share, weighted average shares outstanding |
|
|
28,370,953 |
|
|
|
24,974,613 |
|
|
|
27,673,151 |
|
|
|
22,715,940 |
|
|
Schedule of potentially dilutive securities outstanding |
Potentially
dilutive securities outstanding are summarized as follows:
|
|
September
30, 2015 |
|
|
September
30, 2014 |
|
Exercise of common stock
options |
|
|
2,042,500 |
|
|
|
1,692,500 |
|
Exercise of common stock warrants |
|
|
7,864,013 |
|
|
|
3,398,890 |
|
Conversion of Series
C convertible preferred stock |
|
|
1,857,194 |
|
|
|
2,673,797 |
|
Conversion
of convertible debt |
|
|
9,089,153 |
|
|
|
3,171,776 |
|
Total |
|
|
20,852,860 |
|
|
|
10,936,963 |
|
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details
Name: |
us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details
Name: |
us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
RECEIVABLES (Tables)
|
9 Months Ended |
Sep. 30, 2015 |
Receivables [Abstract] |
|
Schedule of receivables |
Receivables
consist of the following:
|
|
September 30, 2015 |
|
|
December 31, 2014 |
|
Calmare
device sales receivable, net of allowance of $209,533 at September 30, 2015 and December 31, 2014 |
|
$ |
- |
|
|
$ |
- |
|
Royalties,
net of allowance of $101,154 at September 30, 2015 and December 31, 2014 |
|
|
- |
|
|
|
- |
|
Other,
net of allowance of $6,972 at September 30, 2015 and December 31, 2014 |
|
|
2,502 |
|
|
|
2,319 |
|
Total |
|
$ |
2,502 |
|
|
$ |
2,319 |
|
|
X |
- References
+ Details
Name: |
us-gaap_ReceivablesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3,4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)
|
9 Months Ended |
Sep. 30, 2015 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
Schedule of prepaid expenses and other current assets |
Prepaid
expenses and other current assets consist of the following:
|
|
September
30, 2015 |
|
|
December
31, 2014 |
|
Prepaid
insurance |
|
$ |
30,987 |
|
|
$ |
71,651 |
|
Prepaid consulting
services |
|
|
20,000 |
|
|
|
37,500 |
|
Clinical trial |
|
|
- |
|
|
|
109,119 |
|
Other |
|
|
10,866 |
|
|
|
34,832 |
|
Prepaid
expenses and other current assets |
|
$ |
61,853 |
|
|
$ |
253,102 |
|
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.17) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
PROPERTY AND EQUIPMENT (Tables)
|
9 Months Ended |
Sep. 30, 2015 |
Property, Plant and Equipment [Abstract] |
|
Schedule of property and equipment |
Property
and equipment, net, consist of the following:
|
|
September
30, 2015 |
|
|
December
31, 2014 |
|
Property
and equipment, gross |
|
$ |
220,191 |
|
|
$ |
215,491 |
|
Accumulated
depreciation and amortization |
|
|
(192,118 |
) |
|
|
(179,851 |
) |
Property
and equipment, net |
|
$ |
28,073 |
|
|
$ |
35,640 |
|
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph b -Article 5
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)
|
9 Months Ended |
Sep. 30, 2015 |
Payables and Accruals [Abstract] |
|
Schedule of accrued expenses and other liabilities |
Accrued
expenses and other liabilities consist of the following:
|
|
September
30, 2015 |
|
|
December
31, 2014 |
|
Royalties
payable |
|
$ |
375,067 |
|
|
$ |
314,787 |
|
Accrued compensation |
|
|
196,723 |
|
|
|
23,573 |
|
Accrued interest payable |
|
|
1,409,150 |
|
|
|
987,659 |
|
Other |
|
|
346,070 |
|
|
|
264,163 |
|
Accrued
expenses and other liabilities, net |
|
$ |
2,327,010 |
|
|
$ |
1,590,182 |
|
X |
- References
+ Details
Name: |
us-gaap_PayablesAndAccrualsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the components of accrued liabilities.
+ References
+ Details
Name: |
us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
NOTES PAYABLE (Tables)
|
9 Months Ended |
Sep. 30, 2015 |
Schedule of notes payable |
Notes
payable consist of the following:
|
|
September 30, 2015 |
|
|
December 31, 2014 |
|
90 day
Convertible Notes (Chairman of the Board) |
|
$ |
2,498,980 |
|
|
$ |
2,498,980 |
|
24 month Convertible
Notes ($100,000 to Board member) |
|
|
225,000 |
|
|
|
225,000 |
|
10 day Note (Board
member) |
|
|
- |
|
|
|
42,500 |
|
Series A-3 15% OID
Convertible Notes and Warrants |
|
|
14,353 |
|
|
|
11,765 |
|
Series B-1 OID Convertible
Notes and Warrants |
|
|
65,104 |
|
|
|
56,659 |
|
Series
B-2 OID Convertible Notes and Warrants |
|
|
1,035,973 |
|
|
|
244,565 |
|
Notes Payable, gross |
|
|
3,839,410 |
|
|
|
3,079,469 |
|
Less
LPA amount |
|
|
(485,980 |
) |
|
|
(485,980 |
) |
Notes
Payable, net |
|
$ |
3,353,430 |
|
|
$ |
2,593,489 |
|
Details
of notes payable as of September 30, 2015 are as follows:
|
|
Principal
Amount |
|
|
Carrying
Value |
|
|
Cash
Interest Rate |
|
|
Common
Stock Conversion Price |
|
|
Maturity
Date |
90
day Convertible Notes (Chairman of the Board) |
|
$ |
2,498,980 |
|
|
$ |
2,498,980 |
|
|
|
6 |
% |
|
$ |
1.05 |
|
|
Various
2014 |
24
month Convertible Notes ($100,000 to Board member) |
|
|
225,000 |
|
|
|
225,000 |
|
|
|
6 |
% |
|
|
1.05 |
|
|
March
2014 June 2014 |
Series
A-3 15% OID Convertible Notes and Warrants |
|
|
11,765 |
(1) |
|
|
14,353 |
(1) |
|
|
None |
|
|
|
0.25 |
|
|
January
2015 |
Series
B-1 OID Convertible Notes and Warrants |
|
|
80,000 |
|
|
|
65,104 |
|
|
|
None |
|
|
|
0.23 |
|
|
March
2017 |
Series
B-2 OID Convertible Notes and Warrants |
|
|
1,361,177 |
|
|
|
1,035,973 |
|
|
|
None |
|
|
|
0.20-0.25 |
|
|
Aug.
2015 July 2016 |
Notes
Payable, gross |
|
$ |
4,176,922 |
|
|
|
3,839,410 |
|
|
|
|
|
|
|
|
|
|
|
Less
LPA amount |
|
|
|
|
|
|
(485,980 |
) |
|
|
|
|
|
|
|
|
|
|
Notes
Payable, net |
|
|
|
|
|
$ |
3,353,430 |
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Includes $2,588 of accrued loss on conversion
of OID note. |
|
Schedule of notes payable details |
Details
of notes payable as of September 30, 2015 are as follows:
|
|
Principal
Amount |
|
|
Carrying
Value |
|
|
Cash
Interest Rate |
|
|
Common
Stock Conversion Price |
|
|
Maturity
Date |
90
day Convertible Notes (Chairman of the Board) |
|
$ |
2,498,980 |
|
|
$ |
2,498,980 |
|
|
|
6 |
% |
|
$ |
1.05 |
|
|
Various
2014 |
24
month Convertible Notes ($100,000 to Board member) |
|
|
225,000 |
|
|
|
225,000 |
|
|
|
6 |
% |
|
|
1.05 |
|
|
March
2014 June 2014 |
Series
A-3 15% OID Convertible Notes and Warrants |
|
|
11,765 |
(1) |
|
|
14,353 |
(1) |
|
|
None |
|
|
|
0.25 |
|
|
January
2015 |
Series
B-1 OID Convertible Notes and Warrants |
|
|
80,000 |
|
|
|
65,104 |
|
|
|
None |
|
|
|
0.23 |
|
|
March
2017 |
Series
B-2 OID Convertible Notes and Warrants |
|
|
1,361,177 |
|
|
|
1,035,973 |
|
|
|
None |
|
|
|
0.20-0.25 |
|
|
Aug.
2015 July 2016 |
Notes
Payable, gross |
|
$ |
4,176,922 |
|
|
|
3,839,410 |
|
|
|
|
|
|
|
|
|
|
|
Less
LPA amount |
|
|
|
|
|
|
(485,980 |
) |
|
|
|
|
|
|
|
|
|
|
Notes
Payable, net |
|
|
|
|
|
$ |
3,353,430 |
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
Includes $2,588 of accrued loss on conversion
of OID note. |
|
Schedule of debt issuance |
The
Company has issued 90-day notes payable to borrow funds from a director, now the chairman of our Board, as follows:
2013 |
|
$ |
1,188,980 |
|
2012 |
|
|
1,210,000 |
|
2011 |
|
|
100,000 |
|
Total |
|
$ |
2,498,980 |
|
|
Private Placement [Member] | 15% Series A-3 OID Convertible Notes And Warrants [Member] | Warrant [Member] |
|
Schedule of Valuation techniques |
We
estimated the fair value of the warrants on the issue date using a Black-Scholes pricing model with the following assumptions:
|
|
Warrants |
|
Expected term |
|
|
2 years |
|
Volatility |
|
|
184.88 |
% |
Risk Free Rate |
|
|
0.32 |
% |
|
Schedule of proceeds from debt |
The
proceeds of the Notes issued during the three months ended March 31, 2014 were allocated to the components as follows:
|
|
Proceeds allocated
at issue date |
|
Private
Offering Notes |
|
$ |
32,390 |
|
Private Offering Warrants |
|
|
14,845 |
|
Beneficial
Conversion feature |
|
|
7,765 |
|
Total |
|
$ |
55,000 |
|
|
Schedule of debt conversion |
Presented
below is summary information related to the conversion:
Statement
of Operations |
|
|
|
|
Loss on
conversion of notes |
|
$ |
43,288 |
|
Accelerated interest
expense |
|
$ |
35,109 |
|
|
|
|
|
|
Balance
Sheet |
|
|
|
|
Shares issued as of June 30, 2014 |
|
|
798,825 |
|
Shares to be issued
subsequent to June 30, 2014 |
|
|
529,415 |
|
Principal amount of
notes converted |
|
$ |
265,648 |
|
Presented
below is summary information related to the conversion:
Statement
of Operations |
|
|
|
|
Loss on
conversion of notes |
|
$ |
2,588 |
|
Accelerated interest
expense |
|
$ |
- |
|
|
|
|
|
|
Balance
Sheet |
|
|
|
|
Shares issued |
|
|
- |
|
|
|
|
|
|
Principal amount of
notes converted |
|
$ |
11,765 |
|
|
Private Placement [Member] | Series B-1 OID Convertible Notes And Warrants [Member] | Warrant [Member] |
|
Schedule of Valuation techniques |
We
estimated the fair value of the warrants on the issue date using a Black-Scholes pricing model with the following assumptions:
|
|
Warrants
March 20, 2014 |
|
Expected term |
|
|
4 years |
|
Volatility |
|
|
151.52 |
% |
Risk Free Rate |
|
|
1.32 |
% |
|
Schedule of proceeds from debt |
The
proceeds of the Notes were allocated to the components as follows:
|
|
Proceeds allocated
at issue date |
|
Private
Offering Notes |
|
$ |
34,272 |
|
Private Offering Warrants |
|
|
26,811 |
|
Beneficial
Conversion feature |
|
|
3,917 |
|
Total |
|
$ |
65,000 |
|
As
a result of the triggering of the above noted one time anti-dilution provision, the Company reallocated the proceeds of the Notes
during the quarter ended December 31, 2014 as follows:
|
|
Proceeds allocated
at issue date |
|
Private
Offering Notes |
|
$ |
46,222 |
|
Private Offering Warrants |
|
|
18,778 |
|
Beneficial
Conversion feature |
|
|
- |
|
Total |
|
$ |
65,000 |
|
|
Private Placement [Member] | Series B-2 OID Convertible Notes And Warrants [Member] | Warrant [Member] |
|
Schedule of Valuation techniques |
We
estimated the fair value of the warrants on the issue date using a Black-Scholes pricing model with the following assumptions:
|
|
Warrants
three months ended March 31, 2015 |
|
Expected term |
|
|
1
year |
|
Volatility |
|
|
180.15-185.71 |
% |
Risk Free Rate |
|
|
0.18-0.22 |
% |
We
estimated the fair value of the warrants on the issue date using a Black-Scholes pricing model with the following assumptions:
|
|
Warrants
three months ended September 30, 2015 |
|
Expected term |
|
|
1
year |
|
Volatility |
|
|
171.36 |
% |
Risk Free Rate |
|
|
0.28 |
% |
|
Schedule of proceeds from debt |
The
proceeds of the Notes were allocated to the components as follows:
|
|
Proceeds allocated
at issue date |
|
Private
Offering Notes |
|
$ |
197,521 |
|
Private Offering Warrants |
|
|
46,097 |
|
Beneficial
Conversion feature |
|
|
13,382 |
|
Total |
|
$ |
257,000 |
|
The
proceeds of the Notes were allocated to the components as follows:
|
|
Proceeds allocated
at issue date |
|
Private
Offering Notes |
|
$ |
342,857 |
|
Private Offering Warrants |
|
|
120,000 |
|
Beneficial
Conversion feature |
|
|
137,143 |
|
Total |
|
$ |
600,000 |
|
|
X |
- DefinitionRepresent the information about the schedule of debt conversion table text.
+ References
+ Details
Name: |
cttc_ScheduleOfDebtConversionTableTextBlock |
Namespace Prefix: |
cttc_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRepresent the information about the schedule of debt issuance table text.
+ References
+ Details
Name: |
cttc_ScheduleOfDebtIssuanceTableTextBlock |
Namespace Prefix: |
cttc_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRepresent the information about the schedule of proceeds from debt table text.
+ References
+ Details
Name: |
cttc_ScheduleOfProceedsFromDebtTableTextBlock |
Namespace Prefix: |
cttc_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of borrowings which can be exchanged for a specified number of another security at the option of the issuer or the holder. Disclosures include, but are not limited to, principal amount, amortized premium or discount, and amount of liability and equity components.
+ References
+ Details
Name: |
us-gaap_ConvertibleDebtTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of the inputs and valuation techniques used to measure fair value, and a discussion of changes in valuation techniques and related inputs, if any, applied during the period to each separate class of assets, liabilities, and financial instruments classified in shareholders' equity that are measured on a recurring and/or nonrecurring basis.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (bbb) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.
+ References
+ Details
Name: |
us-gaap_ScheduleOfDebtTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesA3OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesB1OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesB2OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
SHAREHOLDERS' DEFICIENCY (Tables)
|
9 Months Ended |
Sep. 30, 2015 |
Stockholders' Equity Note [Abstract] |
|
Schedule of fair value of option weighted average assumptions |
We
estimated the fair value of each option on the grant date using a Black-Scholes option-pricing model with the following weighted
average assumptions:
|
|
Nine
- months ended |
|
|
Nine
- months ended |
|
|
|
September 30,
2015 |
|
|
September 30,
2014 |
|
Dividend yield (1) |
|
|
0.00 |
% |
|
|
0.00 |
% |
Expected volatility (2) |
|
|
159.8-164.5
|
% |
|
|
118.5-122.4 |
% |
Risk-free interest rates (3) |
|
|
1.61 |
% |
|
|
1.19-1.72 |
% |
Expected lives (2) |
|
|
5.0 YEARS
|
|
|
|
4.0-5.0YEARS |
|
|
(1) |
We have not paid cash dividends on our common
stock since 1981, and currently do not have plans to pay or declare cash dividends. Consequently, we used an expected dividend
rate of zero for the valuations. |
|
(2) |
Estimated based on our historical experience.
Volatility was based on historical experience over a period equivalent to the expected life in years. |
|
(3) |
Based on the U.S. Treasury constant maturity
interest rate with a term consistent with the expected life of the options granted. |
|
X |
- DefinitionTabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
nonnum:textBlockItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_StockholdersEquityNoteAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
BASIS OF PRESENTATION (Details Narrative) - USD ($)
|
3 Months Ended |
9 Months Ended |
|
Sep. 30, 2015 |
Sep. 30, 2014 |
Sep. 30, 2015 |
Sep. 30, 2014 |
Dec. 31, 2014 |
Principal amount |
$ 4,176,922
|
|
$ 4,176,922
|
|
|
Notes payable, gross |
$ 3,839,410
|
|
$ 3,839,410
|
|
$ 3,079,469
|
Calmare Device Product [Member] | Sales And Rentals [Member] |
|
|
|
|
|
Percentage of gross revenue |
95.00%
|
94.00%
|
94.00%
|
96.00%
|
|
Other Than Calmare Device Product [Member] | Sales And Rentals [Member] |
|
|
|
|
|
Percentage of gross revenue |
4.00%
|
2.00%
|
4.00%
|
1.00%
|
|
Promissory Notes [Member] |
|
|
|
|
|
Principal amount |
$ 4,177,000
|
|
$ 4,177,000
|
|
|
Notes payable, gross |
$ 3,839,000
|
|
$ 3,839,000
|
|
|
Vector Vision, Inc. [Member] |
|
|
|
|
|
Ownership percentage |
56.10%
|
|
56.10%
|
|
|
X |
- DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
+ Details
Name: |
cttc_NotesPayableGross |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6351-108592
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13531-108611
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=51801978&loc=d3e6404-108592
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13537-108611
+ Details
Name: |
us-gaap_ConcentrationRiskPercentage1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe parent entity's interest in net assets of the subsidiary, expressed as a percentage.
+ References
+ Details
Name: |
us-gaap_MinorityInterestOwnershipPercentageByParent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_ProductOrServiceAxis=cttc_CalmareDeviceProductMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueGoodsNetMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_ProductOrServiceAxis=cttc_OtherThanCalmareDeviceProductMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_PromissoryNotesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=us-gaap_SubsidiariesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
NET LOSS PER COMMON SHARE (Details) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2015 |
Sep. 30, 2014 |
Sep. 30, 2015 |
Sep. 30, 2014 |
Earnings Per Share [Abstract] |
|
|
|
|
Denominator for basic net loss per share, weighted average shares outstanding |
28,370,953
|
24,974,613
|
27,673,151
|
22,715,940
|
Dilutive effect of common stock options |
|
|
|
|
Dilutive effect of Series C convertible preferred stock, convertible debt and warrants |
|
|
|
|
Denominator for diluted net loss per share, weighted average shares outstanding |
28,370,953
|
24,974,613
|
27,673,151
|
22,715,940
|
X |
- DefinitionAmount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of stock options or restrictive stock units (RSUs).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details
Name: |
us-gaap_AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_EarningsPerShareAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAdditional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of convertible preferred stock using the if-converted method.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 40 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1930-109256
+ Details
Name: |
us-gaap_IncrementalCommonSharesAttributableToConversionOfPreferredStock |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 16 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1505-109256
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details
Name: |
us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 45 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1448-109256
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Weighted-Average Number of Common Shares Outstanding -URI http://asc.fasb.org/extlink&oid=6528421
+ Details
Name: |
us-gaap_WeightedAverageNumberOfSharesOutstandingBasic |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
NET LOSS PER COMMON SHARE (Details 1) - shares
|
9 Months Ended |
Sep. 30, 2015 |
Sep. 30, 2014 |
Total |
20,852,860
|
10,936,963
|
Exercise of Common Stock Option [Member] |
|
|
Total |
2,042,500
|
1,692,500
|
Warrant [Member] |
|
|
Total |
7,864,013
|
3,398,890
|
Series C Convertible Preferred Stock [Member] |
|
|
Total |
1,857,194
|
2,673,797
|
Conversion Of Convertible Debt [Member] |
|
|
Total |
9,089,153
|
3,171,776
|
X |
- DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Antidilution -URI http://asc.fasb.org/extlink&oid=6505113
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Diluted Earnings Per Share -URI http://asc.fasb.org/extlink&oid=6510752
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Contingent Stock Agreement -URI http://asc.fasb.org/extlink&oid=6508534
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesCPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
RECEIVABLES (Details) - USD ($)
|
Sep. 30, 2015 |
Dec. 31, 2014 |
Receivables [Abstract] |
|
|
Calmare device sales receivable, net of allowance of $209,533 at September 30, 2015 and December 31, 2014 |
|
|
Royalties, net of allowance of $101,154 at September 30, 2015 and December 31, 2014 |
|
|
Other, net of allowance of $6,972 at September 30, 2015 and December 31, 2014 |
$ 2,502
|
$ 2,319
|
Total |
2,502
|
2,319
|
Calmare device sales receivable,allowance |
209,533
|
209,533
|
Royalties,allowance |
101,154
|
101,154
|
Other,allowance |
$ 6,972
|
$ 6,972
|
X |
- DefinitionA valuation allowance for royalties receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.
+ References
+ Details
Name: |
cttc_AllowanceForDoubtfulRoyaltiesReceivableCurrent |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for royalties in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ References
+ Details
Name: |
cttc_RoyaltiesReceivableNetCurrent |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3-4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a(1) -Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5
+ Details
Name: |
us-gaap_AccountsReceivableNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionA valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=49124121&loc=d3e5074-111524
+ Details
Name: |
us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionA valuation allowance for doubtful other receivables due to an entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible and not separately disclosed.
+ References
+ Details
Name: |
us-gaap_AllowanceForDoubtfulOtherReceivablesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe carrying amount of other receivables, net, due within one year of the balance sheet date (or one operating cycle, if longer) from third parties or arising from transactions not separately disclosed.
+ References
+ Details
Name: |
us-gaap_OtherReceivablesNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_ReceivablesAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3,4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a -Article 5
+ Details
Name: |
us-gaap_ReceivablesNetCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.3.1.900
X |
- DefinitionThe number of shares of common stock or equity participation owned.
+ References
+ Details
Name: |
cttc_NumberOfSecuritiesOwned |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionAmount of equity securities categorized neither as held-to-maturity nor as trading.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 25 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=51813488&loc=d3e22054-111558
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 320 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=49167202&loc=d3e26610-111562
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 320 -Section 50 -Paragraph 2 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803
+ Details
Name: |
us-gaap_AvailableForSaleSecuritiesEquitySecurities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571
+ Details
Name: |
us-gaap_EquityMethodInvestmentOwnershipPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- Details
Name: |
dei_LegalEntityAxis=cttc_SecurityInnovationMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=cttc_XionPharmaceuticalCorporationMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
X |
- DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 55 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=51825145&loc=SL20226008-175313
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958
+ Details
Name: |
us-gaap_DerivativeLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)
|
Sep. 30, 2015 |
Dec. 31, 2014 |
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
|
|
Prepaid insurance |
$ 30,987
|
$ 71,651
|
Prepaid consulting services |
$ 20,000
|
37,500
|
Clinical trial |
|
109,119
|
Other |
$ 10,866
|
34,832
|
Prepaid expenses and other current assets |
$ 61,853
|
$ 253,102
|
X |
- DefinitionAmount of asset related to consideration paid in advance for clinical trial that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
+ Details
Name: |
cttc_ClinicalTrialExpenseCurrent |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for consulting services that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ References
+ Details
Name: |
cttc_PrepaidConsultingServices |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAggregate carrying amount, as of the balance sheet date, of current assets not separately disclosed in the balance sheet. Current assets are expected to be realized or consumed within one year (or the normal operating cycle, if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.8) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_OtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 8 -Article 5
+ Details
Name: |
us-gaap_PrepaidExpenseAndOtherAssetsCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6787-107765
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 1 -Subparagraph (g)(1) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6676-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 05 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=51662447&loc=d3e5865-108316
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 340 -SubTopic 10 -Section 05 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=51662447&loc=d3e5879-108316
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Assets -URI http://asc.fasb.org/extlink&oid=6509628
+ Details
Name: |
us-gaap_PrepaidInsurance |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.3.1.900
PROPERTY AND EQUIPMENT (Details) - USD ($)
|
Sep. 30, 2015 |
Dec. 31, 2014 |
Property, Plant and Equipment [Abstract] |
|
|
Property and equipment, gross |
$ 220,191
|
$ 215,491
|
Accumulated depreciation and amortization |
(192,118)
|
(179,851)
|
Property and equipment, net |
$ 28,073
|
$ 35,640
|
X |
- DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.14) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.13) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 13 -Subparagraph a -Article 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 8 -Article 7
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
v3.3.1.900
X |
- DefinitionThe aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_DepreciationDepletionAndAmortization |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_PropertyPlantAndEquipmentAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($)
|
Sep. 30, 2015 |
Dec. 31, 2014 |
Payables and Accruals [Abstract] |
|
|
Royalties payable |
$ 375,067
|
$ 314,787
|
Accrued compensation |
196,723
|
23,573
|
Accrued interest payable |
1,409,150
|
987,659
|
Other |
346,070
|
264,163
|
Accrued expenses and other liabilities, net |
$ 2,327,010
|
$ 1,590,182
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, and other costs not separately disclosed in the balance sheet that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.
+ References
+ Details
Name: |
us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_AccruedRoyaltiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6911-107765
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677
+ Details
Name: |
us-gaap_AccruedSalariesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionCarrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Current Liabilities -URI http://asc.fasb.org/extlink&oid=6509677
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 9 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e7018-107765
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765
+ Details
Name: |
us-gaap_InterestPayableCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe aggregate carrying amount, as of the balance sheet date, of liabilities not separately disclosed in the balance sheet.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
+ Details
Name: |
us-gaap_OtherLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- References
+ Details
Name: |
us-gaap_PayablesAndAccrualsAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
v3.3.1.900
X |
- DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, and other costs not separately disclosed in the balance sheet that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.
+ References
+ Details
Name: |
us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=cttc_LiabilitiesPurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=cttc_SouthridgeAffiliateASCRecapMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
LIABILITIES ASSIGNED TO LIABILITY PURCHASE AGREEMENT (Details Narrative) - USD ($)
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
Mar. 31, 2014 |
Sep. 30, 2013 |
Sep. 30, 2015 |
Sep. 30, 2014 |
Dec. 31, 2014 |
Decrease in financial obligation |
|
|
$ 936,494
|
$ 1,417,832
|
|
Liabilities Purchase Agreement [Member] | Southridge's Affiliate ASC Recap [Member] |
|
|
|
|
|
Decrease in financial obligation |
|
$ 2,100,000
|
|
|
|
Number of common stock issued |
|
1,618,235
|
|
|
|
Repayment of creditors |
$ 80,000
|
|
|
|
|
Service fee |
$ 27,000
|
|
|
|
|
Liabilities Purchase Agreement [Member] | Southridge, Partners II, L.P. [Member] |
|
|
|
|
|
Payables, accrued expenses and other current liabilities |
|
$ 2,093,303
|
|
|
|
Repayment of accrued expense |
|
|
|
|
$ 18,000
|
X |
- DefinitionAmount of cash outflow for the payment of accrued expenses.
+ References
+ Details
Name: |
cttc_RepaymentsOfAccruedExpense |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of cash outflow for the payment of creditor.
+ References
+ Details
Name: |
cttc_RepaymentsOfCreditors |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionSum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19,20) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of fees and commissions from financial services and banking activities and correspondent clearing. Includes fees from depositor accounts, credit cards, merchant discounts, and fiduciary and trust activities, guarantee fees, investment advisory, management, and administrative fees, transfer agent fees, and insurance commissions.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 225 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04.13) -URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882
+ Details
Name: |
us-gaap_FeesAndCommissions |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=cttc_LiabilitiesPurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=cttc_SouthridgeAffiliateASCRecapMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=cttc_SouthridgePartnersIILPMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
NOTES PAYABLE (Details) - USD ($)
|
Sep. 30, 2015 |
Dec. 31, 2014 |
Mar. 31, 2013 |
Notes Payable, gross |
$ 3,839,410
|
$ 3,079,469
|
|
Less LPA amount |
(485,980)
|
(485,980)
|
|
Notes Payable, net |
3,353,430
|
2,593,489
|
|
90 Day Convertible Notes [Member] |
|
|
|
Less LPA amount |
|
|
$ 485,980
|
24 Month Convertible Notes [Member] |
|
|
|
Notes Payable, gross |
125,000
|
125,000
|
|
15% Series A-3 OID Convertible Notes And Warrants [Member] |
|
|
|
Notes Payable, gross |
14,353
|
11,765
|
|
Series B-1 OID Convertible Notes And Warrants [Member] |
|
|
|
Notes Payable, gross |
65,104
|
56,659
|
|
Series B-2 OID Convertible Notes And Warrants [Member] |
|
|
|
Notes Payable, gross |
1,035,973
|
244,565
|
|
Mr.Peter Brennan [Member] | 90 Day Convertible Notes [Member] |
|
|
|
Notes Payable, gross |
2,498,980
|
2,498,980
|
|
Borad Members [Member] | 24 Month Convertible Notes [Member] |
|
|
|
Notes Payable, gross |
$ 100,000
|
100,000
|
|
Borad Members [Member] | 10 Day Note [Member] |
|
|
|
Notes Payable, gross |
|
$ 42,500
|
|
X |
- DefinitionIt is the amount of liability purchase agreement.
+ References
+ Details
Name: |
cttc_LiabilityPurchaseAgreementAmount |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
+ Details
Name: |
cttc_NotesPayableGross |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.16) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.16) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 13, 16 -Article 9
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20, 22 -Article 5
+ Details
Name: |
us-gaap_NotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_ConvertibleNotesPayable1Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesA3OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesB1OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesB2OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
NOTES PAYABLE (Details 1) - USD ($)
|
9 Months Ended |
|
|
|
|
|
Sep. 30, 2015 |
Dec. 31, 2014 |
Mar. 31, 2013 |
Jun. 30, 2012 |
Apr. 30, 2012 |
Mar. 31, 2012 |
Principal Amount |
|
$ 4,176,922
|
|
|
|
|
|
Carrying Value |
|
3,839,410
|
|
|
|
|
|
Notes Payable, gross |
|
3,839,410
|
$ 3,079,469
|
|
|
|
|
Less LPA amount |
|
(485,980)
|
(485,980)
|
|
|
|
|
Notes Payable, net |
|
3,353,430
|
2,593,489
|
|
|
|
|
90 Day Convertible Notes [Member] |
|
|
|
|
|
|
|
Less LPA amount |
|
|
|
$ 485,980
|
|
|
|
90 Day Convertible Notes [Member] | Mr.Peter Brennan [Member] |
|
|
|
|
|
|
|
Principal Amount |
|
2,498,980
|
|
|
|
|
|
Carrying Value |
|
$ 2,498,980
|
|
|
|
|
|
Cash Interest Rate |
|
6.00%
|
|
|
|
|
|
Common Stock Conversion Price (in dollars per share) |
|
$ 1.05
|
|
|
|
|
|
Maturity Date |
|
Various 2014
|
|
|
|
|
|
Notes Payable, gross |
|
$ 2,498,980
|
2,498,980
|
|
|
|
|
24 Month Convertible Notes [Member] |
|
|
|
|
|
|
|
Principal Amount |
|
125,000
|
|
|
$ 100,000
|
$ 25,000
|
|
Carrying Value |
|
$ 125,000
|
|
|
|
|
|
Cash Interest Rate |
|
6.00%
|
|
|
|
|
6.00%
|
Common Stock Conversion Price (in dollars per share) |
|
$ 1.05
|
|
|
|
|
$ 1.05
|
Maturity Date |
|
March 2014 June 2014
|
|
|
|
|
|
Notes Payable, gross |
|
$ 125,000
|
125,000
|
|
|
|
|
24 Month Convertible Notes [Member] | Borad Members [Member] |
|
|
|
|
|
|
|
Principal Amount |
|
100,000
|
|
|
|
|
$ 100,000
|
Carrying Value |
|
100,000
|
|
|
|
|
|
Notes Payable, gross |
|
100,000
|
100,000
|
|
|
|
|
15% Series A-3 OID Convertible Notes And Warrants [Member] |
|
|
|
|
|
|
|
Principal Amount |
[1] |
11,765
|
|
|
|
|
|
Carrying Value |
[1] |
$ 14,353
|
|
|
|
|
|
Common Stock Conversion Price (in dollars per share) |
|
$ 0.25
|
|
|
|
|
|
Maturity Date |
|
January 2015
|
|
|
|
|
|
Notes Payable, gross |
|
$ 14,353
|
$ 11,765
|
|
|
|
|
Accrued loss on conversion |
|
2,588
|
|
|
|
|
|
Series B-1 OID Convertible Notes And Warrants [Member] |
|
|
|
|
|
|
|
Principal Amount |
|
80,000
|
|
|
|
|
|
Carrying Value |
|
$ 65,104
|
|
|
|
|
|
Common Stock Conversion Price (in dollars per share) |
|
$ 0.23
|
$ 0.23
|
|
|
|
|
Maturity Date |
|
March 2017
|
|
|
|
|
|
Notes Payable, gross |
|
$ 65,104
|
$ 56,659
|
|
|
|
|
Series B-2 OID Convertible Notes And Warrants [Member] |
|
|
|
|
|
|
|
Principal Amount |
|
1,361,177
|
|
|
|
|
|
Carrying Value |
|
$ 1,035,973
|
|
|
|
|
|
Maturity Date |
|
Aug. 2015 July 2016
|
|
|
|
|
|
Notes Payable, gross |
|
$ 1,035,973
|
$ 244,565
|
|
|
|
|
Series B-2 OID Convertible Notes And Warrants [Member] | Minimum [Member] |
|
|
|
|
|
|
|
Common Stock Conversion Price (in dollars per share) |
|
$ 0.20
|
|
|
|
|
|
Series B-2 OID Convertible Notes And Warrants [Member] | Maximum [Member] |
|
|
|
|
|
|
|
Common Stock Conversion Price (in dollars per share) |
|
$ 0.25
|
|
|
|
|
|
|
|
X |
- DefinitionRepresents to the amount of loss incurred on converting the debt.
+ References
+ Details
Name: |
cttc_AccruedLossOnDebtConversion |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionIt is the amount of liability purchase agreement.
+ References
+ Details
Name: |
cttc_LiabilityPurchaseAgreementAmount |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ References
+ Details
Name: |
cttc_NotesPayableGross |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of long-term debt before deduction of unamortized discount or premium. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt, with initial maturities beyond one year or the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20 -Article 5
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 16 -Article 9
+ Details
Name: |
us-gaap_DebtInstrumentCarryingAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 5 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDescription of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDateDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIncluding the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.16) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.16) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 13, 16 -Article 9
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 19, 20, 22 -Article 5
+ Details
Name: |
us-gaap_NotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_ConvertibleNotesPayable1Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesA3OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesB1OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesB2OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_RangeAxis=us-gaap_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_RangeAxis=us-gaap_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
NOTES PAYABLE (Details 2) - USD ($)
|
Sep. 30, 2015 |
Dec. 31, 2013 |
Dec. 31, 2012 |
Dec. 31, 2011 |
Mr.Peter Brennan [Member] | 90 Day Convertible Notes [Member] |
|
|
|
|
Total |
$ 2,498,980
|
$ 1,188,980
|
$ 1,210,000
|
$ 100,000
|
X |
- DefinitionCarrying amount of long-term debt, net of unamortized discount or premium, including current and noncurrent amounts. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.16) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.16) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 20, 22 -Article 5
+ Details
Name: |
us-gaap_LongTermDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
NOTES PAYABLE (Details 3) - Private Placement [Member] - 15% Series A-3 OID Convertible Notes And Warrants [Member] - Warrant [Member]
|
9 Months Ended |
Sep. 30, 2015 |
Expected term |
2 years
|
Volatility |
184.88%
|
Risk Free Rate |
0.32%
|
X |
- DefinitionPeriod the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueAssumptionsExpectedTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionMeasure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRisk-free interest rate assumption used in valuing an instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesA3OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
X |
- DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
+ Details
Name: |
cttc_ProceedsFromNotesPayableAndWarrant |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Beneficial Conversion Feature -URI http://asc.fasb.org/extlink&oid=6505963
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
+ Details
Name: |
us-gaap_ProceedsFromNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
+ Details
Name: |
us-gaap_ProceedsFromWarrantExercises |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=cttc_PrivatePlacement1Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesA3OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
NOTES PAYABLE (Details 5) - USD ($)
|
3 Months Ended |
9 Months Ended |
Mar. 31, 2015 |
Jun. 30, 2014 |
Sep. 30, 2015 |
Sep. 30, 2014 |
Statement of Operations |
|
|
|
|
Accelerated interest expense |
|
|
|
$ 35,109
|
Private Placement [Member] | 15% Series A-3 OID Convertible Notes And Warrants [Member] |
|
|
|
|
Statement of Operations |
|
|
|
|
Loss on conversion of notes |
$ 2,588
|
$ 43,288
|
|
|
Accelerated interest expense |
|
$ 35,109
|
|
|
Balance Sheet |
|
|
|
|
Shares issued |
|
798,825
|
|
|
Shares to be issued subsequent |
|
529,415
|
|
|
Principal amount of notes converted |
$ 11,765
|
$ 265,648
|
|
|
X |
- DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ References
+ Details
Name: |
cttc_DebtConversionConvertedInstrumentSharesIssued2 |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDifference between the fair value of payments made and the carrying amount of convertible debt which is converted prior to or at maturity.
+ References
+ Details
Name: |
cttc_LossOnConversionOfNotes |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586
+ Details
Name: |
us-gaap_DebtConversionConvertedInstrumentAmount1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586
+ Details
Name: |
us-gaap_DebtConversionConvertedInstrumentSharesIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_IncomeStatementAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_InterestExpenseDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- References
+ Details
Name: |
us-gaap_StatementOfFinancialPositionAbstract |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=cttc_PrivatePlacement1Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesA3OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
NOTES PAYABLE (Details 6) - Private Placement [Member] - Series B-1 OID Convertible Notes And Warrants [Member] - Warrant [Member]
|
1 Months Ended |
Mar. 20, 2014 |
Expected term |
4 years
|
Volatility |
151.52%
|
Risk Free Rate |
1.32%
|
X |
- DefinitionPeriod the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueAssumptionsExpectedTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionMeasure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRisk-free interest rate assumption used in valuing an instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesB1OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
NOTES PAYABLE (Details 7) - Private Placement [Member] - USD ($)
|
3 Months Ended |
12 Months Ended |
Sep. 30, 2015 |
Mar. 31, 2015 |
Mar. 31, 2014 |
Dec. 31, 2014 |
Total |
$ 600,000
|
$ 257,000
|
$ 65,000
|
$ 65,000
|
Warrant [Member] |
|
|
|
|
Proceeds allocated to warrants at issue date |
$ 120,000
|
$ 46,097
|
|
|
Series B-1 OID Convertible Notes And Warrants [Member] |
|
|
|
|
Proceeds allocated to notes at issue date |
|
|
34,272
|
$ 46,222
|
Beneficial Conversion feature |
|
|
3,917
|
|
Total |
|
|
65,000
|
|
Series B-1 OID Convertible Notes And Warrants [Member] | Warrant [Member] |
|
|
|
|
Proceeds allocated to warrants at issue date |
|
|
$ 26,811
|
$ 18,778
|
X |
- DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
+ Details
Name: |
cttc_ProceedsFromNotesPayableAndWarrant |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Beneficial Conversion Feature -URI http://asc.fasb.org/extlink&oid=6505963
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
+ Details
Name: |
us-gaap_ProceedsFromNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
+ Details
Name: |
us-gaap_ProceedsFromWarrantExercises |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesB1OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
X |
- DefinitionPeriod the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueAssumptionsExpectedTerm |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionMeasure of dispersion, in percentage terms (for instance, the standard deviation or variance), for a given stock price.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionRisk-free interest rate assumption used in valuing an instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 820 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=36462937&loc=d3e19207-110258
+ Details
Name: |
us-gaap_FairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesB2OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_RangeAxis=us-gaap_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_RangeAxis=us-gaap_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
NOTES PAYABLE (Details 9) - Private Placement [Member] - USD ($)
|
3 Months Ended |
12 Months Ended |
Sep. 30, 2015 |
Mar. 31, 2015 |
Mar. 31, 2014 |
Dec. 31, 2014 |
Total |
$ 600,000
|
$ 257,000
|
$ 65,000
|
$ 65,000
|
Warrant [Member] |
|
|
|
|
Private Offering Warrants |
120,000
|
46,097
|
|
|
Series B-2 OID Convertible Notes And Warrants [Member] |
|
|
|
|
Private Offering Notes |
342,857
|
197,521
|
|
|
Beneficial Conversion feature |
137,143
|
13,382
|
|
|
Total |
$ 600,000
|
$ 257,000
|
|
|
X |
- DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
+ Details
Name: |
cttc_ProceedsFromNotesPayableAndWarrant |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21538-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Beneficial Conversion Feature -URI http://asc.fasb.org/extlink&oid=6505963
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3255-108585
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Financing Activities -URI http://asc.fasb.org/extlink&oid=6513228
+ Details
Name: |
us-gaap_ProceedsFromNotesPayable |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionThe cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
+ Details
Name: |
us-gaap_ProceedsFromWarrantExercises |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesB2OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
NOTES PAYABLE (Details Narrative)
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
|
|
|
|
|
Dec. 18, 2015
USD ($)
shares
|
Sep. 30, 2015
USD ($)
$ / shares
shares
|
Jun. 30, 2015
USD ($)
$ / shares
shares
|
Mar. 31, 2015
USD ($)
$ / shares
shares
|
Sep. 30, 2014
USD ($)
$ / shares
shares
|
Jun. 30, 2014
USD ($)
$ / shares
shares
|
Mar. 31, 2014
USD ($)
$ / shares
shares
|
Sep. 30, 2013
USD ($)
$ / shares
shares
|
Sep. 30, 2015
USD ($)
$ / shares
shares
|
Sep. 30, 2014
USD ($)
$ / shares
shares
|
Dec. 31, 2014
USD ($)
N
$ / shares
|
Dec. 31, 2013
USD ($)
|
Feb. 24, 2016
USD ($)
|
Mar. 31, 2013
USD ($)
|
Jun. 30, 2012
USD ($)
|
Apr. 30, 2012
USD ($)
|
Mar. 31, 2012
USD ($)
$ / shares
|
Additonal interest expenses |
|
|
|
|
|
|
|
|
|
|
$ 35,109
|
|
|
|
|
|
|
|
Liability purchase agreement amount |
|
|
$ (485,980)
|
|
|
|
|
|
|
$ (485,980)
|
|
$ (485,980)
|
|
|
|
|
|
|
Principal amount |
|
|
4,176,922
|
|
|
|
|
|
|
$ 4,176,922
|
|
|
|
|
|
|
|
|
Number of anti diluted securities | shares |
|
|
|
|
|
|
|
|
|
20,852,860
|
10,936,963
|
|
|
|
|
|
|
|
Loss on debt settlement |
|
|
|
|
|
|
|
|
|
|
$ (132,301)
|
|
|
|
|
|
|
|
Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued | shares |
|
470,588
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant term |
|
1 year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from notes payable |
|
|
|
|
|
|
|
$ 55,000
|
|
|
|
|
|
|
|
|
|
|
Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from notes payable |
|
|
$ 600,000
|
|
$ 257,000
|
|
|
$ 65,000
|
|
|
|
65,000
|
|
|
|
|
|
|
Private Placement [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant exercise price (in dollars per share) | $ / shares |
|
|
|
$ 0.60
|
$ 0.60
|
$ 0.60
|
$ 0.60
|
$ 0.60
|
|
|
$ 0.60
|
|
|
|
|
|
|
|
Number of shares issued | shares |
|
|
|
725,000
|
187,500
|
580,000
|
425,000
|
1,250,000
|
|
|
|
|
|
|
|
|
|
|
Warrant term |
|
|
|
3 years
|
3 years
|
3 years
|
3 years
|
3 years
|
|
|
|
|
|
|
|
|
|
|
90 Day Convertible Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liability purchase agreement amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 485,980
|
|
|
|
90 Day Convertible Notes [Member] | Mr.Peter Brennan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
6.00%
|
|
|
|
|
|
|
6.00%
|
|
|
|
|
|
|
|
|
Conversion price (in dollars per share) | $ / shares |
|
|
$ 1.05
|
|
|
|
|
|
|
$ 1.05
|
|
|
|
|
|
|
|
|
Additional interest rate per month |
|
|
1.00%
|
|
|
|
|
|
|
1.00%
|
|
|
|
|
|
|
|
|
Additonal interest expenses |
|
|
|
|
|
|
|
|
|
$ 287,000
|
|
|
|
|
|
|
|
|
Total additonal interest expenses |
|
|
|
|
|
|
|
|
|
906,000
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
$ 2,498,980
|
|
|
|
|
|
|
$ 2,498,980
|
|
|
|
|
|
|
|
|
Description of maturity date |
|
|
|
|
|
|
|
|
|
Various 2014
|
|
|
|
|
|
|
|
|
24 Month Convertible Notes [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest rate |
|
|
6.00%
|
|
|
|
|
|
|
6.00%
|
|
|
|
|
|
|
|
6.00%
|
Conversion price (in dollars per share) | $ / shares |
|
|
$ 1.05
|
|
|
|
|
|
|
$ 1.05
|
|
|
|
|
|
|
|
$ 1.05
|
Principal amount |
|
|
$ 125,000
|
|
|
|
|
|
|
$ 125,000
|
|
|
|
|
|
$ 100,000
|
$ 25,000
|
|
Accrued interest payable |
|
|
28,000
|
|
|
|
|
|
|
$ 28,000
|
|
|
|
|
|
|
|
|
Description of maturity date |
|
|
|
|
|
|
|
|
|
March 2014 June 2014
|
|
|
|
|
|
|
|
|
24 Month Convertible Notes [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt default amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 125,000
|
|
|
|
|
24 Month Convertible Notes [Member] | Borad Members [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
$ 100,000
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
|
|
|
$ 100,000
|
24 Month Convertible Notes [Member] | Borad Members [Member] | Subsequent Event [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt default amount |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
10 Day Note [Member] | Borad Members [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
|
|
|
|
|
|
|
$ 42,500
|
|
|
|
|
|
|
15% Series A-3 OID Convertible Notes And Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion price (in dollars per share) | $ / shares |
|
|
$ 0.25
|
|
|
|
|
|
|
$ 0.25
|
|
|
|
|
|
|
|
|
Principal amount |
[1] |
|
$ 11,765
|
|
|
|
|
|
|
$ 11,765
|
|
|
|
|
|
|
|
|
Description of maturity date |
|
|
|
|
|
|
|
|
|
January 2015
|
|
|
|
|
|
|
|
|
15% Series A-3 OID Convertible Notes And Warrants [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion price (in dollars per share) | $ / shares |
|
|
|
|
$ 0.20
|
|
$ 0.20
|
$ 0.25
|
|
|
|
|
|
|
|
|
|
|
Additonal interest expenses |
|
|
|
|
|
|
$ 35,109
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
|
|
|
$ 64,706
|
|
|
|
|
|
|
|
|
|
|
Proceeds from notes payable |
|
|
|
|
|
|
|
55,000
|
|
|
|
|
|
|
|
|
|
|
Debt issue discount |
|
|
|
|
|
|
|
$ 9,706
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued upon conversion | shares |
|
|
|
|
|
|
798,825
|
|
|
|
|
|
|
|
|
|
|
|
15% Series A-3 OID Convertible Notes And Warrants [Member] | Private Placement [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant exercise price (in dollars per share) | $ / shares |
|
|
|
|
|
|
|
$ 0.60
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued | shares |
|
|
|
|
|
|
|
129,412
|
|
|
|
|
|
|
|
|
|
|
Warrant term |
|
|
|
|
|
|
|
2 years
|
|
|
|
|
|
|
|
|
|
|
Series B-1 OID Convertible Notes And Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion price (in dollars per share) | $ / shares |
|
|
$ 0.23
|
|
|
|
|
|
|
$ 0.23
|
|
$ 0.23
|
|
|
|
|
|
|
Principal amount |
|
|
$ 80,000
|
|
|
|
|
|
|
$ 80,000
|
|
|
|
|
|
|
|
|
Number of shares available for conversion | N |
|
|
|
|
|
|
|
|
|
|
|
347,826
|
|
|
|
|
|
|
Description of maturity date |
|
|
|
|
|
|
|
|
|
March 2017
|
|
|
|
|
|
|
|
|
Series B-1 OID Convertible Notes And Warrants [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion price (in dollars per share) | $ / shares |
|
|
|
|
|
|
|
$ 0.35
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
|
|
|
$ 80,000
|
|
|
|
|
|
|
|
|
|
|
Proceeds from notes payable |
|
|
|
|
|
|
|
65,000
|
|
|
|
|
|
|
|
|
|
|
Debt issue discount |
|
|
|
|
|
|
|
$ 15,000
|
|
|
|
|
|
|
|
|
|
|
Number of anti diluted securities | shares |
|
|
|
|
|
|
|
20,000,000
|
|
|
|
|
|
|
|
|
|
|
Series B-1 OID Convertible Notes And Warrants [Member] | Private Placement [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant exercise price (in dollars per share) | $ / shares |
|
|
|
|
|
|
|
$ 0.45
|
|
|
|
$ 0.33
|
|
|
|
|
|
|
Number of shares issued | shares |
|
|
|
|
|
|
|
185,714
|
|
|
|
|
|
|
|
|
|
|
Warrant term |
|
|
|
|
|
|
|
4 years
|
|
|
|
|
|
|
|
|
|
|
Series B-2 OID Convertible Notes And Warrants [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
$ 1,361,177
|
|
|
|
|
|
|
$ 1,361,177
|
|
|
|
|
|
|
|
|
Description of maturity date |
|
|
|
|
|
|
|
|
|
Aug. 2015 July 2016
|
|
|
|
|
|
|
|
|
Series B-2 OID Convertible Notes And Warrants [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion price (in dollars per share) | $ / shares |
|
|
$ 0.25
|
|
$ 0.20
|
|
|
|
|
$ 0.25
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
$ 705,882
|
|
$ 302,353
|
|
|
|
|
$ 705,882
|
|
|
|
|
|
|
|
|
Proceeds from notes payable |
|
|
600,000
|
|
257,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt issue discount |
|
|
$ 105,882
|
|
$ 45,353
|
|
|
|
|
$ 105,882
|
|
|
|
|
|
|
|
|
Debt original conversion |
|
|
|
$ 5,882
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued upon conversion | shares |
|
|
29,410
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Series B-2 OID Convertible Notes And Warrants [Member] | Private Placement [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant exercise price (in dollars per share) | $ / shares |
|
|
$ 0.60
|
|
$ 0.60
|
|
|
|
|
$ 0.60
|
|
|
|
|
|
|
|
|
Number of shares issued | shares |
|
|
1,411,764
|
|
755,882
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant term |
|
|
1 year
|
|
1 year
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Convertible Notes And Warrants [Member] | Securities Purchase Agreement [Member] | Tonaquint, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Conversion price (in dollars per share) | $ / shares |
|
|
|
|
|
|
|
|
$ 0.30
|
|
|
|
|
|
|
|
|
|
Additional interest rate per month |
|
|
|
|
|
|
|
|
7.00%
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
|
|
|
|
$ 112,500
|
|
|
|
|
|
|
|
|
|
Proceeds from notes payable |
|
|
|
|
|
|
|
|
100,000
|
|
|
|
|
|
|
|
|
|
Debt issue discount |
|
|
|
|
|
|
|
|
10,000
|
|
|
|
|
|
|
|
|
|
Transaction expense |
|
|
|
|
|
|
|
|
$ 2,500
|
|
|
|
|
|
|
|
|
|
Repayment of debt |
|
|
|
|
|
|
$ 144,000
|
$ 98,000
|
|
|
|
|
|
|
|
|
|
|
Loss on debt settlement |
|
|
|
|
|
|
|
$ 34,000
|
|
|
|
|
|
|
|
|
|
|
Description of maturity date |
|
|
|
|
|
|
|
|
May 2014
|
|
|
|
|
|
|
|
|
|
Convertible Notes And Warrants [Member] | Warrant [Member] | Securities Purchase Agreement [Member] | Tonaquint, Inc [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrant exercise price (in dollars per share) | $ / shares |
|
|
|
|
|
|
|
|
$ 0.35
|
|
|
|
|
|
|
|
|
|
Number of shares issued | shares |
|
|
|
|
|
|
|
|
112,500
|
|
|
|
|
|
|
|
|
|
Warrant term |
|
|
|
|
|
|
|
|
5 years
|
|
|
|
|
|
|
|
|
|
6 Months Convertible Notes [Member] | Southridge, Partners II, L.P. [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
|
|
|
|
|
|
|
|
|
|
|
$ 12,000
|
|
|
|
|
|
Number of shares issued upon conversion | shares |
|
|
|
|
|
50,000
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss on debt settlement |
|
|
|
|
|
$ 5,500
|
|
|
|
|
|
|
|
|
|
|
|
|
Description of conversion price terms |
|
|
|
|
|
|
|
|
|
|
|
|
The convertible note was convertible into the Company's
common stock at the greater of $0.25 or 85% of the average closing bid price during the five (5) trading days prior to conversion
and was due in June 2014.
|
|
|
|
|
|
Description of maturity date |
|
|
|
|
|
|
|
|
|
|
|
|
Jun-14
|
|
|
|
|
|
6 Months Convertible Notes [Member] | Subsequent Event [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Principal amount |
|
$ 400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Debt issue discount |
|
$ 70,588
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
X |
- DefinitionAdditional contractual interest rate for funds borrowed, under the debt agreement.
+ References
+ Details
Name: |
cttc_DebtInstrumentAdditionalInterestRateStatedPercentage |
Namespace Prefix: |
cttc_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionRepresent the information about the total of interest expenses during the period.
+ References
+ Details
Name: |
cttc_InterestExpenseDebtTotal |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionIt is the amount of liability purchase agreement.
+ References
+ Details
Name: |
cttc_LiabilityPurchaseAgreementAmount |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionThe cash inflow from a borrowing supported by a written promise to pay an obligation.
+ References
+ Details
Name: |
cttc_ProceedsFromNotesPayableAndWarrant |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionSecurity that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.
+ References
+ Details
Name: |
cttc_WarrantTerm |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Antidilution -URI http://asc.fasb.org/extlink&oid=6505113
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Diluted Earnings Per Share -URI http://asc.fasb.org/extlink&oid=6510752
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Contingent Stock Agreement -URI http://asc.fasb.org/extlink&oid=6508534
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details
Name: |
us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(4)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of shares issued in exchange for the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or payments in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586
+ Details
Name: |
us-gaap_DebtConversionConvertedInstrumentSharesIssued1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of the original debt being converted in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4304-108586
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6367179&loc=d3e4332-108586
+ Details
Name: |
us-gaap_DebtConversionOriginalDebtAmount1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of outstanding long-term debt or borrowing associated with any securities or credit agreement for which there has been a default in principal, interest, sinking fund, or redemption provisions, or any breach of covenant that existed at the end of the period and subsequently has not been cured.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(c)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details
Name: |
us-gaap_DebtDefaultLongtermDebtAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe price per share of the conversion feature embedded in the debt instrument.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 20 -Section 50 -Paragraph 5 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6928298&loc=SL6031898-161870
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleConversionPrice1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(5)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:integerItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionDescription of the conversion terms of a debt instrument which may include the conversion ratio (including all potential conversion ratios if contingently adjustable), type of debt or equity security into which the debt is convertible, the dollars of debt or the number of shares into which the instrument is convertible (or potentially convertible into), the conversion period, any contingencies associated with the conversion terms, and the existence and amount of a beneficial conversion feature.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21521-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(5)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
+ Details
Name: |
us-gaap_DebtInstrumentConvertibleTermsOfConversionFeature |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionContractual interest rate for funds borrowed, under the debt agreement.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_DebtInstrumentInterestRateStatedPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDescription of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(2)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details
Name: |
us-gaap_DebtInstrumentMaturityDateDescription |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionAmount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).
+ References
+ Details
Name: |
us-gaap_DebtIssuanceCosts |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDifference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12317-112629
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 50 -Section 40 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=49170532&loc=d3e12355-112629
+ Details
Name: |
us-gaap_GainsLossesOnExtinguishmentOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionAmount of the cost of borrowed funds accounted for as interest expense for debt.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.8) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_InterestExpenseDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAmount of interest payable on debt, including, but not limited to, trade payables.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.15(a)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
+ Details
Name: |
us-gaap_InterestPayableCurrentAndNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.
+ References
+ Details
Name: |
us-gaap_RepaymentsOfDebt |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=cttc_PrivatePlacement1Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=us-gaap_ConvertibleNotesPayableMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_ConvertibleNotesPayable1Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableOtherPayablesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesA3OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesB1OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_SeriesB2OIDConvertibleNotesAndWarrantsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_ConvertibleNotesPayable2Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=cttc_SecuritiesPurchaseAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=cttc_TonaquintIncMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_ConvertibleNotesPayable3Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=cttc_SouthridgePartnersIILPMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
X |
- DefinitionThe estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe risk-free interest rate assumption that is used in valuing an option on its own shares.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExpected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 14.D.2) -URI http://asc.fasb.org/extlink&oid=27013229&loc=d3e301413-122809
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 14 -Section D -Subsection 2
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_RangeAxis=us-gaap_MinimumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_RangeAxis=us-gaap_MaximumMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
SHAREHOLDERS' DEFICIENCY (Details Narrative) - USD ($)
|
3 Months Ended |
9 Months Ended |
Sep. 30, 2015 |
Mar. 31, 2015 |
Sep. 30, 2014 |
Jun. 30, 2014 |
Mar. 31, 2014 |
Sep. 30, 2015 |
Sep. 30, 2014 |
Recognized share based compensation expense |
|
|
|
|
|
$ 49,181
|
$ 49,185
|
5% Preferred Stock [Member] |
|
|
|
|
|
|
|
Divdend rate |
|
|
|
|
|
5.00%
|
|
Preferential non-cumulative dividends, payable quarterly (in dollars per share) |
|
|
|
|
|
$ 1.25
|
|
Preferred stock redemption price (in dollars per share) |
$ 25
|
|
|
|
|
25
|
|
Preferred stock liquidation preference price (in dollars per share) |
$ 25
|
|
|
|
|
$ 25
|
|
Employees' Directors' And Consultants Stock Option Plan [Member] | Non Employee Directors [Member] |
|
|
|
|
|
|
|
Options granted |
|
50,000
|
|
|
42,500
|
|
|
Recognized share based compensation expense |
|
|
|
|
|
$ 7,963
|
11,178
|
Employees' Directors' And Consultants Stock Option Plan [Member] | Employees [Member] |
|
|
|
|
|
|
|
Options granted |
300,000
|
|
|
320,000
|
|
|
|
Vesting percent |
20.00%
|
|
|
20.00%
|
|
|
|
Vesting period |
4 years
|
|
|
4 years
|
|
|
|
Recognized share based compensation expense |
$ 25,006
|
|
$ 8,062
|
|
|
$ 41,218
|
$ 38,007
|
X |
- DefinitionThe percentage rate used to calculate dividend payments on preferred stock.
+ References
+ Details
Name: |
us-gaap_PreferredStockDividendRatePercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAggregate dividends declared during the period for each share of preferred stock outstanding.
+ References
+ Details
Name: |
us-gaap_PreferredStockDividendsPerShareDeclared |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(d)(1)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5
+ Details
Name: |
us-gaap_PreferredStockLiquidationPreference |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 11 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 5 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644
+ Details
Name: |
us-gaap_PreferredStockRedemptionPricePerShare |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_ShareBasedCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionGross number of share options (or share units) granted during the period.
+ References
+ Details
Name: |
us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPercentage of vesting of share-based compensation awards.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPeriod from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901
+ Details
Name: |
us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=cttc_EmployeesDirectorsAndConsultantsStockOptionPlanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
SHAREHOLDERS' DEFICIENCY (Details Narrative 1) - USD ($)
|
|
3 Months Ended |
9 Months Ended |
|
Aug. 14, 2014 |
Dec. 18, 2015 |
Sep. 30, 2015 |
Jun. 30, 2015 |
Mar. 31, 2015 |
Dec. 31, 2014 |
Sep. 30, 2014 |
Jun. 30, 2014 |
Mar. 31, 2014 |
Sep. 30, 2015 |
Sep. 30, 2014 |
Oct. 15, 2015 |
Description of reverse stock split |
One-for-ten reverse stock split.
|
|
|
|
|
|
|
|
|
|
|
|
Value of shares issued upon services |
|
|
|
|
|
|
|
|
|
$ 2,125
|
|
|
Common stock, authorized revised |
|
|
|
|
|
|
|
|
|
|
|
100,000,000
|
Common stock, authorized |
|
|
40,000,000
|
|
|
40,000,000
|
|
|
|
40,000,000
|
|
40,000,000
|
Share based compensation expense |
|
|
|
|
|
|
|
|
|
$ 2,125
|
$ 4,038
|
|
Non Employee Directors [Member] | Director Compensation Plan [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued upon new issue |
|
|
|
|
12,500
|
|
|
|
10,625
|
|
|
|
Share based compensation expense |
|
|
|
|
$ 2,125
|
|
|
|
$ 4,038
|
|
|
|
Advisory Firm (Consulting Services) [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued upon services |
|
|
|
|
500,000
|
|
|
|
|
|
|
|
Value of shares issued upon services |
|
|
|
|
$ 80,000
|
|
|
|
|
|
|
|
Stock issuance amortized expense |
|
|
$ 20,000
|
|
|
|
|
|
|
60,000
|
|
|
Advisory Firm (Consulting Services) [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued upon services |
|
|
|
|
120,000
|
|
|
|
|
|
|
|
Stock issuance amortized expense |
|
|
|
|
$ 27,600
|
$ 10,800
|
|
|
|
|
|
|
Advisory Firm (Consulting Services) [Member] | Vesting Tranche One [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued upon services |
|
|
|
|
|
60,000
|
|
|
|
|
|
|
Advisory Firm (Consulting Services) [Member] | Vesting Tranche Two [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued upon services |
|
|
|
|
60,000
|
|
|
|
|
|
|
|
Series C Convertible Preferred Stock [Member] | Accounts Payable and Accrued Liabilities [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Dividend payable |
|
|
79,726
|
|
|
|
|
|
|
$ 79,726
|
|
|
Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Value of shares issued upon new issue |
|
|
|
$ 290,000
|
$ 75,000
|
|
$ 232,000
|
$ 170,000
|
$ 500,000
|
|
|
|
Warrant [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued upon new issue |
|
470,588
|
|
|
|
|
|
|
|
|
|
|
Share price (in dollars per share) |
|
$ 0.60
|
|
|
|
|
|
|
|
|
|
|
Warrant term |
|
1 year
|
|
|
|
|
|
|
|
|
|
|
Warrant [Member] | Advisory Firm (Consulting Services) [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued upon services |
|
|
|
|
333,333
|
|
|
|
|
|
|
|
Value of shares issued upon services |
|
|
|
|
$ 75,000
|
|
|
|
|
|
|
|
Warrant [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued upon new issue |
|
|
|
725,000
|
187,500
|
|
580,000
|
425,000
|
1,250,000
|
|
|
|
Exercise price (in dollars per share) |
|
|
|
$ 0.60
|
$ 0.60
|
|
$ 0.60
|
$ 0.60
|
$ 0.60
|
|
$ 0.60
|
|
Warrant term |
|
|
|
3 years
|
3 years
|
|
3 years
|
3 years
|
3 years
|
|
|
|
Common Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued upon services |
|
|
|
|
|
|
|
|
|
12,500
|
|
|
Value of shares issued upon services |
|
|
|
|
|
|
|
|
|
$ 125
|
|
|
Number of shares issued for services (in shares) |
|
|
|
|
|
|
|
|
|
620,000
|
|
|
Common Stock [Member] | Private Placement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Number of shares issued upon new issue |
|
|
|
1,450,000
|
375,000
|
|
1,160,000
|
850,000
|
2,500,000
|
|
|
|
Share price (in dollars per share) |
|
|
|
$ 0.20
|
$ 0.20
|
|
$ 0.20
|
$ 0.20
|
$ 0.20
|
|
$ 0.20
|
|
Series C Convertible Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Description of voting rights |
|
|
|
|
|
|
|
|
|
Equivalent to 1,000 votes per $1,000 par value.
|
|
|
Cumulative dividend rate |
|
|
|
|
|
|
|
|
|
5.00%
|
|
|
Dividend paid |
|
|
4,726
|
|
|
|
|
|
|
$ 14,024
|
|
|
Derivative liability |
|
|
$ 107,871
|
|
|
$ 66,177
|
|
|
|
$ 107,871
|
|
|
Preferred stock, outstanding |
|
|
375
|
|
|
375
|
|
|
|
375
|
|
|
5% Preferred Stock [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
Description of voting rights |
|
|
|
|
|
|
|
|
|
One vote.
|
|
|
Cumulative dividend rate |
|
|
|
|
|
|
|
|
|
5.00%
|
|
|
Preferred stock, outstanding |
|
|
2,427
|
|
|
2,427
|
|
|
|
2,427
|
|
|
X |
- DefinitionThe revised maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ References
+ Details
Name: |
cttc_CommonStockSharesAuthorizedRevised |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionRefers to the amortization expense of issuing a stock.
+ References
+ Details
Name: |
cttc_StockIssuanceAmortizedExpense |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
cttc_StockIssuedDuringPeriodSharesIssuedForServices1 |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionSecurity that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.
+ References
+ Details
Name: |
cttc_WarrantTerm |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionExercise price per share or per unit of warrants or rights outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08.(i)(4)) -URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details
Name: |
us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.29) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 30 -Article 5
+ Details
Name: |
us-gaap_CommonStockSharesAuthorized |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionFair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 55 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=51825145&loc=SL20226008-175313
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 20 -Section 50 -Paragraph 3 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312
Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611
Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41271-113958
Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 10 -Section 45 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=6945355&loc=d3e41228-113958
+ Details
Name: |
us-gaap_DerivativeLiabilities |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionAmount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 405 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817
+ Details
Name: |
us-gaap_Dividends |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionCarrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.15(5)) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 15 -Subparagraph a -Article 7
+ Details
Name: |
us-gaap_DividendsPayableCurrentAndNoncurrent |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe percentage rate used to calculate dividend payments on preferred stock.
+ References
+ Details
Name: |
us-gaap_PreferredStockDividendRatePercentage |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.28) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5
+ Details
Name: |
us-gaap_PreferredStockSharesOutstanding |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionDescription of voting rights of nonredeemable preferred stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 3 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29 -Article 5
+ Details
Name: |
us-gaap_PreferredStockVotingRights |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionValue of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.
+ References
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueIssuedForServices |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- DefinitionThe noncash expense that accounts for the value of stock or unit options distributed to employees as compensation.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=56944662&loc=d3e3602-108585
+ Details
Name: |
us-gaap_StockOptionPlanExpense |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionDescription of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 4 -Subparagraph (SAB TOPIC 4.C) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 4 -Section C
+ Details
Name: |
us-gaap_StockholdersEquityReverseStockSplit |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:stringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_PlanNameAxis=cttc_DirectorCompensationPlanMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=cttc_AdvisoryFirmMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
dei_LegalEntityAxis=cttc_AdvisoryFirm1Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsPayableAndAccruedLiabilitiesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_SeriesCPreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
X |
- DefinitionRefers to Obligation percentage of net sales paid during the period.
+ References
+ Details
Name: |
cttc_ObligationPercentageOfNetSalesPaid |
Namespace Prefix: |
cttc_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe element represents the percentage of revenue earned during the period as an obligation.
+ References
+ Details
Name: |
cttc_ObligationPercentageOfRevenue |
Namespace Prefix: |
cttc_ |
Data Type: |
num:percentItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAmount of contractual obligation, including but not limited to, long-term debt, capital lease obligations, operating lease obligations, purchase obligations, and other commitments.
+ References
+ Details
Name: |
us-gaap_ContractualObligation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- Details
Name: |
dei_LegalEntityAxis=us-gaap_SubsidiariesMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=cttc_LicensingSupportedProductsMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
v3.3.1.900
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
|
3 Months Ended |
9 Months Ended |
12 Months Ended |
Sep. 30, 2015 |
Sep. 30, 2014 |
Sep. 30, 2015 |
Sep. 30, 2014 |
Dec. 31, 2010 |
Service charge per day |
|
|
$ 1,000
|
|
|
Notes payable to related parties |
$ 2,593,489
|
|
2,593,489
|
|
|
Sales revenue |
197,204
|
$ 400,000
|
405,154
|
$ 937,080
|
|
Mr.Peter Brennan [Member] |
|
|
|
|
|
Notes payable to related parties |
2,498,980
|
|
2,498,980
|
|
|
Borad Members [Member] |
|
|
|
|
|
Notes payable to related parties |
$ 100,000
|
|
$ 100,000
|
|
|
Mr.Stephen J.D'Amato, M.D (Calmar Pain Relief, LLC.) [Member] |
|
|
|
|
|
Sales revenue |
|
|
|
|
$ 550,000
|
X |
- DefinitionExpenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_OfficersCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionAggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(a)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_SalesRevenueGoodsNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
v3.3.1.900
SUBSEQUENT EVENTS (Details Narrative) - USD ($)
|
|
|
3 Months Ended |
9 Months Ended |
Jan. 08, 2016 |
Oct. 15, 2015 |
Dec. 18, 2015 |
Jun. 30, 2015 |
Mar. 31, 2015 |
Sep. 30, 2014 |
Jun. 30, 2014 |
Mar. 31, 2014 |
Sep. 30, 2015 |
Monthly officer compensation |
|
|
|
|
|
|
|
|
$ 1,000
|
Debt face amount |
|
|
|
|
|
|
|
|
$ 4,176,922
|
Warrant [Member] |
|
|
|
|
|
|
|
|
|
Number of shares issued upon new issue |
|
|
470,588
|
|
|
|
|
|
|
Share price (in dollars per share) |
|
|
$ 0.60
|
|
|
|
|
|
|
Warrant term |
|
|
1 year
|
|
|
|
|
|
|
Private Placement [Member] |
|
|
|
|
|
|
|
|
|
Value of shares issued upon new issue |
|
|
|
$ 290,000
|
$ 75,000
|
$ 232,000
|
$ 170,000
|
$ 500,000
|
|
Private Placement [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
Number of shares issued upon new issue |
|
|
|
725,000
|
187,500
|
580,000
|
425,000
|
1,250,000
|
|
Warrant term |
|
|
|
3 years
|
3 years
|
3 years
|
3 years
|
3 years
|
|
Mr. Thomas P. Richtarich [Member] |
|
|
|
|
|
|
|
|
|
Monthly officer compensation |
$ 9,500
|
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Private Placement [Member] | 6 Months Convertible Notes [Member] |
|
|
|
|
|
|
|
|
|
Hybrid debt funding |
|
|
$ 400,000
|
|
|
|
|
|
|
Debt face amount |
|
|
400,000
|
|
|
|
|
|
|
Debt discount |
|
|
$ 70,588
|
|
|
|
|
|
|
Subsequent Event [Member] | Mr. VADM Robert T. Conway [Member] | Consulting Agreement [Member] |
|
|
|
|
|
|
|
|
|
Monthly officer compensation |
|
$ 7,500
|
|
|
|
|
|
|
|
Subsequent Event [Member] | Mr. VADM Robert T. Conway [Member] | Consulting Agreement [Member] | Warrant [Member] |
|
|
|
|
|
|
|
|
|
Number of shares issued upon new issue |
|
167,000
|
|
|
|
|
|
|
|
Share price (in dollars per share) |
|
$ 0.60
|
|
|
|
|
|
|
|
Value of shares issued upon new issue |
|
$ 33,734
|
|
|
|
|
|
|
|
Warrant term |
|
5 years
|
|
|
|
|
|
|
|
X |
- DefinitionSecurity that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.
+ References
+ Details
Name: |
cttc_WarrantTerm |
Namespace Prefix: |
cttc_ |
Data Type: |
xbrli:durationItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFace (par) amount of debt instrument at time of issuance.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399
+ Details
Name: |
us-gaap_DebtInstrumentFaceAmount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
instant |
|
X |
- DefinitionThe amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 1A -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28541-108399
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400
+ Details
Name: |
us-gaap_DebtInstrumentUnamortizedDiscount |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionFair value as of the balance sheet date of hybrid instruments.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 815 -SubTopic 15 -Section 45 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6437212&loc=d3e50806-113969
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 10 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13433-108611
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=49121117&loc=d3e13495-108611
+ Details
Name: |
us-gaap_HybridInstrumentsAtFairValueNet |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
instant |
|
X |
- DefinitionExpenditures for salaries of officers. Does not include allocated share-based compensation, pension and post-retirement benefit expense or other labor-related non-salary expense. For commercial and industrial companies, excludes any direct and overhead labor that is included in cost of goods sold.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.4) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688
+ Details
Name: |
us-gaap_OfficersCompensation |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
debit |
Period Type: |
duration |
|
X |
- DefinitionPrice of a single share of a number of saleable stocks of a company.
+ References
+ Details
Name: |
us-gaap_SharePrice |
Namespace Prefix: |
us-gaap_ |
Data Type: |
num:perShareItemType |
Balance Type: |
na |
Period Type: |
instant |
|
X |
- DefinitionNumber of new stock issued during the period.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30 -Article 5
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodSharesNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:sharesItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionEquity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644
Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 505 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 29, 30, 31 -Article 5
+ Details
Name: |
us-gaap_StockIssuedDuringPeriodValueNewIssues |
Namespace Prefix: |
us-gaap_ |
Data Type: |
xbrli:monetaryItemType |
Balance Type: |
credit |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_DebtInstrumentAxis=cttc_ConvertibleNotesPayable3Member |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_TypeOfArrangementAxis=cttc_ConsultingAgreementMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=us-gaap_WarrantMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
Calmare Therapeutics (CE) (USOTC:CTTC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calmare Therapeutics (CE) (USOTC:CTTC)
Historical Stock Chart
From Apr 2023 to Apr 2024